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Recent advances in biotechnology have enabled the development and large scale 
production of protein therapeutics, thereby providing new treatments for numerous 
diseases. However, oral delivery of biologics remains a challenge as macromolecules are 
poorly absorbed and rapidly degraded in the gastrointestinal tract. Several strategies have 
been studied to improve bioavailability, but to date, no safe, efficient and clinically 
relevant delivery system has been discovered.  Here, the reprogramming of bacterial 
toxins for therapeutic purposes was investigated. Following cellular uptake, Pseudomonas	
aeruginosa exotoxin A (PE) and Vibrio	 cholerae cholix toxin (Cho) escape lysosomal 
degradation and are capable of both trafficking to the cytosol of non-polarised (NP) cells 
and undergoing transcytosis across polarised cells. This project aimed to investigate the 
trafficking routes exploited by these toxins to determine how they avoid degradation, and 
define their potential as vehicles for oral protein delivery. 
 
The nature of the conformational change experienced by PE in acidic conditions was first 
investigated. It was shown that this transition consists of a subtle alteration in the 
protein’s structure which does not affect its overall size, but results in the exposure of 
additional trypsin cleavage sites and hydrophobic residues. It was concluded that the 
transition is involved in the protein’s escape from lysosomal degradation and was most 
likely caused by the protonation of two histidine residues when the pH was lowered, 
resulting in the formation of additional salt bridges and  thus different structural 
constraints. 
 
The interaction between PE and monosialoganglioside GM1 was also examined to 
determine whether it could act as a secondary receptor for PE. High-affinity binding was 
established in both acidic and physiological conditions, and interaction with GM1 was 
shown to be required for efficient protein internalisation by NP cells. These findings were 
concluded to be in agreement with GM1 acting as a secondary receptor for PE, leading the 
toxin away from lysosomal degradation following conformational change. 
 
The potential of PE as a vehicle for delivery of biologics was studied using several versions 
of the toxin connected to a cargo protein. Results showed that a truncated version of PE is 
capable of carrying a cargo protein (green fluorescent protein, human growth hormone) 
inside NP cells in	vitro and across polarised epithelium in	vivo. These data strongly support 
the idea that PE has the potential to be used as a vehicle for oral delivery of biologics. 
      iv 
Similarly, these studies were also carried out on cholix to assess its ability to act as a drug 
carrier. Cholix was shown to undergo a conformational change similar to that experienced 
by PE. It was also demonstrated that an interaction with GM1 occurred, although in this 
case, increased binding appeared to result in decreased internalisation by NP cells. Finally, 
full-length and truncated cholix could transport a payload inside NP cells in	 vitro and 
across polarised epithelial cells in	 vivo. These results confirm that cholix could also 
represent a powerful tool for oral administration of macromolecular drugs. 
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Since the approval of the first recombinant protein drug by the US Food and Drug 
Administration (FDA) in 1982 (human insulin), the rapid development of new 
technologies within the pharmaceutical industry has enabled the large scale production of 
a wide range of recombinant proteins, offering new perspectives for the treatment of 
numerous diseases. Overall, the market is dominated by oncology, insulins, auto-immune 
and auto-suppressive agents (Figure 1-1) [1, 2]. Protein therapeutics represent an ever 
expanding market whose global sales increased from $33 billion in 2003 up to $137 billion 
in 2013 [1, 3], when seven out of the ten top global selling drugs were proteins and 
included five antibodies (Table 1-1) [4]. The sales of these seven compounds only 
accounted for more than $56 billion in 2013. 
 





Table 1-1 – The world’s top 10 best-selling prescription drugs in 2013 [4] and their 
current mode of administration. Stars indicate protein therapeutics. 

































GlaxoSmithKline Asthma 8.3 Inhalation [8, 9] 
5* Lantus Sanofi Diabetes 7.6 
Subcutaneous 
injection [10] 
6* Rituxan Roche Rheumatoid arthritis 7.5 
Intravenous 
infusion  [11] 
7* Avastin Roche Bowel cancer 6.8 
Intravenous 
infusion [12] 
8* Herceptin Roche Breast cancer 6.6 
Intravenous 
infusion [13] 
9 Crestor AstraZeneca Cholesterol 5.6 Oral [14] 








Protein therapeutics present several advantages over small-molecule drugs. First, they are 
highly specific molecules and their administration usually results in fewer side effects, less 
interference with regular biological processes and a more predictable behaviour [15]. 
Secondly, as most of these molecules are naturally produced by the body, they are often 
poorly immunogenic and well-tolerated [16]. Finally, proteins often fulfil various intricate 





biologics the potential for far-reaching patent protection, thereby making them 
particularly attractive for pharmaceutical companies [17]. 
The use of protein therapeutics remains limited due to their poor oral bioavailability 
owing to the presence of physical, chemical and enzymatic barriers [18]. On average, less 
than 1% of most administered protein drugs reach the systemic circulation [18]. As a 
consequence, most biologics are currently delivered via parenteral injections (Table 1-1). 
However, the appearance of local reactions at the site of administration, systemic side-
effects and immunogenicity concerns restrict the extent of their use as drugs [19]. For 
these reasons, the need for a new system, which allows for safe and efficient oral drug 
delivery, is greater than ever. Such a system would bring major improvements to the 
treatment of numerous chronic diseases. First, the convenience and ease of use would 
greatly improve patient compliance. Drug administration would also be safer, as the use of 
needles and syringes would no longer be required. As a result, the social stigma associated 
with the use of these items would be dramatically reduced, thereby improving the quality 
of life for patients [20]. Finally, from the economic standpoint, development of such 
systems is highly attractive, given that costs associated with prolonged patient 
hospitalisation and use of expensive devices could be significantly reduced [21]. 
In order to develop a system that is adequate for the oral delivery of macromolecules, 
numerous strategies have been investigated. These include the use of enzyme inhibitors 
and absorption enhancers, mucoadhesive polymeric and particulate carrier delivery 
systems [22, 23]. However, all of these strategies present major drawbacks and only a few 
approaches have reached the latter phases of clinical trials [24]. Another concept involves 
the use of virulence factors secreted by several bacterial pathogens, including 
Corynebacterium	diphtheriae, Vibrio	cholerae and Pseudomonas	aeruginosa. The relevance 
of these toxins in the treatment of various types of cancers has been widely investigated 
[25]. Recently, it was suggested that they could be reprogrammed for drug delivery 
purposes [26, 27]. 
This chapter aims to provide an understanding of the various challenges faced during oral 
protein delivery and to discuss bacterial toxins as potential therapeutic tools. First, it 
offers an insight into how drug absorption takes place from the small intestine. In order to 
appreciate the requirements of successful oral protein delivery, a brief description of the 
anatomy of the gastrointestinal tract, the characteristics of the epithelium lining the small 
intestine, the different transport routes across this barrier, and the obstacles faced during 
oral protein administration are presented. The second part covers the use of bacterial 





immunotoxins, as well as a detailed account of the intoxication pathway and 
structure/function relationship of one particular toxin, Pseudomonas exotoxin A. The use 
of bacterial toxins as carriers for oral protein delivery is also introduced. This information 
predominantly aims to give a foundation to the studies described in this thesis and to 
underpin the main themes addressed in the following chapters. 
1.1 Oral protein delivery 
1.1.1 Anatomy	of	the	gastro-intestinal	tract	
 
The role of the human gastro-intestinal tract (GIT) is to break down food particles and 
reduce them to small nutrients, which can be absorbed into the body to provide energy. 
The GIT is divided into several segments. Food uptake occurs in the oral cavity, where 
foodstuffs are mixed with saliva and mechanically processed. Food is then transported 
through the pharynx and oesophagus to the stomach, and further to the small intestine 
(SI), which is divided between the duodenum, jejunum and ileum. Digestion is initiated in 
the stomach: proteins, fats and carbohydrates are chemically broken into smaller peptides. 
Digestion is then completed in the small intestine, where most of the absorption of 
nutrients, via the epithelium, into the blood circulation, takes place. Undigested material 
travels from the ileum to the colon, before reaching the rectum and being evacuated. 
Due to its large surface area (between 200 and 500 cm² [28]), absorption properties and a 
milder environment compared to the stomach, the SI represents a primary target for the 
absorption/uptake of drugs. 
1.1.2 Epithelium	in	the	SI	
 
The SI epithelium performs several functions essential to the integrity of the body. It 
constitutes a physical barrier that separates the internal milieu from the exterior 
environment, while maintaining the homeostatic conditions of the body. To perform this 
function, the intestinal epithelium must establish and maintain a selective barrier 
regulating the movement of water and solutes between the intestinal lumen and the 
underlying matrix. In this way, the controlled absorption (nutrients) and secretion (waste 
products) of specific molecules can be performed, while the body remains protected from 







The epithelium represents the innermost layer of the various segments of the GIT, 
including the SI. It is supported by a basement membrane, which is a specialised acellular 
structure that is organised through a process known as “self-assembly” [29]. It consists of 
laminins, collagens (mostly type IV), proteoglycans, calcium binding proteins such as 
fibulin, and various other structural or adhesive proteins [30]. Interactions between 
epithelial cells and the basement membrane influence their behaviour by controlling their 
shape, gene expression, adhesion, migration, proliferation and apoptosis [31]. Epithelial 
cells are anchored to components of the basement membrane by hemi-desmosomes [32]. 
The basement membrane is itself supported by an underlying layer of connective tissue 
called the lamina propria, which contains blood vessels, nerves, glands, lymphoid tissue 
and immune cells [33]. Beneath the lamina propria is the muscularis mucosa, which 
comprises layers of smooth muscles which can contract to change the shape of the lumen 
to mix and propel luminal contents [34] (Figure 1-2). 
 
 
Figure 1-2 – Structure of the SI wall. The epithelium in the SI is supported by a 
basement membrane, which rests upon an underlying layer of connective tissue, the 
lamina propria. The lamina propria is itself supported by layers of smooth muscles 

















Epithelial cells are polarised cells: their plasma membrane is divided between an apical 
surface which faces the intestinal lumen, and a basolateral domain which faces the 
neighbouring cells and establishes contact and communication between them [35]. Lateral 
cell-cell interactions are stabilised by desmosomes [36, 37], which form strong adhesive 
intercellular junctions and are also linked to cytoskeletal filaments, and gap junctions, 
which form channels connecting the cytoplasm of two adjacent cells, thus enabling rapid 
exchange of ions and small molecules (< 1 kDa) between adjacent cells [38]. 
The apical and basolateral domains of the plasma membrane are delimited by the apical 
junctional complex (AJC), which is composed of the tight junctions (TJs) and adherens 
junctions (AJs) [39]. Tight junctions are closely associated areas of the cells where 
membranes come together in such close approximation as to restrict the passage of water 
and electrolytes in the intercellular space. This is referred to as the “barrier” function of 
the TJs. The apical and basolateral domains of the plasma membrane are composed by 
different sets of proteins and lipids. For instance, the apical membrane is enriched in 
sphingolipids and cholesterol, while the basolateral membrane is mainly constituted of 
phospholipids [40]. TJs also regulate the lateral movement of these components between 
domains that could otherwise freely diffuse in the plasma membrane [41]. This is referred 
to as the “fence” function of the TJs. 
Tight junctions are composed of several transmembrane proteins that include occludin, 
claudins and JAM-1 [42]. These proteins form the seal that limits the paracellular space 
and interact with proteins from the ZO family, connecting TJ structures to the cellular 
cytoskeleton [43]. Extracellular interactions established between claudins create 
paracellular pores that show size as well as charge selectivity and contribute to regulating 
the movement of molecules in the intercellular space [44, 45]. AJs are adhesive junctions 
that lie just below TJs on the basolateral cell membrane. A major constituent of AJs is a 
protein called E-cadherin, which forms calcium-dependent extracellular interactions and 
brings the adjacent cells into close proximity [39]. While TJs are impermeable barriers 
that seal the intercellular space completely, AJs and desmosomes establish 15-20 nm gaps 









The small intestine is lined by a monolayer of columnar absorptive epithelial cells called 
enterocytes, with scattered goblet cells and some enteroendocrine and microfold cells (M 
cells) [46]. The epithelium in the SI forms folds called villi. This particular geometry 
multiplies the surface area available for nutrient absorption by around 30-fold [47]. The 
crypts of Lieberkühn are located at the base of the villi, and the epithelium there also 
includes Paneth cells and stem cells [46] (Figure 1-3). 
The apical surface of enterocytes is covered with small hair-like projections called 
microvilli, which can be as numerous as 3,000 per cell and are organised in a structure 
known as the brush border. The primary site for endocytosis is located between microvilli, 
which further increase the area of the epithelium available for nutrient digestion and 
uptake by 600-fold [47]. The membrane of enterocytes contains micro-domains enriched 
in cholesterol and sphingolipids and resistant to solubilisation by non-ionic detergents in 
physiological temperatures that are known as lipid rafts, or detergent-resistant membrane 
(DRM) micro-domains [48]. Lipids within DRMs are more ordered and tightly packed than 
in the surrounding membrane bilayer, and while these domains are mainly located on the 
apical membrane of enterocytes, they are also present within intracellular compartments 
(e.g. endosomes, Golgi network) [49, 50]. Many proteins involved in intracellular signal 
transduction are gathered in DRMs (e.g. G proteins, growth factor receptors and protein 
kinase C), which appear to act as signalling platforms by facilitating the interaction 
between various signalling pathway components [51]. 
While enterocytes are responsible for absorption through the epithelium, goblet and 
entero-endocrine cells have secretory functions. Goblet cells arise from differentiation of 
stem cells at the bottom of the crypts. They are responsible for the secretion of mucus and 
contain granules that fill with mucins as they migrate from the bottom to the opening of 
the crypt and release their content at the surface [52, 53]. Enteroendocrine cells secrete 
hormones regulating a variety of GIT functions. M cells are located individually or in 
lymphoid follicle-associated epithelium (Peyer’s patches). They play an important role in 
immune response as they internalise antigens from the intestinal lumen via endocytosis 
and deliver them to the underlying lymphoid tissue [54, 55]. Stem cells also divide into 
Paneth cells that are located at the base of the crypts and secrete antimicrobial peptides, 
including lysosomal enzymes and α-defensins, into the crypt lumen. These peptides diffuse 
from the crypts and disperse further into the mucus layer, where they contribute to the 






Figure 1-3 – The SI epithelium forms a barrier which maintains the homeostasis 
between the internal and external milieus. The epithelium is folded into villi and is 
mainly composed of a single layer of enterocytes interspersed with goblet cells. 
Paneth cells, entero-endocrine and epithelial stem cells are found in the crypts and 
M cells are associated with Peyer’s patches. Secreted IgA are transported across 
epithelial cells by transcytosis and promote the clearance of antigens and 
pathogenic microorganisms from the intestinal lumen. 
1.1.3 Transport	across	the	intestinal	epithelium	
 
The transport of various materials across epithelial cells generally occurs using the 
paracellular pathway (between adjacent cells), transcellular pathway (through individual 
cells using pathways that access the cell cytosol), or via transcytosis (through individual 


























Figure 1-4 – Schematic representation of the intestinal epithelium and the pathways 
available for drug absorption. Depending on their properties, molecules can cross 
the epithelium via the transcellular or paracellular pathways, or by transcytosis. 
1.1.3.1 Paracellular	pathway	
 
Transport of molecules across the intestinal epithelium via the paracellular pathway is a 
passive diffusion process that is limited by the presence of TJs. These molecular 
organisations form small pores that only allow compounds < 3.5 kDa to pass [57-59]. TJs 
also form claudin-dependent charge-selective channels that regulate the passage of ions 
and electrolytes [60]. Claudin proteins constitute a family of 24 transmembrane proteins 
localised exclusively at TJ structures. Each epithelium expresses a different pattern of 
claudin proteins that establish its permeability properties. Most epithelia express more 
than two claudin types in different combinations to form TJ strands. For instance, it has 
been shown that claudin-2, -4, -7 and -15 are the predominant types expressed in the 
mouse small intestine, with claudin-2 present in the deep crypt while claudin-7 is most 
favourably expressed in the upper villi [44, 61]. As a result of these combinations of 








To cross the intestinal epithelial barrier using the transcellular pathway, molecules need 
to be reasonably small (< 700 Da), and able to passively and successively partition and 
diffuse through both lipidic (cell membrane) and aqueous (cytosol) compartments 
following a chemical potential gradient [62]. The flux of molecules crossing the epithelium 






Where   J diffusion flux (mol/m²·s) 
D diffusion coefficient specific to each molecule and obtained from the 
Stokes-Einstein equation (m²/s) 
∂Ø variation in concentration between the apical and basolateral side of 
the epithelium (mol/m3) 
    ∂x path length of the flux route (m). 







Where   D diffusion coefficient of the spherical particle (m²/s) 
    a radius of the spherical particle (m) 
    R ideal gas constant (= 8.314 J/mol·K) 
    T is the temperature (K) 
    NA  is Avogadro’s number (6.022 x1023 mol-1) 
    η is the viscosity of the fluid (Pa·s) 
Molecule transport by the transcellular route can be either passive, when no energy is 
provided by the cell, or active, when cellular energy is required for transport. Passive 
transcellular transport can take place via simple diffusion, in which case movement is non-
selective, and the flux of molecules can occur either in the apical to basolateral direction 
(absorption) or in the basolateral to apical direction (secretion) depending on the 
chemical gradient. In the context of ions and small molecules transport (e.g. some sugars 





or carrier proteins) which assist in the transit of specific substrates across the membrane 
bilayer [63]. During active transcellular transport, energy derived from ATP hydrolysis is 
used to modify the conformation of a carrier protein which then carries the substance 
across the plasma membrane against its concentration gradient [47, 62]. 
1.1.3.3 Transcytosis	pathway	
 
Transcytosis, with regard to the intestinal epithelium, describes the process of materials 
moving across enterocytes using an intracellular route involving vesicles. This process can 
occur in either direction, i.e. apical to basolateral or basolateral to apical. Materials 
transported by this process remain inside the vesicular structures and do not come in 
direct contact with the cytosol of the cell. The vesicular transport events involved in 
transcytosis are energy-dependent processes, which can be initiated by several endocytic 
mechanisms [64]. For instance, the process involving the bulk uptake of solid matter, 
including cell debris and microorganisms, is termed phagocytosis. In the SI, it can be 
carried out by specialised cells such as M cells, which specifically deliver their content to 
the underlying lymphoid tissue of the follicle-associated epithelium [65, 66]. Different 
types of fluid-phase uptake by pinocytosis can be classified according to the size and 
coating of the endocytic vesicle formed (Figure 1-5). Macropinocytosis is a non-specific 
uptake mechanism that accompanies cell-surface ruffling. It involves internalisation of 
large volumes of extracellular fluids and soluble macromolecules. The vesicles formed are 
usually > 500 µm in diameter [65] (Figure 1-5). Macropinocytosis is often induced as part 
of the response to stimulation by growth factors, but this process does not usually result in 
transcytosis [67]. Macropinocytosis is distinct from micropinocytosis, which includes 
clathrin-mediated endocytosis, caveolin-mediated endocytosis as well as clathrin- and 
caveolin-independent mechanisms [65, 68]. These processes proceed by invagination of 
selective plasma-membrane domains that are pinched off to form early stage endosomes 
as a first step in the process of transcytosis [65, 68]. These endocytic processes can be 
made more efficient through binding of extracellular molecules to the cell membrane by 
specific cell-surface receptors (i.e. receptor-mediated endocytosis) [65, 68]. Receptor-
mediated endocytosis (RME) is involved in the transcytosis of molecules such as 
immunoglobulin G proteins [69] or Vitamin B12 [70] from the apical to the basolateral 






Figure 1-5 – Multiple pathways of entry into cells. Large particles can be taken up by 
phagocytosis, whereas fluid uptake occurs by macropinocytosis. The size of vesicles 
formed by these two processes is much larger than endocytic vesicles formed by 
micropinocytosis. Clathrin- and caveolin-mediated endocytosis usually depend on 
dynamin, a large GTPase which was suggested to play a role in the scission of newly 
formed vesicles from the plasma membrane [71]. Some clathrin- and caveolin-




The low oral bioavailability of biologics and consequently the limited use of such 
molecules as therapeutic agents are partly due to intrinsic properties of the protein drugs 
themselves. It is also linked, however, to the hostile conditions and other defence and 
upkeep mechanisms of the GI tract; these represent obstacles to non-selective protein 
absorption from the intestine into the systemic circulation. 
1.1.4.1 Charge	and	size	of	protein	drugs	
 
Donovan et	al (1990) demonstrated, using polyethylene glycol molecules, that transport 
across epithelia was independent of molecular weight for molecules smaller than 500-700 
Da, but that permeation decreased steeply when molecular weight exceeded 700 Da [72]. 
For molecules to partition into cell membranes and be passively absorbed via the 
transcellular pathway, a minimum degree of lipophilicity is required [73]. However, most 
protein drugs are too hydrophilic to use this route of absorption, which represents a major 
obstacle for their oral intake. Besides, peptide and protein drugs are usually 





















paracellular pathway either, as the movement of molecules through this route is limited by 
the presence of TJs. The role of net protein charge in the degree of penetration of 
molecules is more controversial and, although some studies suggest that an overall 
positive charge could enhance transcellular protein transport across epithelial monolayers 
[74, 75], variations in global charge would affect mostly paracellular transport of low 
molecular weight compounds [76, 77]. Therefore, these conclusions do not apply to 
protein drugs. 
1.1.4.2 Causes	of	protein	degradation	in	the	GIT	
1.1.4.2.1 Acidity in the stomach 
 
Before reaching the intestine, protein drugs have to travel through the stomach, where the 
harsh environmental conditions often lead to profound modifications or degradation of 
the molecule. In fact, due to secretion of hydrochloric acid by gastric glands, the stomach 
typically presents a very acidic environment (pH ~ 1-2) [78]. These conditions are 
essential for the efficient degradation of food materials. However, exposure of a protein to 
such a low pH can modify its ionisation state, which can in turn affect the drug’s solubility, 
stability and conformation by modifying the electrostatic interactions and hydrogen 
bonding within the molecule. A change in conformation is often irreversible and may lead 
to protein denaturation [18]. Acidity can also result in proteolysis, breaking proteins into 
peptides [18]. Moreover, due to variations in gastric and pancreatic secretions between 
preprandial and postprandial states, the pH in the stomach (and more generally the GIT) 
can fluctuate significantly between fasting and fed states. This further complicates oral 
drug delivery as these differences can considerably influence protein drug release, 
stability and solubility [79]. Finally, secretion of pepsinogen (converted to its active form, 
pepsin, by acid cleavage) by mucosal cells further contributes to protein degradation in 
the stomach [18]. 
1.1.4.2.2 Enzymes in the small intestine 
 
Biologics are exposed to a wide variety of enzymes along the GIT, and enzymatic 
degradation is one of the main factors reducing the bioavailability of orally administered 
drugs. This process has been coined as “pre-systemic metabolism” [80]. Degradation can 
occur either by hydrolysis of peptide bonds or by chemical modifications of the protein 





Peptidases are numerous in the SI as they originate both from pancreatic secretions and 
from the enterocytes. Endopeptidases present in the intestinal lumen include trypsin, 
chymotrypsin and elastases, while the main exopeptidases are amino- and 
carboxypeptidases. Trypsin, chymotrypsin and other pancreatic enzymes are also present 




Mucus covers the surface of the intestinal epithelium [83, 84], with the exception of M cells 
[85]. In the small intestine, mucus is secreted by goblet cells located at the top of the 
crypts of Lieberkühn and spreads between the villi [53]. The main components of 
intestinal mucus are gel-forming mucin proteins. Mucins are high molecular weight 
glycosylated proteins with oligosaccharide side chains attached to approximately 75% of 
the protein core [86]. This composition gives mucus its gel-like structure and water-
retaining properties. The main mucin constituent of intestinal mucus is the gel-forming 
MUC2 glycoprotein [86]. Mucins are produced inside granules in goblet cells located at the 
base of the crypts.  They become progressively glycosylated and densely packed in the 
granules as goblet cells migrate toward the villus tip [53]. Mucins are released into the 
extracellular milieu via exocytosis, at the top of the crypts, where they expand 
dramatically upon contact with water to form a gel-like structure [87, 88]. 
Mucus forms a semi-permeable barrier allowing for the exchange of nutrients and water 
while maintaining a hydrated surface which physically protects the epithelium against 
digestion enzymes, abrasive materials and pathogens present in the lumen. In fact, mucus 
is enriched in antimicrobial molecules from Paneth cells (α-defensins, lysozymes, etc.) [89] 
and secretory IgA from the enterocytes [69], which are entrapped within this viscous layer 
and thus maintained at high concentrations close to the cell surface. At the apical cell 
surface, mucus interacts with the glycocalyx structure [86], which forms a ~500 nm-thick 
coating layer between the cells and the mucus. It is composed of a negatively charged 
network of proteoglycans, glycolipids and glycoproteins, including densely packed 
transmembrane mucins (possibly MUC-3, -12 and -17 [83]), and a set of membrane-bound 
enzymes secreted by the enterocytes and present on the microvilli (brush border 
enzymes) [90, 91]. Due to the close association of these elements, the glycocalyx forms a 
size-selective diffusion barrier that prevents large particles such as pathogens from 
reaching the epithelium. Frey et	al (1996) have shown that the functional pore size of the 





smaller than the average size of a bacterium (~1 μm) or even a virus (~50 nm), and 
therefore greatly impedes the penetration of these agents across the glycocalyx [92].  
Together, mucus and glycocalyx prevent auto-digestion and diffusion of pathogens from 
the intestinal lumen. They also constitute an important obstacle for oral drug delivery. Due 
to its viscosity, mucus can entrap lipophilic drugs and large delivery devices, blocking 
them from reaching the mucosal surface and consequently penetrating the epithelium 
[93], [94]. Brush border enzymes can also potentially reduce the bioavailability of orally 
administered biologics. Finally, mucus is continuously produced at a rate of ~10 L/day in 
the GIT [88]. As high volumes of fluids are secreted and washed away, drug residence 
times in the intestine are decreased, thereby reducing the amount of drug capable of 
crossing the epithelium. 
1.1.4.4 Immunogenicity	
 
Protein drugs used to treat patients can be either derived from non-human sources (e.g. 
salmon calcitonin) or produced from human genetic sequences using recombinant DNA 
technologies (e.g. human growth hormone, insulin). As a result, they sometimes present 
subtle differences with the endogenous compound(s), such as sequence variations, 
denaturation or alterations in their glycosylation pattern [95]. These factors, as well as the 
formulation, length of treatment, or genetic patient characteristics for example, account 
for the potential immunogenicity of biologics. The immune response induced by protein 
therapeutics can result in the formation of neutralising antibodies leading to decreased 
drug efficacy (e.g.  interferon α-2b [96]), or to more serious adverse reactions if the 
secreted antibodies neutralise some physiologically important function [97]. Casadevall et	
al (2002) identified 22 patients presenting pure red-cell aplasia following treatment for 
anaemia from chronic renal failure, using recombinant erythropoietin alpha or beta (EPO), 
and suggested that the inhibition of erythropoiesis was caused by the development of 
neutralising anti-erythropoietin antibodies after an initial response to EPO [98]. 
Although the route of administration of a protein cannot make the protein less 
immunogenic per	se, it can influence the extent of an immune response. Intramuscular and 
subcutaneous injections are viewed as more likely to induce severe immunogenic 
reactions compared to intravenous drug delivery [19] and topical application is 
considered the safest option. In the SI, the presence of numerous food-related antigens 
and a large population of commensal bacteria have allowed the intestinal mucosa to 
develop a mechanism of oral tolerance [99]. Therefore, despite the mechanism of mucosal 





GIT and controls the immune response in case these antigens penetrate further inside the 
body [100], the SI remains a target of choice for the delivery of potentially immunogenic 
protein therapeutics. 
1.2 Bacterial toxins as therapeutic tools 
1.2.1 Bacterial	toxins	
 
Bacterial pathogens secrete toxins as virulence factors in order to break through the 
body’s defences. Some bacterial proteins are highly toxic to mammalian cells due to their 
ability to hijack cellular mechanisms to enter cells, reach the cytosol and attack essential 
constituents; events that can lead to cell death or modifications of cellular physiology 
[101]. Their toxicity is enhanced by the fact that these molecules have very few inhibitors. 
Most of these proteins belong to the family of A-B toxins, a class of cytotoxic proteins that 
require cellular uptake through receptor-mediated endocytosis for activity [102, 103]. 
These toxins are structurally divided between a receptor-binding fragment (B subunit) 
that ferries an enzymatic fragment (A subunit) to its intracellular site of action. A-B toxins 
are secreted as pro-enzymes and their activation requires complete separation of the A 
and B subunits [102]. Toxins belonging to this family include diphtheria toxin (DT) 
secreted by Corynebacterium	diphtheriae, Pseudomonas aeruginosa exotoxin A (PE), and 
one of the virulence factors secreted by Vibrio	cholerae, cholix toxin (Cho) [101, 104, 105]. 
The A subunit of DT, PE and Cho is covalently linked to one B subunit that interacts with a 
single membrane receptor. The cellular receptors for DT and PE have long been identified 
as the heparin-binding epidermal growth factor-like precursor [106, 107] and the low 
density lipoprotein receptor-related protein 1 (LRP1), respectively [108]. The receptor for 
cholix remains unknown [105]. On the contrary, cholera toxin (CT) and Shiga toxin (Stx) 
present the characteristic structure of AB5 toxins, in which the A subunit is non-covalently 
associated to a pentamer of B subunits, each interacting with a single receptor. The B 











The medical benefit of bacterial toxins has been demonstrated by the construction of 
recombinant immunotoxins (RITs), which are recombinant fusion proteins that have been 
engineered to replace the receptor-binding domain of the toxin by a ligand or variable 
fragment (Fv) of a monoclonal antibody (Figure 1-6) [25]. The toxin is delivered to the 
target cell by the new targeting moiety whereby it enters the cell and kills it. 
DT, PE and the more recently identified cholix toxin, have been widely used to create new 
immunotoxins [25, 112, 113]. These proteins are all ADP-ribosylating toxins and share 
similar structures. In fact, they are composed of three distinct structural and functional 
domains. Domain I is responsible for cell-recognition and receptor-binding, while domain 
II mediates protein transport inside cells. Domain III is the catalytic domain carrying the 
cytotoxic activity [114].  Domains I and II compose the A subunit and domain III 
constitutes the B subunit. While PE and cholix domains I and III are located at the N- and 
C-termini of the protein, respectively, the orientation of DT is reversed, with its receptor-
binding and catalytic domains positioned at the C- and N-terminal extremities of the 
sequence, respectively [114]. 
RITs are highly toxic and have been widely studied as a strategy for the treatment of 
different types of cancer such as B cell malignancies (RIT moxetumomab pasudotox), or 
lung cancer and mesothelioma (RIT SS1P). These RITs employ a strategy whereby the 
receptor-binding domain is replaced by a disulphide-stabilised Fv that targets the CD22 
receptor and mesothelin, respectively. Both of these RITs are derived from PE and have 
reached clinical trials [115-120]. Similarly, a RIT constructed from DT and targeting the 
interleukin-2 receptor (denileukin diftitox) was approved by the FDA for treatment of T-
cell lymphoma [120-122]. Compared to other cancer treatments, RITs selectively target 
cancer cells by recognition of specific cell-surface antigens, resulting in reduced toxicity 
issues for healthy tissues. Immunogenicity, leading to the development of neutralizing 
antibodies against the toxic domain present in the RIT, is the major obstacle hindering the 
development of RITs. In order to overcome this challenge, several strategies have been 
envisaged, including elimination of immunogenic B or T cell epitopes by mutation [123-





   
Figure 1-6 – ADP-ribosylating toxins are reprogrammed into immunotoxins for 
therapeutic purposes.  (A) Immunotoxins are recombinant proteins in which the 
cell-recognition domain of the toxin has been replaced by another cell-binding 
ligand or antibody. (B), (C) and (D) Ribbon representations of ADP-ribosylating 
toxins PE, Cho and DT, respectively (PDB_ID: 1IKQ, 2Q5T and 1F0L, respectively). All 
three proteins are composed of a cell-binding domain, a translocation domain, and a 
catalytic domain. Cell-binding, translocation and catalytic domains are represented 
in blue, green and red, respectively. Figures were generated using PyMOL [128]. 
1.2.3 PE	intoxication	pathway	in	non-polarised	cells	
 
The cytotoxic pathway used by PE is now well characterised (Figure 1-7). In the 
extracellular milieu, carboxypeptidases can cleave the C-terminal lysine residue of the 
REDLK sequence carried by the protein in order to reveal the endoplasmic reticulum (ER) 
localisation sequence REDL [129]. PE then binds to the LRP1/B transmembrane receptor 
(also called CD91) [108, 130] and is internalised via receptor-mediated endocytosis (RME) 





which undergoes proteolytic cleavage within the TGN by furin (recognition sequence: 
RHRR) [132]. Mature LRP1 consists in a non-covalently associated heterodimer, 
constituted of an extracellular (515 kDa) α-chain and a transmembrane (85 kDa) β-chain. 
This proteolytic processing was shown to be dispensable for intracellular trafficking but 
suggested to be required for normal receptor activity [132]. The cytoplasmic domain of 
LRP1 is phosphorylated and carries multiple potential endocytosis motifs including two 
NPXY, one YXXL and two dileucine motifs [133]. Li et	 al (2000) have shown that the 
majority of LRP1 endocytosis is mediated by the YXXL and the distal dileucine motifs, 
whereas the two NPXY motifs and the proximal dileucine motif do not contribute to initial 
endocytosis [133]. Moreover, phosphorylation of this domain is mediated by protein 
kinase A at residue Ser76 and also contributes to RME [134]. The extracellular part of 
LRP1 can be cleaved, resulting in the formation of a soluble receptor which remains non-
covalently bound to the transmembrane domain, retains ligand-binding capacity and acts 
as a decoy receptor [135]. A role for soluble LRP1 has also been suggested in inflammation 
[136]. The impact of soluble LRP1 on PE intoxication pathway remains unknown. 
 
Following RME, PE-loaded vesicles traffic to the early endosome (EE), where a decrease in 
pH triggers a conformational change of the protein [137], allowing a furin cleavage site to 
be cut between residues Arg279 and Gly280 [138, 139]. This cleavage results in the 
separation of the polypeptide backbone between subunits A and B, and has been shown to 
be required, but not sufficient for, toxin activation, as the two fragments remain covalently 
linked by a disulphide bond between C265-C287 [140]. From the EE, PE was shown to 
exploit several pathways in order to reach the cytosol. In one scenario, the toxin can follow 
a Rab9/Arf1-dependent pathway which drives it to the late endosomes (LE) and further to 
the trans Golgi network (TGN) where interaction between the C-terminal REDL sequence 
and KDEL receptors (KDEL-R) facilitates its retrieval to the ER [141]. In another scenario, 
PE can traffic directly from the EE to the TGN using a Rab6/Syn16-dependent route, and 
subsequently transport to the ER using a lipid-dependent sorting pathway [142]. While 
Chaudhary et	al (1990) demonstrated that the cytotoxic activity of PE in Swiss mouse 3T3 
cells is fully dependent on the Rab9-mediated pathway and the presence of the REDL 
sequence [143], Smith et	al (2006) showed that in HeLa cells, PE can use either pathway to 
reach the ER [142]. Therefore, the intracellular trafficking mechanism used by the toxin 
may be cell-dependent. McKee and FitzGerald (1999) showed that in the ER, the 
disulphide bond linking subunits A and B is reduced by protein-disulphide isomerases 
(PDIs) or PDI-like enzymes, resulting in the formation of two fragments of 37 kDa and 28 





fragment is then transported to the cytosol. Although no direct evidence has been 
reported yet, PE might associate with the Sec61p translocon pore and exploit the ER-
associated protein degradation (ERAD) pathway to exit the ER and reach the cytosol [144, 
145]. There, the A subunit functions enzymatically to ADP-ribosylate eukaryotic 
elongation factor 2 (eEF2) and block its ability to transfer an ADP-ribosyl group from 










Figure 1-7 – PE intoxication pathway in NP cells. 1) PE binds to LRP1 on the cell 
surface and is internalised via RME. 2) In the endosome, PE is cleaved by furin at a 
site in domain II though the two fragments remain linked by a disulphide bond. 3) 
PE is transported to the Golgi network using a Rab6- or Rab9-dependent pathway 
((a) and (b), respectively). There, it interacts with KDEL-R via its C-terminal REDL 
sequence. 4) Interaction with KDEL-R results in the transport of PE to the ER in a 
retrograde manner. 5) In the ER, the disulphide bond is reduced by PDIs. 6) Only the 
A fragment retro-translocates to the cytosol using Sec61p. 7) In the cytosol, PE 
catalyses the ADP-ribosylation of eEF2 leading to arrest of protein synthesis and cell 


































































Most extracellular components internalised following RME are transported to the EE, 
where they are either directed to the recycling endosome (RE) and further carried to the 
plasma membrane (receptors), or transferred to lysosomes through the LE for 
degradation (cargos) [148, 149]. Interestingly, bacterial toxins hijack the early endocytic 
pathway to penetrate target cells and traffic to their destination within cells, but avoid 
lysosomal degradation [104]. How this is achieved remains unclear. It has been suggested 
that following exposure to low pH in the EE, some bacterial toxins would undergo a 
conformational change that would allow them to escape lysosomal degradation [101, 150-
152]. Although PE was demonstrated to experience such a transition in acidic conditions, 
the conversion remains poorly characterised and the mechanism used by the toxin to 
evade endosomes has yet to be established [150, 153, 154]. 
Two trafficking routes from the plasma membrane to the Golgi can be exploited by PE, but 
the mechanisms involved in sorting the toxin to the Rab6- or Rab9- dependent pathway 
remain incompletely understood. Recent studies by Carter (2014) suggested that the 
monosialoganglioside GM1 could be involved in directing PE to follow one route or the 
other [27]. GM1 is the host receptor for CT [109, 155, 156] and, as a ganglioside, is 
composed of a hydrophilic head group linked to a hydrophobic ceramide moiety which 
anchors the lipid into the cell membrane. Chinnapen et	al (2012) showed that alterations 
in the ceramide chains led to variations in the intracellular transport of GM1 and 
associated CT molecules [157]. Furthermore, preliminary studies by Mrsny et	al (personal 
communication) suggested that PE could also bind to GM1, which might therefore act as a 
secondary receptor for the toxin and be involved in sorting mechanisms within cells. 
1.2.5 Structure/function	relationship	of	PE	
 
Pseudomonas exotoxin A is the virulence factor secreted by the bacterium Pseudomonas	
aeruginosa. PE is a 66 kDa protein made of 613 amino acids, and analysis of its three-
dimensional crystal structure have shown that the toxin is a single polypeptide chain 
divided into three distinct domains (Figure 1-8) [158]. Domains I and II compose the A 
subunit and domain III constitutes the B subunit. The N-terminal domain is composed of 
domain Ia (1-252), responsible for cell recognition and receptor binding, and domain Ib 





suggested that this Ib domain may be required for secretion by the bacterium [160]. 
Although Ia and Ib are not sequential, they are structurally adjacent. Domain II (253-364) 
is responsible for protein translocation across the cells and intracellular trafficking, and 
the C-terminal domain III (405-613) is the catalytic domain which carries the cytotoxic 
activity of the protein [159]. Domain III contains a terminal KDEL-like sequence (REDLK) 
that is required for cytotoxicity in certain cell lines [143]. The native toxin contains eight 
cysteine residues that are arranged into four disulphide bonds: C11-C15 and C197-C214 
(domain Ia), C265-C287 (domain II) and C372-C379 (domain Ib) [158]. Douglas et	 al 
(1987) have shown that the amino acid Glu553 within domain III is crucial for cytotoxic 
activity, as a punctual mutation replacing it by Asp dramatically reduced the cytotoxicity 
of the mutant protein, termed ntPE [161]. A furin-cleavage site (RQPR) is located within 
the protein’s second domain between Arg279 and Gly280 [138, 162].  
       
Figure 1-8 – (A) Schematic and (B) Ribbon representations of the structure of 
Pseudomonas exotoxin A. The protein is divided into domain Ia (1-252) responsible 
for cell recognition and receptor binding (blue), domain II (253-364) that controls 
protein translocation and contains the furin-cleavage site (green), domain Ib (364-
404) (yellow) and domain III (405-613), which is the enzymatic domain of the toxin 
(red). Disulphide bonds are indicated orange in (A). Note the deletion of E553 in 
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As previously described (Section 1.1.4), one of the hurdles in oral delivery of protein 
therapeutics is the presence of an impermeable layer of polarised epithelial cells in the 
intestine. Macromolecules are too large to transport through this barrier using the 
paracellular pathway, and most of them are too hydrophilic to passively cross the lipid 
bilayer of cell membranes. Remarkably, PE specifically targets non-polarised cells in the 
body, especially antigen-presenting cells present in the submucosal space, and also 
appears to translocate across polarised epithelial cells. The transcytosis pathway used by 
the toxin to traffic through polarised cells is currently poorly understood. However, this 
characteristic was exploited, and PE has been used as a tool for mucosal immunisation 
[163, 164]. 
Alternatively, PE has been used for intracellular delivery of biologics by replacement of its 
catalytic domain by a therapeutic protein. Mohammed et	al (2012) exploited PE’s ability to 
reach the cytosol following internalisation and showed that fusion of a cell-penetrating 
peptide (CPP) sequence to the N-terminus of PE domain II facilitated the cytosolic delivery 
of a cargo protein [165]. 
Recently, Carter (2014) showed that PE could not only deliver siRNA into macrophages to 
elicit a knockdown effect, but also transport the siRNA cargo across polarised cells and 
deliver it into macrophages [27]. Furthermore, Mrsny et	 al (personal communication) 
showed that a molecule of green fluorescent protein (GFP) attached to the C-terminal of 
ntPE could be carried across intact epithelium both in	 vitro and in	 vivo. Besides, 
replacement of PE domain III by GFP, rat or human growth hormones led to the same 
observation. These studies have concluded that ntPE is organised in a carrier-cargo 
format: the first two domains being essential for transport across polarised cells, while 
presence of domain III is not required for transcytosis (Figure 1-9). A remarkable fact is 
that cargo proteins seemed fully functional after transport across the epithelial layer. 
These findings suggest that ntPE could be used as a carrier for delivery of orally 







Figure 1-9 – PE is constructed on a carrier-cargo format and could be used as a drug 
delivery system. PE can transport a C-terminal molecule of GFP (dark green) across 
polarised monolayers, and replacement of domain III (red) by GFP results in the 
same outcome. Therefore domain I (blue) and domain II (light green) could be used 
as a carrier system for delivery of protein therapeutics (purple) across the 
intestinal barrier. The carrier domain constituted of PE domains I and II (residues 
1-364) will be referred to as PE364. 
Jørgensen et	al (2008) characterised a new ADP-ribosylating toxin, cholix toxin (Chapter 
4), which presents striking structural similarities with PE [105]. Both proteins are divided 
in three distinct domains, critical disulphide bonds align in each toxin, and sequence 
alignment revealed that they share 33% identity [105]. While PE originates from the 
airway bacterium Pseudomonas	aeruginosa, cholix is the virulence factor secreted by the 
intestinal pathogen Vibrio	cholerae and, if operating in a similar way to PE, might therefore 
be more efficient than PE with regards to oral drug delivery. It therefore appears essential 
to determine if the similarities observed between the structures of the two toxins extend 
to their respective functions, and if cholix could also be able to carry proteins across 
polarised epithelial cells.  
For these reasons, it is crucial to study the transcytosis mechanisms of both PE and cholix 
in polarised cells to further understand the potential and limitations of these toxins as 
protein carriers for oral drug delivery. 
1.2.7 Potential	cargo	proteins	
 
The use of PE (and potentially cholix) as a vehicle for the transport of biopharmaceuticals 
(such as therapeutic proteins and peptides) across the intestinal epithelial cell barrier 
would undoubtedly improve delivery prospects for this class of therapeutic agents. 
However, not all protein therapeutics would represent appropriate cargo drugs for this 





the body at high concentrations would not constitute a plausible candidate, as such 
elevated quantities would probably not be achieved following oral administration. 
Therefore, cargo proteins would have to be judiciously considered with regards to their 
target site and mechanism of action as well as the dose they need to be delivered at in 
order to show therapeutic effects. Here, the human growth hormone and interleukin-10 
are proposed as potential cargo candidates. 
Human growth hormone 
Human growth hormone (hGH) is a peptide hormone that stimulates cell growth, 
reproduction and regeneration in tissues [166]. It has been broadly used as a medicine to 
treat human diseases such as growth hormone deficiency syndrome or AIDS-associated 
wasting [167, 168] and is, at present, mainly administered via subcutaneous or 
intramuscular injections [169, 170]. Due to its most common use in paediatric patients, 
development of a non-injectable dosage form would greatly improve patient compliance. 
As the highest concentration of growth hormone receptors is found in the liver [171], oral 
delivery of this protein using PE as a vehicle would result in direct absorption following 
administration (first-pass effect), thereby increasing protein targeting and making hGH a 
possible cargo candidate. 
Interleukin-10 
Interleukin-10 (IL10) is an anti-inflammatory cytokine that plays a central role in 
immunoregulation and inflammation by limiting and ultimately terminating inflammatory 
responses [172, 173]. IL10 is being investigated as a potential treatment for several 
diseases, including inflammatory bowel disease, malignant neoplasms, skin disorders (e.g. 
psoriasis and reduction of scarring), rheumatoid arthritis and hepatitis C [172, 174, 175]. 
In these studies, IL10 was administered by subcutaneous or intravenous routes and was 
found to induce side-effects (flu-like symptoms) at doses of up to 100 µg/kg [176]. 
Because the IL10 receptor is particularly expressed at the surface of immune cells [176], 
oral administration of IL10 would enable its targeted delivery to the cells of the mucosal 
immune system in the intestine, and would therefore allow for a decrease of the doses 






1.3 Aims and objectives 
 
Despite all the research that has taken place over the years, the mechanism that allows PE 
to escape lysosomal degradation and traffic through cells remains unclear. A possible role 
for GM1 in this process has been suggested, but no evidence yet exists to substantiate this 
hypothesis. Furthermore, although the catalytic activity of bacterial toxins has been widely 
used to produce immunotoxins and kill targeted harmful cells, their ability to traffic 
through intact polarised epithelial cells and carrier-cargo organisation has not been fully 
investigated.  
Therefore, the aim of this project was two-fold. Firstly, some aspects of the intracellular 
trafficking of PE, which appear crucial to explain its ability to transport across cells, were 
investigated. Secondly, the ability of bacterial toxins to cross epithelial barriers and their 
potential as vehicles for oral delivery of macromolecular drugs were explored. Defining 
the interactions that govern the trafficking route exploited by PE within a cell might help 
enhance its potential as drug carrier.   
In Chapter	 3, the conformational change experienced by PE in acidic conditions was 
investigated in terms of protein size, structure rearrangement and domains/residues 
involved. This chapter aimed to define the characteristics of this transition and 
understand its role in the protein’s escape from the intracellular degradation pathway that 
terminates in delivery to lysosomes. 
Chapter	4 describes the study of the interaction between PE and GM1 and its impact on the 
protein’s intracellular trafficking route. The aim here was to provide a better 
understanding of the role of GM1 as a possible secondary receptor for PE. 
Chapter	 5 investigates the respective and combined effects of toxin truncation and 
addition of a cargo protein on the trafficking of PE. This chapter aimed to characterise 
some of the structural requirements for PE to function as an efficient drug carrier in non-
polarised cells and across the intestinal epithelium. 
In Chapter	6, the effects of pH on the conformation of cholix were examined, along with the 
protein’s interaction with GM1 and the effects of truncation and attachment of a cargo 
molecule. The aim of this chapter was to provide a better understanding of the 
intracellular pathway used by cholix, and to supply sufficient information to allow for a 












2 GENERAL MATERIALS AND 
METHODS 
2.1 Cell culture 
 
Caco-2 cells were obtained from American Type Culture Collection (ATCC). This cell line 
was originally derived from a human colorectal adenocarcinoma [177].  
M40-1 hybridomas were a gift from Dr David FitzGerald (NCI/NIH, Bethesda, MD). These 




2% EDTA solution: 0.5 g EDTA dissolved in 25 ml PBS and sterile-filtered using a 0.2 μm 
filter 
0.25% trypsin/0.02% EDTA solution:   100 ml 10X trypsin 
        10 ml 2% EDTA solution 
        890 ml sterile PBS 
 






Different media were employed in order to culture various cell lines. 
- Caco-2 cells growth medium: DMEM containing 10% heat-inactivated foetal bovine 
serum (FBS) and 50 IU of each penicillin/streptomycin (P/S) 
- M40-1 hybridomas growth medium: RPMI containing 10% heat-inactivated FBS and 
50 IU P/S 
- M40-1 hybridomas secretion medium: RPMI containing 50 IU P/S 
2.1.3 Subculture	of	adherent	cells	
 
Caco-2 cells are adherent cells and were trypsinized one to three times a week in order to 
maintain them in the exponential phase and at a desired confluency of 70-80%. After 
trypsinization, they were seeded into T75 flasks in fresh growth medium. 
Medium was removed from flasks and discarded. Cells were washed with PBS and 
incubated with 0.25% trypsin/0.02% EDTA at 37 °C under 5% CO2 until they detached. 
The trypsin medium was then inactivated by adding growth medium in a 1:1 ratio. The 
resulting suspension was centrifuged at 125 x g	for 10 min. Pelleted cells were suspended 
in fresh growth medium, counted under a light microscope using a haemocytometer and 
diluted before being seeded at an appropriate density into a new T75 flask. 
2.1.4 Subculture	of	suspension	cells	
 
M40-1 hybridomas are suspension cells that were grown in T175 flasks. When the cell 
density reached ~1 x106 cells/ml, 90% of the cell suspension was aspirated and replaced 
by fresh complete growth medium. 
2.1.5 Thawing	and	freezing	cell	lines	
 
Vials containing frozen cells were removed from liquid nitrogen storage and quickly 
thawed by gently swirling the tube in a 37 °C water bath. The cells were added drop wise 
to 10 ml of pre-warmed complete growth medium, gently mixed, and spun at 125 x g	for 
10 min. The pellet was subsequently suspended in complete growth medium. Cells were 
seeded in a T25 flask and subcultured as described in 2.1.3 after reaching confluency.	




Cells were frozen while still in the log phase of growth. They were trypsinized and 
centrifuged at 125 x g for 10 min before being suspended in freezing medium (DMEM or 
RPMI + 20% FBS + 10% DMSO) at a density of ~1 x106 cells/ml. Aliquots were placed in 
cryotubes and frozen slowly by storing initially at -20 °C for 1 h, followed by -80 °C 
overnight before being transferred to liquid nitrogen the following day.  
2.2 Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western blot (WB) 
2.2.1 SDS-PAGE	
2.2.1.1 Recipes	
Reducing sample buffer 2X (1ml): 
Reagent Volume (μl) 
4X NuPAGE® LDS buffer  500 
NuPAGE® reducing agent  200 
dH2O  300 
 
Running buffer (Tris-Glycine) 10X (1 l): 
Reagent Weight (g) 
Tris 30.3 
Glycine 144 
Sodium dodecyl sulphate (SDS) 10.0 
 
Staining solution (1 l): 
Reagent Amount 
Coomassie brilliant blue R-250 (mg) 500 
Ethanol (EtOH) (ml) 400 
Glacial acetic acid (AA) (ml) 100 
dH2O (ml) 500 
 




Destain solution (1 l): 
Reagent Volume (ml) 
Methanol (MeOH) 100 
Glacial AA 70 
dH2O 830 
 
Polyacrylamide gels recipe for 10 gels, 12% Bis-tris acrylamide, 1 mm thick gels: 
Resolving gel: 
Reagent Volume (ml) 
MQ H2O 24.0 
40% Bis-Tris acrylamide 16.8 
1.5 M Tris-HCl pH 8.8 14.0 
10% SDS 0.560 
10% ammonium persulfate (APS) 0.560 
Tetramethylethylenediamine (TEMED) 0.056 
 
Stacking gel: 
Reagent Volume (ml) 
MQ H2O 11.6 
40% Bis-Tris acrylamide 3.00 
0.5 M Tris-HCl pH 6.8 5.00 
10% SDS 0.20 
10% APS 0.20 
TEMED 0.02 
 
All the resolving gel reagents were mixed together and poured into gel cassettes to about 
75% total volume. A layer of butanol was applied in the remaining volume to ensure that 
the gel set flat and that they were no bubbles. Gels were left to polymerise for 45 min. 




Once set, the butanol was discarded and the stacking gel solution applied. Gel combs 
containing either 10, 12 or 15 wells were inserted into the stacking gel at the top of the 
cassette prior to polymerisation and gels were left to set. 
2.2.1.2 Method	
 
A fully polymerised gel was placed in an XCellTM Sure Lock® Mini-cell tank with running 
buffer. Samples were mixed with reducing sample buffer in a 1:1 ratio and loaded in the 
wells. The first well was generally filled with 5 μl of a standard protein ladder (10-170 
kDa). Gels were run for 35-40 min at 250 V. 
2.2.1.3 Coomassie	staining	
 
Following sample separation, gels were incubated overnight in Coomassie stain solution 
on a rocking platform. They were then destained as many times as required in order to 
observe the bands. 
2.2.1.4 Silver	staining	
 
Gels were silver-stained using the SilverXpress® Silver staining kit. Following sample 
separation, gels were fixed in MeOH:AA:MQ H2O in a 10:2:9 ratio for 10 min on a rocking 
platform. They were then sensitized, stained and developed according to the 




Transfer buffer (1 l):  
Reagent Amount 
Tris (g) 3.0 
Glycine (g) 14.4 
MeOH (ml) 200 
dH2O (ml) 800 




Tris Buffer Saline (TBS) (1 l): 
Reagent Volume (ml) 
Tris, HCl 1M pH 8.0 (ml) 10.00 
NaCl 4M (ml) 37.50 
dH2O (ml) 952.5 
 
TBS-T: 1 l of TBS + 1 ml Tween-20 
Blocking solution: depending on the antibody, dissolve 2.5 g of either non-fat dry milk or 
2.5 g bovine serum albumin (BSA) in 50 ml TBS-T. 
2.2.2.2 Method	
 
Following SDS-PAGE, proteins were transferred to a 0.2 μm polyvinylidene difluoride 
(PVDF) membrane at 30 V (170 mA) for 1.5 h using XCell IITM Blot Module. The membrane 
was briefly washed with distilled water, blocked for 1 h at room temperature (RT) and 
incubated overnight at 4 °C with a primary antibody diluted in TBS-T (Table 9-2). The 
membrane was then washed three times with TBS-T before being incubated for 1 h at RT 
with an enhanced chemiluminescence (ECL)-linked secondary antibody diluted in TBS-T 
(Table 9-3). The membrane was washed again three times with TBS-T, incubated with the 














2.3 Cloning of PE364-hGH and Cho386-hGH 
 
Human growth hormone (hGH) was earlier suggested as a cargo protein that could be 
orally delivered in association with PE or possibly cholix. It is a 22.1 kDa protein whose 
nucleotide sequence contains 573 bp coding for the mature protein.  A 24-nucleotide long 
N-terminal pre-sequence was engineered by Goeddel et	 al (1979) and inserted into 
pHGH107 to allow synthesis and secretion of hGH in microbial cells [178]. In order to test 
the ability of PE or cholix to transport hGH across polarised epithelium, two fusion 
proteins were engineered, composed of either PE364 or Cho386 (residues 1-364 and 1-
386, respectively) linked to a C-terminal hGH molecule via a flexible poly glycine-serine 
linker. The resulting proteins were called PE364-hGH and Cho386-hGH. 
The cloning strategy followed and primers employed for polymerase chain reaction (PCR) 
and sequencing are detailed in Figure 2-1 and Table 2-1, respectively. 
Table 2-1 – Sequences of primers used during cloning of PE364-hGH and Cho386-
hGH. PCR and S indicate primers used for PCR and sequencing, respectively. 
Name PCR/S Sequence 
hGH_F PCR 5’-ACTCTTAAGTTCCCAACTATACCACTATCTCGTCTATTCGAT-3’ 
hGH_R PCR 5’-AGTCGAATTCGAAGCCACAGCTGCCCTCCAC-3’  
GS linker PCR 5’-GGTAGTGGTAGTGGTTCTGGTAGT-3’ 
Cholix_F PCR 5’-CCAATTCATATGGTCGAAGAAGCTTTAAAC-3’ 
Cho386_R PCR 5’-CCATATACTAFTATAATCGTTATAGATCTGACG-3’  
T7_F S Provided by Source Bioscience 
PE_Nterm_F S 5’-CAAATGGGCGGTAGGCGTGTAC-3’ 
PE_mid_F S 5’-CAACCAGCTCAGCCACATGTC-3’ 
PE_mid_R S 5’-GACATGTGGCTGAGCTGGTTG-3’ 
PE364_F S 5’-CGACCAGGTGATCCGCAAC-3’ 
Cho_mid_F S 5’-CGGTAACGCGTCCTGAAC-3’ 
Cho_mid_R S 5’-GCCACCAAACCAATTATCCCCT-3’ 
Cho386end_R S 5’-CTTGTGCACCCGCACTGGT-3’ 





Figure 2-1 – Cloning of PE364-hGH and Cho386-hGH. PE364 and Cho386 are orange 
and purple, respectively, GFP is green, hGH is light grey, and the ampicillin 
resistance gene is depicted yellow. 






hGH was amplified from pHGH107 (ATCC) by PCR using Phusion High-Fidelity DNA 
Polymerase and either GC buffer, GC buffer + DMSO or HF buffer according to 
manufacturer’s instructions. The forward (hGH_F) and reverse (hGH_R) primers carried 
an AflII and EcoRI restriction sites, respectively. The thermocycling conditions used to 
amplify the DNA fragment are detailed in Table 2-2. 
 
Table 2-2 – Thermocycling conditions used for amplification of hGH from pHGH107. 
 Step Temperature (°C) Duration 
1 Initialisation 95 5 min 
2 Denaturation 98 30 sec 
3 Annealing 60 30 sec 
4 Elongation 72 60 sec 
5 Amplification Go to step 2 20 x 
6 Final elongation 72 5 min 
7 End 10 - 
 
pPE364-GFP is a plasmid containing PE364 linked to a C-terminal GFP inserted between 
the AflII and EcoRI restriction sites (Figure 2-1). The two protein sequences are separated 
by a poly glycine-serine linker of SGSGSGSGS (5’-AGTGGTAGTGGTAGTGGTTCTGGTAGT-
3’). It also includes an N-terminal 10X His tag and a resistance gene for ampicillin. 
Both pPE364-GFP and the amplified hGH fragment were digested by the restriction 
endonucleases AflII and EcoRI-HF® in the conditions specified by the manufacturer and 
purified by agarose gel electrophoresis (1% agarose in 40 mM Tris containing 20 mM AA 
and 1 mM EDTA at pH 8.0, 20 min) using GeneJETTM Gel Extraction Kit. The digested 
plasmid and hGH fragment were then ligated together using Quick Ligation Kit and 10 μl 
competent DH5α cells were transformed with the resulting plasmid, termed pPE364-hGH 
(DH5α) (Figure 2-1). This plasmid was further transformed into 10 μl competent One 
ShotTM BL21 StarTM cells for expression of the fusion protein PE364-hGH, and labelled 
pPE364-hGH (BL21).  






The sequence of Cho386 was obtained from pETCHO, a plasmid that encodes for the full-
length, non-toxic, cholix sequence (Appendix 1, Figure 9-1). It was amplified by PCR using 
the Phusion High-Fidelity DNA Polymerase and the same thermocycling conditions used 
for amplification of hGH (Table 2-2). The forward (Cholix_F) and reverse (Cho386_R) 
primers contain the NdeI and SpeI restriction sites, respectively. 
Both pPE364-hGH (DH5α) and the amplified Cho386 fragment were digested using NdeI 
and SpeI-HF® endonucleases before being ligated together using Quick Ligation Kit. The 
plasmid obtained after transformation of 10 μl competent DH5α cells was named 
pCho386-hGH (DH5α) (Figure 2-1). This plasmid was used for further transformation of 
10 μl competent Shuffle cells for expression of Cho386-hGH and the resulting plasmid was 
labelled pCho386-hGH (Shuffle). 
2.4 Protein expression in E.	coli 
 
For each protein, information about the expression plasmid, calculated molecular weight 
and isoelectric point can be found in Appendix 1 (Table 9-1). 
2.4.1 Expression	of	ntPE	
 
A non-toxic mutant of Pseudomonas	exotoxin A, termed ntPE, was engineered to delete the 
glutamic acid at position 553 [161]. The plasmid containing ntPE (pVC45D) was kindly 
provided by Dr David FitzGerald (NCI/NIH, Bethesda, MD, USA) [179]. 
 
Protein expression in the periplasm 
50 ml of Lysogeny broth (LB) medium containing 50 μg/ml ampicillin was inoculated with 
pVC45D and grown overnight at 37 °C with shaking at 250 RPM. LB medium (1 l) 
containing 50 μg/ml ampicillin was inoculated with 25 ml overnight culture and grown at 
37 °C with shaking at 250 RPM until the OD600 reached 0.6-0.8. Monitoring of the OD600 
was achieved using a NanoDropTM 2000c. The incubation temperature was then dropped 
to 18 °C and the cultures were induced with 0.5 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and grown overnight. 





In order to collect the secreted protein, the outer membrane was broken by osmotic shock, 
releasing the protein present in the periplasm while keeping the cell membrane intact. 
Cells were centrifuged (JA-10 fixed angle rotor on Beckman J2-MC centrifuge) at 6,400 x g 
at 4 °C for 20 min and the pellets were resuspended in 30 mM Tris-HCl, 20% sucrose, pH 
8.0 at 80 ml per gram wet weight and kept on ice. EDTA was added drop wise until a final 
concentration of 1 mM was reached and the cells were incubated on ice for 10 min with 
gentle shaking. They were then centrifuged at 8,000 x g (JA-14 fixed angle rotor) for 20 
min at 4 °C and the supernatants were collected. Pellets were suspended in the same 
volume (80 ml per gram wet weight) of ice-cold water and cells were incubated on ice for 
10 min with gentle shaking. They were then centrifuged at 8,000 x g (JA-14 fixed angle 
rotor) for 20 min at 4 °C and the supernatant was collected and concentrated to 50 ml 
using a Vivaflow 200 with a 30 kDa MWCO membrane. The supernatant was then dialysed 
overnight at 4 °C against 50 mM Tris pH 7.4, 50 mM NaCl, 1 mM EDTA. 
 
Protein purification 
Following overnight dialysis, ntPE was purified by anion-exchange (AE) chromatography 
and size exclusion chromatography as described in Sections 2.6.1 and 2.6.4. 
2.4.2 Expression	of	ntPE	GS	TEV	and	ntCho	GS	TEV	
 
ntPE GS TEV and ntCho GS TEV are modified versions of PE and cholix that are non-toxic 
and were engineered to contain the poly glycine-serine linker of SGSGSGSGS (5’-
AGTGGTAGTGGTAGTGGTTCTGGTAGT-3’) between the protein and a C-terminal TEV 
cleavage sequence (ENLFQS). This sequence is located between two cysteine residues that 
form a disulphide bond. The flexible linker was added to increase cleavage efficiency by 
making the digestion site more accessible to the TEV enzyme. The resulting protein can be 
coupled to various elements (including fluorescent tags or other proteins) via a thiol 
linkage. Both ntPE GS TEV and ntCho GS TEV were soluble when expressed in E.	coli. 
 
Protein expression 
50 ml LB medium containing 50 μg/ml kanamycin was inoculated with plasmids 
containing ntPE GS TEV or ntCho GS TEV and grown overnight at 37 °C with shaking at 




250 RPM. LB medium (1 l) containing 50 μg/ml of kanamycin was inoculated with 25 ml 
overnight culture and grown at 37 °C with shaking at 250 RPM until the OD600 reached 0.6-
0.8. Monitoring of the OD600 was achieved using a NanoDropTM 2000c. The temperature 
was then dropped to 18 °C and cultures were induced with 0.25 mM IPTG and grown 
overnight. Cells were harvested by centrifugation (J2-MC with JA-10 fixed angle rotor) at 
6,400 x g at 4 °C for 20 min. Pellets were suspended in 50 mM Tris pH 8.0, 300 mM NaCl, 
20 mM imidazole in the presence of cOmplete EDTA-free protease inhibitors. Cells were 
then sonicated on ice twice at 30% power 6 during 3 min. Samples were then centrifuged 
(J2-MC with JA-20 fixed angle rotor) at 48,300 x g	at 4 °C for 30 min to remove any 
unbroken cells. The supernatant was collected and dialysed overnight at 4 °C against 50 
mM Tris pH 7.4, 50 mM NaCl, 1 mM EDTA. 
 
Protein purification 
ntPE GS TEV and ntCho GS TEV were purified using anion exchange chromatography 
(Section 2.6.1). The protein-containing fractions were collected and further enriched by 
size exclusion chromatography as described in Section 2.6.4. 
2.4.3 Expression	of	PE	GS	TEV	and	Cho	GS	TEV	mutants	
 
While ntPE GS TEV and ntCho GS TEV were soluble and expressed as described above, 
their respective mutants were insoluble and had to be expressed as inclusion bodies. 
Isolation of proteins expressed into inclusion bodies entails three major steps prior to 
purification: first, the aggregates have to be extracted from the bacterial cytoplasm (cell 
lysis), then isolated from the cellular debris, and finally solubilised and refolded, before 
being purified. 
 
Expression of PE GS TEV and Cho GS TEV mutants as inclusion bodies 
In order to express these proteins as inclusion bodies, 50 ml LB medium containing 50 
μg/ml kanamycin was inoculated with the relevant plasmids and grown overnight at 37 °C 
with shaking at 220 RPM. 
LB medium (1 l) containing 50 μg/ml of kanamycin was then inoculated with 25 ml 
overnight culture (1:40 dilution) and grown at 37 °C with shaking at 220 RPM until the 
OD600 reached 0.6-0.8. Monitoring of the OD600 was achieved using a NanoDropTM 2000c. 




The temperature was then dropped to 16 °C and the cultures induced with 1 mM IPTG and 
grown overnight. 
The cells were centrifuged (JA-10 fixed angle rotor on J2-MC) at 6,400 x g for 20 min at 4 
°C. Pellets were suspended in 50/20 TE buffer (50 mM Tris, 20 mM EDTA, pH 8) and 
lysozyme was added at a concentration of 0.01 mM in order to disrupt the cells. Samples 
were incubated at RT for 30 min on a rocking platform. They were then sonicated on ice 
twice for 1.5 min (power 6, 30%) and incubated for another 30 min at RT on a rocking 
platform to ensure maximal cell disruption. In order to completely disintegrate membrane 
fragments, 0.3 M NaCl and 2% Triton X-100 were added to the samples, which were 
incubated at RT for 30 min on a rocking platform and centrifuged (JA-14 fixed angle rotor 
on J2-MC) at 15,300 x g for 45 min at 4 °C. Pellets were suspended in 50/20 TE buffer 
containing 2% Triton X-100. Samples were homogenised (Tissue Master 240) and 
centrifuged (JA-14 fixed angle rotor on J2-MC) at 15,300 x g for 30 min at 4 °C. Again, 
pellets were suspended in 50/20 TE buffer, homogenised and centrifuged (JA-20 fixed 
angle rotor on J2-MC) at 17,400 x g for 30 min at 4 °C. This step was repeated three times 
in order to wash the pellets from any detergent residues. 
 
Solubilisation of PE GS TEV and Cho GS TEV mutants 
Solubilisation of the aggregates was achieved by complete unfolding of the protein: the 
pellets were suspended in 6 M guanidine-HCl, 100 mM Tris pH 8, 2 mM EDTA. Guanidine is 
a strong chaotropic agent that denatures proteins by disrupting intramolecular 
interactions mediated by non-covalent forces, such as hydrogen bonds and van der Waals 
forces [180]. Samples were homogenised, incubated at RT for 1.5 h on a rocking platform 
and centrifuged (JA-20 fixed angle rotor on J2-MC) at 27,200 x g for 15 min at 4 °C. The 
concentration of soluble protein in the supernatant was then determined by Bradford 
assay. In order to reduce disulphide bonds and further increase protein solubility, 
dithiothreitol (DTT) was added to the supernatant to a final concentration of 10 mg/ml 
and samples were incubated at RT for 1.5 h on a rocking platform. 
 
Refolding of PE GS TEV and Cho GS TEV mutants by dilution and dialysis 
After solubilisation, removal of the denaturant and reducing agent was necessary in order 
to provide the protein with a suitable environment for spontaneous and correct refolding.  
Full-length PE and cholix contain four disulphide bonds [105, 140], and at least three of 
them should be conserved among the mutants. The solubilised protein was added drop 




wise to 100 mM Tris buffer pH 8.0 containing 500 mM L-Arginine, 2 mM EDTA, and 0.9 
mM oxidised glutathione (GSSG) and left stirring overnight at 4 °C. These low molecular 
weight compounds promote correct refolding and disulphide bond formation. Protein 
concentration was maintained at a final concentration < 100 μg/ml to prevent 
aggregation. 
The refolded protein was then dialysed 1:10 against 20 mM Tris pH 8, 100 mM urea. This 
step was performed four times at 4 °C, the dialysis buffer being changed every 3 h. 
Samples were subsequently concentrated using Vivaflow 200 (30 kDa MWCO membrane) 
to an adequate volume for purification, typically about 50 ml. Finally, proteins were 
dialysed overnight at 4 °C stirring against 50 mM Tris pH 7.4, 50 mM NaCl, 1 mM EDTA. 
 
Purification of PE GS TEV and Cho GS TEV mutants 
All proteins were filtered using a 0.45 μm filter and purified using anion-exchange 
chromatography (Section 2.6.1). They were then further enriched using size exclusion 
chromatography (Section 2.6.4). 
2.4.4 Expression	of	Cho-GFP	mutants	
 
ntCho-GFP is a fusion protein constituted of full-length, non-toxic (deletion of E581), 
cholix connected by the previously described poly glycine-serine (GS) flexible linker to a C-
terminal GFP molecule. The resulting protein carries an N-terminal 6X His tag, which 
allows ntCho-GFP to be purified by immobilised-metal affinity chromatography (IMAC). 
While ntCho-GFP was soluble and expressed as ntCho GS TEV, its mutants were insoluble 
and had to be expressed as inclusion bodies. All proteins belonging to the Cho-GFP series 
were purified by immobilised metal affinity chromatography (Section 2.6.2) followed by 
size exclusion chromatography (Section 2.6.4). 
2.4.5 Expression	of	PE364-hGH	and	Cho386-hGH	
 
Both PE364-hGH and Cho386-hGH were insoluble and therefore had to be expressed as 
inclusion bodies using pPE364-hGH (BL21) and pCho386-hGH (Shuffle), respectively. 
Proteins were then purified using AE (Section 2.6.1) and size exclusion chromatography 
(Section 2.6.4). 




The calculated molecular weight and pI values for PE364-hGH and Cho386-hGH are 
presented in Table 2-3. 







PE364-hGH 66.4 5.84 
Cho386-hGH 67.8 5.34 
 
2.5 Antibody expression in mouse hybridomas 
 
In order to express the M40-1 monoclonal antibody, the culture medium containing this 
hybridoma was collected when the cell density reached ~1 x106 cells/ml and spun at 500 
x g	for 10 min. Pelleted cells were suspended and seeded in serum-free medium in triple 
T175 flasks and left to secrete the antibody. After 10 days, the culture medium was 
collected and 0.45 μm-filtered. The filtered medium of at least four flasks was 
concentrated down to ~50 ml using a stirred Amicon-type ultrafiltration cell and dialysed 
overnight against 20 mM sodium-phosphate, pH 7.0 (binding buffer). 
2.6 Protein purification using fast protein liquid 
chromatography 
 
Fast protein liquid chromatography (FPLC) is a technique commonly used to purify 
mixtures of proteins. Here, all chromatography methods were performed using a ӒKTA 
FPLC system with the eluted protein, detected by monitoring absorbance at 280 nm, being 
captured using an automated fraction collector. The letters/numbers indicated above 
protein purification gels and chromatograms therefore correspond to the fractions 
collected from the fraction collector tray used for these studies (Figure 2-2). 





Figure 2-2 – Schematic representation of the trays used with the automated fraction 
collector during protein purification. (A) represents the tray used for ion exchange 
and immobilised metal ion affinity chromatography. X-labelled tubes were used to 
collect flow-through fractions, and tubes placed in rows A-J were used to collect 
elution fractions. (B) represents the tray used to collect fractions following ion 
exchange, protein G or gel filtration chromatography. 
2.6.1 Ion	exchange	chromatography	
 
Ion exchange (IX) chromatography is a technique that allows for separation of proteins 
according to their net charge. It relies on the reversible adsorption of charged molecules to 
opposite charge ions immobilised on a matrix support. The IX columns used in this project 
are anion-exchange (AE) Q columns, i.e. they are functionalised with positively charged 
quaternary amine groups. Proteins bearing a positive net charge do not bind to the 
positively charged beads and thus are eluted first. On the contrary, negatively charged 
proteins adsorb to the support. The stronger their negative charge, the stronger proteins 
will adsorb to the matrix. These molecules are released and eluted from the column using 
a gradient of increasing ionic strength (Figure 2-3).  
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Figure 2-3 – Principle of IX chromatography. On an AE column functionalised with 
quaternary ammonium groups (purple), proteins bearing a net positive charge (red 
and orange) will be eluted first while molecules which overall charge is negative 
(light and dark blue) will bind to the column with more or less strength.  
The sample was applied to an AE column (HiTrap Q HP column) which was eluted with a 
linear gradient of NaCl (0 to 1.0 M) in 50 mM Tris pH 7.4, 1 mM EDTA at a flow rate of 1 
ml/min. Fractions containing the protein were collected and concentrated to 1 ml sample 
using a Millipore 10 kDa MWCO spin filter. 
2.6.2 Immobilised	metal	ion	affinity	chromatography	
 
Proteins carrying an N- or C-terminal His tag can be purified on a nickel column using 
immobilised metal ion affinity chromatography (IMAC). These protein samples were 0.45 
μm-filtered and loaded on an agarose column functionalised with chelating ligands that 
are Ni2+-charged (HisTrap FF column). 
His-tagged proteins bind to nickel ions with high affinity and were eluted from the column 
using a linear gradient of imidazole (20 to 500 mM) in 50 mM Tris pH 8.0, 300 mM NaCl at 
a flow rate of 1 ml/min. Due to their structural resemblance (Figure 2-4), imidazole 
competes with the His tag for Ni2+ binding, progressively releasing the tagged protein from 
the column. Protein-containing fractions were collected and concentrated to 1 ml using 10 
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Figure 2-4 – Molecular structures of imidazole and histidine. 
2.6.3 Immobilised	protein	G	affinity	chromatography	
 
Protein G is a modified version of the bacterial cell wall protein isolated from 
Streptococcus group G. It binds to the constant domain of immunoglobulins from various 
species but lacks the albumin-binding region. Immobilised protein G affinity 
chromatography was used to purify the M40-1 mouse monoclonal antibody against PE. 
M40-1 samples were loaded on a HiTrap protein G HP column, which is functionalised 
with immobilised protein G. The unbound material was washed off with binding buffer (20 
mM sodium-phosphate, pH 7.0), after what the antibody was eluted with 0.1 M Glycine-
HCl, pH 2.7 at a flowrate of 1 ml/min. The collection tubes were prefilled with 1 M Tris-
HCl, pH 9.0 as a precaution to prevent degradation of the antibody in acidic conditions. 
IgG-containing fractions were collected and buffer-exchanged into PBS before being 
concentrated down to 1 ml using 10 kDa MWCO spin filters. 
Several characteristics of the final product were examined by SDS-PAGE and WB. 
Following the gel filtration step, fractions corresponding to the peak that could contain 
antibody were separated by SDS-PAGE and Coomassie stained to confirm the size of the 
final compound.  
To confirm that the final product specifically targeted ntPE as antigen, 10 μg of both the 
toxin and BSA were loaded on a gel and transferred to a PVDF membrane, which was first 
blocked with 5% milk in TBS-T for 1 h at RT before being incubated overnight at 4 °C with 
the collected product. The antibody concentrations used ranged from 1/1,000 to 1/20,000 
from a 1 mg/ml stock solution. The membrane was finally incubated with an anti-mouse 




















Size exclusion chromatography (SEC), also known as gel filtration (GF) chromatography, is 
a technique used to separate molecules according to their size. Proteins migrate through a 
porous matrix at different speeds: large proteins are excluded from the pores of the beads 
and are thus eluted first, while smaller molecules diffuse through these pores and are 
eluted last from the column (Figure 2-5). The molecular weight (MW) and three 
dimensional structure of proteins both affect migration of a compound through the resin. 
Size exclusion chromatography is usually used as the last “polishing” step, in order to 
remove any aggregates that would have co-migrated with the protein of interest during 
the previous purification steps, and to place the protein into a desired buffer appropriate 
for storage and/or subsequent applications. 
 
 
Figure 2-5 – Size exclusion chromatography. While large proteins are excluded from 
the pores of the resin and are eluted first, smaller molecules travel through these 
pores and thus are eluted last from the column. 
The column matrix used for GF chromatography was SuperdexTM 200 HR10/30. It is useful 
to purify samples containing proteins whose MW ranges from 10 to 600 kDa. Samples 
previously enriched by IX, IMAC or protein G chromatography were concentrated down to 
1 ml before being loaded on the GF column and eluted with PBS at a flow rate of 0.5 
ml/min. Components corresponding to the UV peaks were separated by SDS-PAGE to 
identify which fractions contained the protein of interest. 
Initial mixture of proteins
Porous beads
Molecules are eluted from the 
column according to their size
High molecular weight protein
Medium molecular weight protein
Low molecular weight protein




2.7 Determination of protein concentration 
2.7.1 By	UV	spectrophotometry	
 
Concentration of various samples was determined by measuring the absorbance of 
proteins at 280 nm using a NanoDropTM 2000c spectrophotometer. This instrument was 
used in pedestal and UV-VIS modes. A blank measurement was first performed on 1.5 μl of 
the buffer in which the protein was diluted. Then, the absorbance of the sample was 
assessed and, using Beer-Lambert’s law (Equation 2-1), converted to a concentration. 
 




With  c concentration of the protein solution (M) 
  A sample absorbance at 280 nm 
  l path length (cm) 
  ε molar absorptivity (mol-1.l.cm-1) 




Bradford assay is a colorimetric method that involves the use of Coomassie blue to 
quantify proteins in solution. When Coomassie blue binds to a protein in solution its 
absorption maximum shifts from 465 nm (unbound dye, brown) to 595 nm (dye-protein 
complex, blue). Here, Bradford assay was performed using a Coomassie protein assay kit 
according to the manufacturer’s instructions. 
First, a standard curve was established using bovine serum albumin (BSA) samples over 
the 100-1,500 μg/ml working range (Table 2-4). Standards were prepared in the same 








Table 2-4 – Preparation of BSA standards for Bradford assay. Adapted from [182]. 
Vial Volume of diluent (μl) Volume of BSA (μl) 
Final BSA 
concentration (μg/ml) 
A 0 300 at 2mg/ml 2,000 
B 125 375 at 2mg/ml 1,500 
C 325 325 at 2mg/ml 1,000 
D 175 175 of B 750 
E 325 325 of C 500 
F 325 325 of D 250 
G 325 325 of E 125 
H 400 100 of G 25 
I 400 0 0 
 
Each standard, blank (buffer) and protein sample were run on a microplate in triplicate: 
10 μl was added to three microplate wells and 300 μl of Coomassie blue reagent was 
added to each well.  The plate was placed on a microplate shaker for 30 sec and incubated 
at RT for 10 min before absorbance was measured at 595 nm (A595nm). 
After subtracting the average blank value to all other measurements, the standard curve 
representing A595nm vs. BSA concentration was plotted and used to determine the 
unknown protein concentration of each sample. 
2.8 Protein labelling 
2.8.1 TEV	cleavage	
 
Proteins which carry a C-terminal TEV cleavage sequence (ENLYFQS) [183] can be used 
for chemical coupling via thiol linkage (Figure 2-6). The enzyme used for cleavage is the 
AcTEV, which is an enhanced version of the native TEV protease. 2 mg of TEV substrate 
containing protein was diluted into 50 mM Tris-HCl pH 8.0, 0.5 mM EDTA in presence of 
0.5 mM DTT. After addition of the AcTEV enzyme, the mixture was left to incubate for 2 h 
at RT or overnight at 4 °C. The sample was then separated using a Ni2+ affinity 
chromatography column that was eluted with PBS. The protein was finally buffer-
exchanged into PBS and sample concentration was assessed using a NanoDropTM 2000c. 





Figure 2-6 – PE coupling strategy using TEV cleavage. Following cleavage, reduction 
of the disulphide bond and purification, the protein carries a free cysteine that is 
used for further coupling via thiol linkage. 
2.8.2 Protein	coupling	to	a	fluorescent	tag	
 
Thiol reactive Alexa Fluor® dyes carrying a maleimide group (Table 2-5) were added drop 
wise to the TEV-cleaved protein in a 20-fold molar excess. The mixture was incubated at 
RT for 2 h. The sample was then concentrated down to 1 ml using 10 kDa MWCO spin 
filters and purified using GF chromatography. The tagged protein was eluted with PBS at a 
flow rate of 0.5 ml/min. 
 
Table 2-5 – Molecular weight, excitation and emission maximum wavelengths of 
Alexa Fluor® C5 maleimide dyes used in this study. All parameters were obtained 









488 496 519 720.66 
546 556 573 1034.37 
568 578 603 880.92 






Protein biotinylation was achieved using the sulfhydryl-reactive EZ-Link® Maleimide-
PEG2-Biotin reagent (MW = 525.62 g/mol). The biotinylation reagent was dissolved in PBS 
to obtain a 20 mM stock solution and added drop wise to the TEV-cleaved protein in a 50-
fold molar excess. The mixture was incubated at RT for 3 h. At this point, labelling was 
considered complete and the excess biotinylation reagent was removed using a Zeba® 
Desalting Spin Column with a 7 kDa MWCO. 
2.9 Size exclusion high pressure liquid chromatography 
(HPLC) 
 
All experiments were performed on a Flexar HPLC system using a BioSep-SEC-s3000 (300 
x 7.8 mm) size exclusion column. The HPLC system contained a LC column oven, pump, 
solvent manager and UV-VIS detector. Before any run, the column was rinsed with mobile 
phase for 30 min at 1 ml/min. 10 μl of sample was manually loaded on the column and 
injected. For all experiments, samples were run at 1 ml/min in 0.1 M potassium-phosphate 
buffer (kPB), containing 0.1 M NaCl at pH 5.8 or 7.4 at 37 °C for 15 min and the compounds 
eluted were detected by UV measurement at 254 nm. 
2.10 Trypsin digestion 
 
To obtain the first trypsin cut of the protein, 10 μg of protein was diluted up to 10 μl in 
citrate-phosphate buffer containing 0.1 M NaCl at different pH values. The protein was 
then incubated in presence of 0.4 μg trypsin on ice for 30 min. Control samples 
(undigested protein) were prepared by diluting 10 μg protein in PBS before incubation on 
ice. The reaction was stopped by addition of reducing sample buffer in a 1:1 ratio and 
heating at 95 °C for 10 min. Digestion fragments were separated by SDS-PAGE, and gels 
were either stained with Coomassie blue, silver-stained or transferred to PVDF membrane 
for immunodetection. 
For N-terminal sequencing, the bands of interest were cut out of the gel and sent to Alta 
Bioscience Ltd., Birmingham, UK. 




2.11 Dynamic light scattering 
 
Principle 
Dynamic light scattering (DLS) is a technique used to assess the size of particles in a 
monodisperse solution [184]. It measures Brownian motion of the sample, i.e. the random 
movement of molecules caused by collision between particles themselves and solvent 
molecules around them. The larger the particles, the slower they will move. The velocity of 
the Brownian motion is defined by the translational diffusion coefficient D, which enables 






Where  d(H) hydrodynamic diameter of the particle (m)  
   k the Boltzman constant (k = 1.38 m².kg.s-2.K-1) 
	 	 	 T absolute temperature (K) 
    η viscosity of the solvent (kg.m-1.s-1) 
	 	 	 D translational diffusion coefficient (m².s-1) 
The hydrodynamic diameter refers to how a particle diffuses within the solvent and, for a 
protein, represents the diameter of a perfect sphere which has the same translational 
diffusion coefficient as the molecule in solution. Therefore, due to its low limit of detection 
(0.3 nm for a 30% w/v sucrose solution in water [185]), DLS can discriminate between 
two protein conformations if the difference in size or shape between them is sufficient to 
affect their diffusion speed in solution. 
 
Experimental conditions 
Samples were diluted in citrate-phosphate buffer containing 0.1 M NaCl at different pH 
values. Buffers were filtered through Minisart® 0.20 μm filters before use to eliminate dust 
particles present in solution. For each run, 100 μl of sample at 1 mg/ml were dialysed 
against buffer at the desired pH for 2 h at RT using Slide-A-Lyser dialysis devices (10 kDa 
MWCO). The buffer was then changed and dialysis carried on overnight at 4 °C. Samples 
were then filtered through a 0.20 μm filter and introduced in a quartz cuvette, which had 
been rinsed twice with 0.20 μm-filtered water and twice with 0.20 μm-filtered buffer. Size 




measurements were performed on a Zetasizer Nano S at 37 °C using a viscosity of 0.67 
mPa.s. (= 0.000692 kg.m-1.s-1). The instrument was equipped with Zetasizer Software V. 




8-anilinonaphthalene-1-sulfonic acid (ANS) is a dye (Figure 2-7) whose fluorescence is 
minimal in polar solvents such as aqueous solutions, but increases drastically in non-polar 
environments. This increase in fluorescence intensity is accompanied by a blue shift in the 
wavelength of the maximum emission from about 520 nm in water to 464 nm in very non-
polar solvents [186]. ANS readily binds to exposed hydrophobic residues on proteins via 
hydrophobic interactions mediated by the aromatic rings [187]. This binding is reflected 
by alterations in the fluorescence spectrum of the dye, which makes it an ideal probe to 
study protein behaviour in solution, and more specifically to characterise protein 
conformational changes as well as kinetics of folding and unfolding [188, 189], exposure of 
accessible hydrophobic surfaces [190] and ligand binding (displacement assays) [191, 
192]. 
 
Figure 2-7 – Molecular structure of 8-anilinonaphthalene-1-sulfonic acid (ANS). 
ANS is anionic over most of the commonly used pH range and therefore can also bind to 
external cationic sites on a protein’s surface via electrostatic interactions. However, as 
ANS molecules bound to cationic sites exposed to the aqueous solvent are quenched due to 
monopolisation of the charge, it is assumed that the characteristic strong fluorescence 
observed when the dye binds to proteins is due to hydrophobic interactions. 
Here, ANS was used to further characterise ntPE conformational change by investigating 
the effect of pH on the protein surface hydrophobicity. 
 
 





Fluorescence measurements were performed on a Hitachi F-4500 fluorescence 
spectrophotometer connected to a water bath for temperature control. Buffers used for 
these experiments were citrate-phosphate containing 0.1 M NaCl at pH 5.8 or 7.4. Stock 
solutions of ANS 200 µM and protein 3.04 µM were prepared in buffer at both pHs. First, 
fluorescence measurements were carried out on 100 μM ANS alone in buffer in order to 
establish a blank. The dye was then mixed with protein in the corresponding buffer in a 
1:1 volume ratio and fluorescence was measured [193, 194]. Final protein and ANS 
concentrations were always 1.52 μM and 100 μM, respectively.  In all studies, emission slit 
width was 2.25 nm and excitation wavelength was set to 380 nm. Fluorescence spectra 
were acquired by scanning from 400 to 700 nm at a speed of 240 nm/min. Shifts in λem,max 
were obtained by averaging the values collected for several independent runs. The 
difference in fluorescence intensity under various conditions, defined as the ratio  !, was 
examined by comparing the respective areas under the curve (AUC) minus the background 
fluorescence due to ANS alone at the studied pH.  
"# =	
$%	& + (), +. , − $%	(), +. ,
$%	& + (), -. . − $%	(), -. .
 
With AUC = area under curve, P = protein 
When the influence of an additional compound (C) was examined, samples were blanked 
with the fluorescence of ANS + C. 
2.13 Bio-layer interferometry 
 
Principle 
Bio-layer interferometry (BLI) is an optical analytical technique which uses a fibre-optic 
biosensor to measure the shifts in interference patterns between waves of reflected light. 
The biosensor tip is made of two interfaces: an optical layer (reference layer) and a 
biocompatible layer on the surface of the tip (Figure 2-8). Ligand molecules are 
immobilised on the latter and the tip is dipped into an analyte sample. White light is then 
directed down the biosensor and reflects from each of the reference and ligand-coated 
surfaces. The reflected beams can interfere either constructively or destructively, creating 
changing interference patterns at different wavelengths in the spectrum.  As analyte 
molecules bind to the immobilised ligands on the sensor surface, a layer of molecules is 
formed and its thickness increases as more analyte molecules bind to the surface. As a 




result, the distance between the two reflective layers of the tip also increases, resulting in 
changes in the interference pattern detected. These fluctuations are proportional to the 
extent of binding and are hence reported on a sensorgram as a change in wavelength (nm 
shift). Monitoring the spectral shifts in real time provides kinetic data on molecular 
interactions. 
BLI presents several advantages with regards to binding kinetics and affinity 
measurements. In fact, due to the use of standard microplates (96- or 384-well plates), the 
volume of sample required for analysis can be as low as 40 μl. Moreover, BLI is not a 
destructive technique, and depending on the immobilisation method employed, samples 
can be recovered intact after the assay. The biosensors used are disposable and cost-
effective, and because measurements can be performed in parallel in microplates, assay 
time is significantly reduced (compared to surface plasmon resonance for instance). 
Finally, high sensitivity allows for measurement of binding affinity up to the millimolar 
range, which represents a considerable improvement compared to techniques such as 
ELISA or immunoprecipitation, where the requirement for washing steps might result in 
dissociation between the species studied. 
Here, streptavidin-functionalised biosensors were used to immobilise biotinylated ntPE on 
the sensing surface during BLI measurements (Figure 2-9). This method of ligand 
immobilisation presents several advantages: the interaction between streptavidin and 
biotin is non-covalent but rapid, stable and essentially non-reversible. Moreover, 
biotinylation is performed at neutral pH and therefore gentle on proteins. Finally, the 
coupling can be easily monitored and controlled biotinylation of ntPE in one specific 
location ensured that one molecule of protein was bound per functional group and 










Figure 2-8 – Diagrammatic representation of the principles involved in BLI. A ray of 
white light illuminates the sample, and interference patterns from the reflected 
beams are analysed. Variations in the number of molecules bound on the sensor tip 
surface result in shifts in the interference pattern which are proportional to the 
total number of bound analyte molecules. Adapted from [195]. 
 
 
Figure 2-9 – Streptavidin-functionalised sensor tip. Biotinylated ntPE was 
immobilised on the surface of the biosensor via streptavidin-biotin interactions, 
and the tip was subsequently dipped into a solution of analyte. 
 
 





Studies were performed on an Octet® RED96 instrument (Pall ForteBio Corp., CA, USA). All 
measurements were carried out in 0.1 M potassium-phosphate buffer at 37 °C at a flow 
rate of 1,000 RPM (plate shaking). For each sample, three independent measurements 
were performed in parallel. The biosensor was first exposed to 0.1 M potassium-
phosphate buffer at 37 °C for 60 sec in order to establish a stable baseline. It was then 
immersed in biotinylated protein for 120 sec to allow for immobilisation of the protein on 
streptavidin-coated tips. Protein concentration at the surface was 1 nM. The biosensor 
was exposed to buffer for another 35 sec before being dipped in a 103.6 nM (= 159.5 µg/l) 
solution of GM1. Complex formation was monitored in real time over 120 sec. Finally, the 
biosensor was moved to buffer one last time and dissociation of the protein-GM1 complex 
was monitored over 95 sec. A reference well devoid of attached ligand but exposed to the 
same ganglioside concentration was used to measure the effect of analyte passing through 
the cell, i.e. when the concentration of unbound analyte remained constant. Data were 
collected as sensorgrams representing the evolution of the shift in the interference pattern 
over time. The reference well was subtracted from the raw data and the data obtained was 
then Y- and X-aligned (i.e. the curves were zeroed on baseline and the starts of injection 
were aligned with respect to each other). 
2.14 Generation of antigen-binding fragments (Fab) 
 
The monoclonal antibody (mAb) M40-1 was expressed in mouse hybridomas as explained. 
It was fragmented using Pierce Fab preparation kit following the manufacturer’s 
instructions: 3.8 mg of IgG diluted to a total volume of 500 μl in PBS were incubated in 
presence of papain for 5 h at 37 °C in an end-over-end mixer. The sample was then loaded 
on an immobilised protein A column, and unbound Fab fragments were eluted with PBS. 
Crystallisable fragments (Fc) and intact IgG were later detached from the column using the 
elution buffer provided with the kit (Figure 2-10). Samples collected following the 
different elution washes were separated by SDS-PAGE following mixture 1:1 with reducing 
sample buffer and then maintained at room temperature or heated at 95 °C for 10 min. 





Figure 2-10 – Generation of Fab fragments by enzymatic cleavage. The IgG is 
digested by papain and the resulting mixture of Fc and Fab fragments is run on a 
protein A column, which retains only the Fc fragments and potential undigested IgG. 
After purification, the Fab concentration was assessed by measuring the absorbance of the 
sample at 280 nm using an extinction coefficient of ε = 1.4. 
PE and Fab (M40-1) were then mixed in a 1:1 ratio and the resulting sample was 
subsequently loaded on FPLC gel filtration column for purification of the complex. 
 
2.15 Protein uptake by non-polarised epithelial cells 
 
Caco-2 cells were cultured in complete growth medium on 12 mm glass coverslips in 12-
well plates at a density of ~10 x104 cells/ml. After 48-72 h, cells were washed with fresh 
medium twice and 20 μg of protein diluted in 100 µl fresh medium was applied on the 
cells. For each assay, final molar concentrations are detailed individually in the 
corresponding Results section. Following 2 h incubation at 37 °C, cells were washed three 
times with PBS in order to remove excess protein and fixed using 4% (w/v) 
paraformaldehyde (PFA) in PBS for 20 min. When the Golgi network was visualised, cells 
were subsequently permeabilised and blocked in 5% BSA in PBS containing 0.5% Triton 
X-100 for 1 h at RT and incubated with an anti-GM130 antibody diluted in 3% BSA in PBS 
containing 0.5% Triton X-100 overnight at 4 °C (Appendix 2, Table 9-2). After being 
washed three times with PBS, cells were incubated with an Alexa Fluor® 568 (A568)-
conjugated anti-rabbit secondary antibody diluted in 3% BSA in PBS + 0.5% Triton X-100 
for 1 h at RT (Appendix 2, Table 9-3), washed again and treated with 4',6-diamidino-2-
Ab fragmentation 
by papain
Purification of Fab fragments 
on Protein A column
M40-1 = whole IgG
(150 kDa)
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phenylindole (DAPI) for 20 min before being mounted on microscope slides. Finally, 
samples were observed under confocal microscope (Section 2.18). 
For competition assays, 20 μg of each cholera toxin B subunit (CTB) (final concentration = 
3.5 µM) and protein diluted in 100 µl complete medium were simultaneously applied to 
the cells for 2 h. When applicable, cells were pre-incubated with 1 U/ml neuraminidase for 
15 min or 2 h at 37 °C. A solution containing the protein(s) and 1 U/ml neuraminidase was 
then applied to the cells for 2 h. 
2.16 In	vitro transport assay in polarised epithelial cells 
2.16.1 Transcytosis	
 
Caco-2 cells were plated on Transwell® filters (polycarbonate membrane, 12 mm, 0.4 μm 
pore size) at a density of 70,000 cells/well and grown in 500 µl complete growth medium 
for 14-21 days. The volume of medium applied to the basolateral compartment was 1 ml. 
Transepithelial electrical resistance (TEER) was measured using EVOM2 epithelial 
voltohmmeter and cells were considered polarised when TEER > 350 Ω·cm2. Both apical 
and basolateral compartments were then washed twice with HBSS, and cells were left to 
equilibrate in HBSS for 30 min at 37 °C. The protein was then diluted in 300 µl HBSS and 
applied to the apical compartment of the filters and to a blank well (filter with no cells) in 
order to assess the effect on the polycarbonate semi-permeable membrane on protein 
transport. HBSS from the basolateral well was collected at t = 15, 30, 60, 120 and 240 min 
of incubation and replaced each time with fresh medium. Total basolateral HBSS volume 
was kept constant at 600 µl. Each sample collected was plated in triplicate (90 µl) in a 
black 96-well plate (to minimise fluorescence background), using HBSS as a blank, and 
fluorescence intensity was measured using a fluorescence microplate reader. Excitation 
and emission filters are indicated in Table 2-6. 
Table 2-6 – Excitation and emission filters used for quantification of Alexa Fluor®-











A488 496 519 480 520 
A568 578 603 540 610 
 






Dextran is a polymer of glucose which is unable to transport efficiently across polarised 
epithelial barriers. Therefore, it can be used to assess monolayer integrity by monitoring 
permeability across Caco-2 cells cultured on Transwell® filters. Dextran labelled with a 
fluorescent dye (e.g. fluorescein isothiocyanate (FITC)-labelled dextran) was applied to 
the apical cell surface, and measurement of the amount that transported to the basal 
compartment provided information about the integrity of the cell monolayer. 
After the last time point of a transport study was collected, the filters were washed and 
200 μl of 0.5 mg/ml 4 kDa FITC-dextran were added to the apical compartment. Cells were 
then incubated for 30 min at 37 °C, with the medium from the basal compartment 
collected and its fluorescence intensity measured (excitation and emission filters: 480 nm 
and 520 nm, respectively). 
2.16.3 Cell	preparation	for	confocal	microscopy	
 
Following transcytosis and evaluation of dextran permeability, Transwell® filters were 
rinsed three times with PBS and cells were fixed in 4% PFA for 20 min at RT. After another 
three washes in PBS, cell nuclei were stained with DAPI for 20 min at RT. Membranes were 
then cut off the wells and mounted on microscope slides. 
2.16.4 Analysis	
 
Dextran fluorescence intensities of each sample well (FDex), a blank well (no cells) (FDex,blank) 
and background HBSS (Fbackground) were measured using a microplate reader and used to 





P allows for the normalisation of fluorescence values obtained for each well with regards 
to the well’s dextran permeability. Therefore, the basolateral fluorescence (Fprotein) due to 
protein transport across the monolayer is calculated from the measured fluorescence (F) 
and defined by: 
#8459/:7 	= 	 # −	#1234567	–	# −	#1234567 ∗ &	




2.17 In	vivo transport assay in rat small intestine 
2.17.1 Transepithelial	transport	assay	
 
Adult (7-8 weeks old) male Wistar rats (250-300 g) were anesthetised using 5% 
isoflurane and maintained in an anesthetised state using 4% isoflurane (administered by 
mask) during surgery. A midline abdominal incision was made in order to expose the 
gastrointestinal system. A dose of 1.86 x10-9 mol protein was injected into the lumen of the 
small intestine as a 50 μl bolus in PBS. After 5-10 min, animals were euthanized using CO2 
and a 2 cm tissue section originating at the injection site was collected, cut longitudinally 
and washed free of luminal contents with PBS. Each segment was then fixed overnight in 
4% PFA in PBS at 4 °C. 
2.17.2 Immunohistochemistry	
 
Fixed tissue samples were dehydrated by successive 2 h-immersions in diluted ethanol 
solutions (70, 80, 90 and 100% ethanol). They were then immersed in paraffin for 2 h 
twice before being embedded and placed overnight at 4 °C. Sections of small intestine (5 
μm) were subsequently cut using a microtome and mounted onto polylysine slides that 
were left to dry overnight at RT. 
Paraffin-embedded tissues were rehydrated by successive 5-min immersions into 
Histoclear (solution 1), Histoclear (solution 2), and 100%, 90%, 80%, 70% ethanol 
solutions. They were then washed three times with PBS for 5 min. Antigen retrieval was 
achieved by immersing the slides into boiling 10 mM sodium-citrate buffer at pH 6.0 for 10 
min. Tissue sections were washed three times with PBS for 5 min, permeabilised for 30 
min at RT using 0.2% Triton X-100 in PBS and blocked with 2% BSA in PBS for 1 h at RT. 
Finally, they were incubated overnight at 4 °C in a humidified container with primary 
antibodies diluted into PBS containing 0.1% Triton X-100 and 1% BSA (Appendix 2, Table 
9-2). 
Slides were washed again in PBS and tissue sections were incubated for 2 h at RT with 
fluorescent secondary antibodies diluted in PBS containing 0.1% Triton X-100 (Appendix 
2, Table 9-3). Following another three washes in PBS, slides were incubated with DAPI for 
30 min at RT and rinsed again. Water was used for the last wash in order to remove any 
remaining salts. Slides were finally dehydrated by successive immersion into 70% and 




100% ethanol for a few minutes each, Histoclear 1 for 5 min, 100% ethanol, and mounted 
using Vector Shield mounting medium. 
2.18 Confocal microscopy 
 
Confocal fluorescent images were obtained using a Zeiss LSM 510 META confocal laser 
scanning fluorescence microscope with a 63x objective. Sequential excitation at 405 nm, 
488 nm and 543 nm was achieved using a laser diode and argon and helium-neon (HeNe) 
gas lasers, respectively (Table 2-7). Emission filters BP420-480, BP505-530 and LP550 
were used for collecting blue, green and red fluorescence, respectively. Maximum 
excitation and emission wavelengths (λex and λem, respectively) for the fluorophores used 
are detailed in Table 2-8. Images were analysed using Zeiss LSM Image Browser software. 
The term co-localisation refers to the coincidence of green and red fluorescence, as 
measured by the confocal microscope. 
Table 2-7 – Lasers used for observation of fluorescently-labelled samples in 
confocal microscopy. 
Laser Excitation line (nm) Corresponding fluorophore  
Diode 405 DAPI 
Argon/2 458, 477, 488, 514 GFP, fluorescein (FITC), A488 
HeNe 543 A546, A568 
 
Table 2-8 – Maximum excitation and emission wavelengths of the various 
fluorophores used in confocal microscopy. 
Fluorophore λex (nm) λem (nm) 
DAPI 358 461 
GFP 488 509 
FITC 490 525 
A488 490 525 
A546 556 573 
A568 578 603 




2.19 FlexPred, Protparam and ProtScale 
 
FlexPred is an online software which predicts, from a protein sequence or crystal 
structure, amino acid residues within a protein that are likely to be involved in 
conformational changes due to high flexibility [196, 197]. Here, the crystal structure of PE 
and cholix (PDB_ID: 1IKQ and 2Q5T, respectively) were submitted for estimation of amino 
acids that could be involved in the conformational changes experienced by these proteins. 
ProtParam and ProtScale are also both online software applications. ProtParam was used 
to calculate the molecular weight and isoelectric point (pI) values of the various truncated 
and GFP-tagged versions of PE and cholix [181]. ProtScale was used to calculate and 
represent the profiles produced by three amino acid scale on PE and cholix from each 
protein’s sequence. The scales “% buried residues”, “% accessible residues” [198] and 
“Average flexibility” [199] were here of interest to gain information about the 
conformational change undergone by these two toxins. 
2.20 Statistical analysis 
 
The statistical significance of the data obtained was tested using either an unpaired t-test 
(for comparison of two groups of data) or a 1-way ANOVA followed by Tukey post-hoc 
test. P values < 0.05 were considered to be statistically significant. 
  




2.21 Reagents and Materials 
 






dilactate (DAPI, dilactate) 
D3571 Invitrogen, Paisley, UK 
8-Anilinonaphthalene-1-
sulfonic acid (ANS) 
A1028 Sigma-Aldrich, Dorset, UK 
Acrylamide/bis-acrylamide, 
40% solution 
A7802 Sigma-Aldrich, Dorset, UK 
AcTEV Protease 12575 Invitrogen, Paisley, UK 
AflII restriction endonuclease R0520 New England BioLabds, Herts, UK 
Agarose BP-1356 Fisher Scientific, Loughborough, UK 
Alexa Fluor® C5 maleimide 488 A-10254 Invitrogen, Paisley, UK 
Alexa Fluor® C5 maleimide 546 A-10258 Invitrogen, Paisley, UK 
Alexa Fluor® C5 maleimide 568 A-20341 Invitrogen, Paisley, UK 
Alexa Fluor® 546-conjugated 
anti-rabbit IgG (donkey) 
A-10004 Invitrogen, Paisley, UK 
Alexa Fluor® 568-conjugated 
anti-rabbit IgG 
A10042 Invitrogen, Paisley, UK 
Ampicilin for LB media BP-1760 Fisher Scientific, Loughborough, UK 
Ammonium persulfate A/P470/46 Fisher Scientific, Loughborough, UK 
Anti-Cho386 GS TEV antibody  INNOVAGEN AB, Lund, Sweden 
Anti-GM130 antibody Ab52649 Abcam, Cambridge, UK 
Anti-hGH antibody AF1067 R&D Systems, Abington, UK 
Anti-Pseudomonas exotoxin A 
whole antiserum 
P2318 Sigma-Aldrich, Dorset, UK 




Arginine W381918 Sigma-Aldrich, Dorset, UK 
β-Mercaptoethanol 63689 Sigma-Aldrich, Dorset, UK 
Bovine Serum Albumin (BSA) A7906 Sigma-Aldrich, Dorset, UK 
Butanol B/4800/08 Sigma-Aldrich, Dorset, UK 
Caco-2 cells, C2BBe1 clone CRL-2102 ATCC, Teddington, UK 
Cholera toxin B subunit C9903 Sigma-Aldrich, Dorset, UK 
Cholera toxin B subunit, Alexa 
Fluor™ 488 conjugate 
C22841 Invitrogen, Paisley, UK 
cOmplete EDTA-free protease 
inhibitors 
11873580001 
Roche Diagnosted Ltd., Burgess Hill, 
UK 
Coomassie brilliant blue R-250 BP101 Fisher Scientific, Loughborough, UK 
Coomassie Plus (Bradford) 
Assay Reagent 
23238 Fisher Scientific, Loughborough, UK 
DH5α competent cells C2987 New England BioLabds, Herts, UK 
Dialysis tubing SnakeSkin, 10 
kDa 
10781755 Fisher Scientific, Loughborough, UK 
Dithiothreitol (DTT) R0862 Fisher Scientific, Loughborough, UK 
DMEM cell culture medium 41965039 Invitrogen, Paisley, UK 
DMSO D1435 Sigma-Aldrich, Dorset, UK 
DNA gel loading dye B7021S New England BioLabds, Herts, UK 
ECL Western Blotting Detection 
Reagent 
RPN2209 GE Healthcare, Amersham, UK 
EcoRI-HF® restriction 
endonuclease 
R3101 New England BioLabds, Herts, UK 
Ethanol 32221 Sigma-Aldrich, Dorset, UK 
Ethidium bromide E1510 Sigma-Aldrich, Dorset, UK 
Ethylenediaminetetraacetic 
acid (EDTA) 
BP118 Fisher Scientific, Loughborough, UK 






21901BID Fisher Scientific, Loughborough, UK 
Fermentas PageRulerTM 
Prestained Protein Ladder (10-
170 kDa) 
26616 Fisher Scientific, Loughborough, UK 
Fluorescein-conjugated anti-
goat IgG (rabbit) 
FI-5000 
Vector Laboratories Ltd., 
Peterborough, UK 
Fluorescein Isocyanate (FITC) 
Dextran, 4 kDa 
FD4 Sigma-Aldrich, Dorset, UK 
Foetal bovine serum, heat-
inactivated (FBS) 
16000036 Invitrogen, Paisley, UK 
Glacial acetic acid 27225 Sigma-Aldrich, Dorset, UK 
Glutathione, oxidised G4376 Sigma-Aldrich, Dorset, UK 
Glycine BP381-1 Fisher Scientific, Loughborough, UK 
Guanidine hydrochloride BP178-500 Fisher Scientific, Loughborough, UK 
Hanks’ Balanced Salt Solution 
(HBSS), 1X 
14025050 Invitrogen, Paisley, UK 
Heat inactivated foetal bovine 
serum 
10500-064 Invitrogen, Paisley, UK 
Histo-Clear HS-200 National Diagnostics,  
HRP-liked anti-mouse IgG NXA931 GE Healthcare, Amersham, UK 
HRP-linked anti-rabbit IgG NA934 GE Healthcare, Amersham, UK 
Hydrochloric acid 07102 Sigma-Aldrich, Dorset, UK 
Imidazole 301870010 Fisher Scientific, Loughborough, UK 
IsoFlo® (isoflurape, USP) 05260-05 Abbott Laboratories, Maidenhead, UK 
   
Isopropyl β-D-1-
thiogalactopyranoside (IPTG) 
BPE1755 Fisher Scientific, Loughborough, UK 
L-Arginine W381918 Sigma-Aldrich, Dorset, UK 




L-cysteine 168149 Sigma-Aldrich, Dorset, UK 
L-Glutathione, oxidized G4376 Sigma-Aldrich, Dorset, UK 
Lyso-monosialoganglioside, 
lysoGM1 
G5660 Sigma-Aldrich, Dorset, UK 
Lysozyme chloride L2879 Sigma-Aldrich, Dorset, UK 
M40-1 antibody  David FitzGerald, NIH/NCI, MD, USA 
Methanol 34860 Sigma-Aldrich, Dorset, UK 




Vector Laboratories Ltd., 
Peterborough, UK 
Neuraminidase N2876 Sigma-Aldrich, Dorset, UK 
NdeI restriction endonuclease R0111 New England BioLabds, Herts, UK 
Non-fat dry milk 
 
Morrisons 
NuPAGE™ LDS Sample Buffer 
(4X) 
NP0007 Invitrogen, Paisley, UK 
NuPAGE™ Sample Reducing 
Agent 
NP0009 Invitrogen, Paisley, UK 
One ShotTM BL21 StarTM (DE3) 
chemically competent cells 
C6010 New England BioLabs, Herts, UK 
Tissue-Tek V.I.P.TM Paraffin 62580-08 Science Services, Munich, Germany 
Paraformaldehyde P6148 Sigma-Aldrich, Dorset, UK 
Penicillin/Streptomycin P0781 Sigma-Aldrich, Dorset, UK 
pHGH107 plasmid 31538 ATCC, Teddington, UK 
Phosphate Buffer Saline (PBS) BR0014G Fisher Scientific, Loughborough, UK 
Phusion High-Fidelity DNA 
Polymerase 
M0530 New England BioLabs, Herts, UK 
Primer synthesis  Sigma-Aldrich, Dorset, UK 
   




Protease Inhibitor Cocktail III 
Animal Free for Mammalian 
Cells 
P2302-1 Fisher Scientific, Loughborough, UK 
Rat tail collagen I A10486-01 Invitrogen, Paisley, UK 
RPMI 1640 cell culture medium A1049101 Invitrogen, Paisley, UK 
Shuffle competent cells C3026 New England BioLabds, Herts, UK 
SilverXpress® Silver staining 
kit 
LC6100 Invitrogen, Paisley, UK 
Sodium chloride S9625 Sigma-Aldrich, Dorset, UK 
Sodium citrate, dehydrate W302600 Sigma-Aldrich, Dorset, UK 
Sodium dodecyl sulphate (SDS) S/5200/53 Fisher Scientific, Loughborough, UK 
Sodium phosphate, dibasic 71636 Sigma-Aldrich, Dorset, UK 
Sodium phosphate, monobasic 71507 Sigma-Aldrich, Dorset, UK 
SpeI-HF® restriction 
endonuclease 
R3133 New England BioLabds, Herts, UK 
Sucrose 16104 Sigma-Aldrich, Dorset, UK 
TEMED T/P190/04 Fisher Scientific, Loughborough, UK 
Tris T6066 Sigma-Aldrich, Dorset, UK 
Tri-sodium citrate, dihydrate S1804 Sigma-Aldrich, Dorset, UK 
Triton X-100 X100 Sigma-Aldrich, Dorset, UK 
Trypsin (protein digestion) T1426 Sigma-Aldrich, Dorset, UK 
Trypsin, 10X (cell culture) SV30037.01 Fisher Scientific, Loughborough, UK 
Tryptone T1332 Fisher Scientific, Loughborough, UK 
Tween-20 P1379 Sigma-Aldrich, Dorset, UK 




Vector Laboratories Ltd, 
Peterborough, UK 
Yeast Extract BP1422 Fisher Scientific, Loughborough, UK 









AccuSpinTM 400 Benchtop 
centrifuge 
FB56652 Fisher Scientific, Loughborough, UK 
ӒKTA Explorer FPLC system 
 
GE Healthcare, Amersham, UK 
BioSep-SEC-s3000 GF HPLC 
column  
Phenomenex Inc., Macclesfield, UK 
Centrifure J2-MC 
 
Beckman Coulter Ltd., High Wicombe, 
UK 
Chromera Chromatography 
Data System V 3.3.0  
Perkin  Elmer Inc., West Midlands, UK 
Confocal laser scanning 
microscope  
LSM 510 META Carl Zeiss Ltd., Cambridge, UK 
Costar® 10 ml Stripette® 
Serological Pipets, Sterile 
4488 
Corning B.V. Life Sciences, 
Amsterdam, The Netherlands 
Coverslips, glass, 12 mm 
diameter 
A67761333 Fisher Scientific, Loughborough, UK 
Dialysis flask, 10K MWCO, 
250mL 
87762 Fisher Scientific, Loughborough, UK 
Dialysis tubing 10 kDa 68100 Fisher Scientific, Loughborough, UK 
Disposable gel cassette, 1 mm NC2010 Invitrogen, Paisley, UK 
Disposable PD10 Desalting 
columns 
17-0851-01 GE Healthcare, Amersham, UK 
Evom2 epithelial voltohmmeter EVOM2 
World Precision Instruments, Hitchin, 
UK 
Extra thick blot paper 1703966 Bio-rad, Hertfordshire, UK 
   
F-4500 fluorescence 
spectrophotometer  
Hitachi Ltd., Tokyo, Japan 




Fab preparation kit 10269923 Fisher Scientific, Loughborough, UK 
Fixed angle rotor JA10 
 
Beckman Coulter Ltd., High Wicombe, 
UK 
Fixed angle rotor JA14 
 
Beckman Coulter Ltd., High Wicombe, 
UK 
Fixed angle rotor JA20 
 
Beckman Coulter Ltd., High Wicombe, 
UK 
Flexar HPLC system 
 
Perkin  Elmer Inc., West Midlands, UK 
Fuji X-Ray film 2731261 Fisher Scientific, Loughborough, UK 
Gel Cassette Combs,  1.0 mm, 
12 well 
NC3012 Invitrogen, Paisley, UK 
Gel Cassette Combs,  1.0 mm, 
15 well 
NC3015 Invitrogen, Paisley, UK 
Gel Cassette Combs, 1.0 mm, 10 
well 
NC3010 Invitrogen, Paisley, UK 
Glass coverslips BB018018A0D3 Thermo Scientific Gerhard Menzel 
Glass pasteur pipette FB502553 Fisher Scientific, Loughborough, UK 
GeneJETTM Gel Extraction Kit K0691 Fisher Scientific, Loughborough, UK 
GeneJETTM Plasmid Miniprep K0502 Fisher Scientific, Loughborough, UK 
Haemocytometer AC1000 Hawksley, Lancing, UK 
Hellma® fluorescence cuvettes Z802433 Sigma-Aldrich, Dorset, UK 
HisTrap FF column for ӒKTA 
FPLC system, 1 ml 
17-5319-01 GE Healthcare, Amersham, UK 
HisTrap HP Crude column for 
ӒKTA FPLC system, 5 ml 
17-5248-01 GE Healthcare, Amersham, UK 
HiTrap Protein G HP column for 
ӒKTA FPLC system, 1 ml 
17040403 GE Healthcare, Amersham, UK 
HiTrap Q HP column for ӒKTA 
FPLC system, 1 ml 
17-1153-01 GE Healthcare, Amersham, UK 




ImmEdge hydrophobic barrier 
pen 
H-4000 
Vector Laboratories Ltd, 
Peterborough, UK 
Membrane filter ultrafiltration, 
1 kDa NMWL 
PLAC06210 Fisher Scientific, Loughborough, UK 
Microplate reader, FluoStar 
Omega  
BMG LABTECH Ltd., Bucks, UK 
Microtome Biocut 2035 
Leica Microsystems (UK) Ltd., Milton 
Keynes, UK 
Microscope slide Polysine 
adhesion 
J2800AMNZ Fisher Scientific, Loughborough, UK 
Millipore 0.45 μm filters FDR-050-071N Fisher Scientific, Loughborough, UK 
Millipore 10 kDa MWCO spin 
filter, 15 ml 
UFC901008 Fisher Scientific, Loughborough, UK 
Millipore 10 kDa MWCO spin 
filter, 4 ml 
UFC801024 Fisher Scientific, Loughborough, UK 
Millipore 100 kDa MWCO spin 
filter 
UFC810024 Fisher Scientific, Loughborough, UK 
Minisart® high flow Syringe 
filters, 0.2 μm 
16532 Sartorius UK Ltd., Surrey, UK 
NanoDropTM 2000c ND2000c Fisher Scientific, Loughborough, UK 
Nunc® cell culture-treated 12-
well plate 
150628 Fisher Scientific, Loughborough, UK 
Nunc® cell culture-treated 24-
well plate 
142475 Fisher Scientific, Loughborough, UK 
Nunc® cell culture-treated 6-
well plate 
140675 Fisher Scientific, Loughborough, UK 
Nunc® CryoTubes®, 1 ml Z763659 Fisher Scientific, Loughborough, UK 
Nunc® MicroWell™ 96-well 
microplates  
167008 Fisher Scientific, Loughborough, UK 
N-terminal protein sequencing  Abington Health Laboratory Services, 





Octet® RED96 instrument  
 
Pall ForteBio Corp., CA, USA 
Polypropylene tube for 
ultracentrifuge, 3.2 ml 
362333 Beckman, High Wycombe, UK 
Prism 4 software 
 
GraphPad Software Inc., CA, USA 
PVDF membrane, 0.2 μm 88520 Fisher Scientific, Loughborough, UK 
Quick Ligation Kit M2200 New England BioLabs, Herts, UK 
Slide-A-Lyser MINI Dialysis 
Device, 10 KDa MWCO, 0,5 ml 
88401 Fisher Scientific, Loughborough, UK 
Sonicator 102c and Sonifier 
250  
Branson Ultrasonics, Danbury, UK 
Sponge pad for blotting EI9052 Invitrogen, Paisley, UK 
Sterilin polystyrene tubes, 
sterile 
128B/FS Fisher Scientific, Loughborough, UK 
Stirred ultrafiltration cell 5123 Fisher Scientific, Loughborough, UK 
SuperdexTM 200 HR10/30 17-1088-01 GE Healthcare, Amersham, UK 
Syringe filter, 0.45 μm SLHA033SS Fisher Scientific, Loughborough, UK 
Syringe needles, gauge 27, L 1 
¼ in., BD Precisionglide® 
Z192376 Sigma-Aldrich, Dorset, UK 
T100TM Thermal cycler for PCR 186-1096 Bio-rad, Hertfordshire, UK 
Tissue culture flask 
TripleFlasks, 500 cm2 
132913 Fisher Scientific, Loughborough, UK 
Tissue culture flask, 175 cm2 159910 Fisher Scientific, Loughborough, UK 
Tissue culture flask, 25 cm2 156367 Fisher Scientific, Loughborough, UK 
Tissue culture flask, 75 cm2 156499 Fisher Scientific, Loughborough, UK 
Tissue Master 240 
 
Omni International, Kennesaw, GA, 
USA 
Tissue Master 240 
homogeniser  
Omni International, kennesaw, GA, 
USA 




Tissue processor TP 1020 
Leica Microsystems (UK) Ltd., Milton 
Keynes, UK 
Transwell polycarbonate 
membrane, 12 mm, 0.4 μm 
CLS3401 Sigma-Aldrich, Dorset, UK 
Vivaflow 200 VFS204 Vivascience, Goettingen, Germany 
Vivaflow 200, PES membrane, 
30 kDa MWCO 
VF20P2 Vivascience, Goettingen, Germany 
Wax embedder EG 1150 c 
Leica Microsystems (UK) Ltd., Milton 
Keynes, UK 
Whatman® Anatop® 10 syringe 
filter, 0,1 μm, 10 mm 
WHA68091012 Sigma-Aldrich, Dorset, UK 
XCell IITM Blot Module  EI9051 Invitrogen, Paisley, UK 
XCellTM Sure	 Lock® Mini-cell 
electrophoresis system 
EI0001 Invitrogen, Paisley, UK 
X-ray film developer 
 
Photon Imaging Systems, Swindon, 
UK 
Zeba® Desalting Spin Column, 7 
Kda MWCO, 2ml 
89890 Fisher Scientific, Loughborough, UK 
Zeba® Desalting Spin Column, 7 
Kda MWCO, 5ml 
89892 Fisher Scientific, Loughborough, UK 
Zetasizer Nano S 
 

















Although major steps of the Pseudomonas	 aeruginosa exotoxin A (PE) intoxication 
pathway have now been elucidated, the potential for a pH-induced conformational change 
experienced by the protein in the endosomes and its implications in terms of protein 
translocation across polarised epithelial cells remain obscure. 
It is now widely acknowledged that domain II is responsible for translocation of the toxin 
across membranes [159, 160, 200]. Domain II of PE comprises amino acids 253-364 and is 
made of six α-helices (Figure 3-1)[158]. Helices B (Glu282-Ala301) and E (Pro333-Gly354) 
are long enough to span a membrane [201], although domain II does not contain any 
hydrophobic stretches that could explain how PE inserts into lipidic membranes [202], as 
in the case of DT where the B fragment becomes hydrophobic at low pH, driving the A 
fragment of the protein into the cytosol [203, 204]. Helices A (Leu267-Arg274), C (Ser304-
Ser318), D (Gly322-Glu331) and F (358-364) are much shorter, and while deletion of any 
of the helices A-E was shown to significantly impair the translocation process, removing 
helix F actually enhanced it [205]. 





Figure 3-1 – Ribbon representation of PE translocation domain. α-helices are 
lettered and the white loop carries the four residues constituting the furin cleavage 
site (RQPR). The figure was generated using PyMOL [128]. 
Although researchers were, at the time, looking for an explanation to PE’s entry into non-
polarised cells, a pH-induced conformational change within domain II was first suggested 
in the late 1990s [150, 206, 207]. Since, several techniques such as measurement of 
tryptophan intrinsic fluorescence [150],  trypsin digest [202, 206], detergent affinity and 
insertion into vesicles [150, 154, 206, 207], and 125I-labelling [202] have been employed to 
investigate how this structural rearrangement happened. 
Several hypotheses have been advanced. Méré et	 al (2005) put forward a mechanism 
involving an N-cap residue and a “membrane anchor” which would explain how PE could 
translocate directly from endosomes to ER. At neutral pH, Trp305 is buried into a 
hydrophobic pocket closed by helix F. Following access to the endosomal compartment 
and a drop in pH, Asp358 (the N-cap residue of helix F proposed here to act as a pH 
sensor) would become protonated. As a result, helix F would be destabilised and the side 
chain of Trp305 (membrane anchor) would become exposed to a more hydrophilic 
environment, leading to its insertion into the endosomal membrane [208] and, somehow, 
to the transport of the entire protein through the membrane to the ER. As several 
trafficking routes have previously been suggested for PE (Section 1.2.3), this mechanism 
would be applicable only in a scenario in which PE would use the Rab9-independent 
pathway to bypass the LE and reach the Golgi directly from the early endosome [142]. 




Using a refined crystallographic structure of PE, Wedekind et	al (2001) suggested that 
various ionic interactions within domain I and II might control the toxin’s pH-induced 
conformational change [209]. Although it is now acknowledged that PE undergoes this 
structural reorganisation when the pH drops below pH 6.0, the aforementioned authors 
rightly pointed out that whether the conversion occurs as a localised perturbation of the 
furin cleavage site or in a more “global” dissociation of domain I from domain II remains 
unknown. Simulations involving individual protonation of the carboxyl groups of His, Asp 
or Glu side chains did not show any significant perturbation within the protein structure. 
Therefore, Wedekind et	 al concluded from these studies that such a conformational 
change couldn’t result from the protonation of a single residue within the protein. Thus, 
these authors proposed that a combination of destabilisations (due to protonation of 
several amino acids) might be more likely to trigger the observed transformation. 
However, experimental data corroborating any of these theories has yet to be published. 
The aim of the work presented in this chapter was to investigate the modifications in the 
protein structure which lead to this conformational change. A thorough characterisation of 
the behaviour of PE would be invaluable to understand how large and hydrophilic 
molecules may translocate to the cytosol and to elucidate PE’s transcytosis pathway. In 
fact, a similar conversion is thought to take place in the endosomes of polarised cells and 
could be a major step in getting the protein across the epithelial barrier. Further 
characterisation of this conversion was attempted by comparing and combining data 
obtained at neutral and acidic pH by various techniques, including trypsin digestion, DLS, 




Determination of possible trypsin cleavage sites from digestion fragments 
Following digestion of PE GS TEV mutants by trypsin, the size of the resulting fragments 
was used to estimate potential cleavage sites. The protein sequence (PDB_ID: 1IKQ) was 
run into PeptideCutter and only digestion sites with a 100% cleavage probability were 
displayed [183]. The molecular weight of the resulting fragments was then calculated with 
ProtParam [181]. 








pVC45D encodes a non-toxic version of PE lacking the Glu553 codon [161]. It contains an 
OmpA signal sequence that triggers protein secretion into the bacterial periplasm. This 
method of protein expression is of particular interest for molecules which, like ntPE, 
contain disulphide bonds [210], as it provides a milieu that contributes to their proper 
folding. In fact, the environment in the periplasm is more oxidizing than in the cytoplasm, 
and it contains two foldases (disulphide oxidoreductase and disulphide isomerase) that 
catalyse the formation and isomerisation of disulphide bonds [211, 212]. 
After protein expression (into the periplasm) and fractionation of the periplasm, ntPE was 
purified in a two-phase procedure that included a first purification step using AE 
chromatography, followed by a polishing step involving size exclusion chromatography. 
Protein loading on an AE column and elution with a gradient of NaCl resulted in the 
detection of two peaks of UV-absorbing materials (Figure 3-2 (A)). The first peak (~220 
mAU) corresponded to the flow-through i.e. elements that did not interact with the column 
and were eluted before the NaCl gradient was applied to the system. The second peak 
(~230 mAU) corresponded to material eluted at 0.12 to 0.65 M NaCl (12 to 65% gradient).  
Fractions containing the compounds eluted in these two peaks were separated by SDS-
PAGE (Figure 3-2 (B)). 
In the flow-through fractions, a strong band was observed at ~72 kDa (fractions E2 and 
E3).  This band could also be observed in the fractions corresponding to the eluted protein 
of interest.  This suggests that some ntPE did not interact with the column and was eluted 
with the non-specific materials.  This could be due to overloading of the column as 
suggested by the relatively high peak intensity for the flow-through. In this case, the flow-
through fractions were re-run on the column in order to collect the excess protein and 
maximise the amount of protein purified.  Fractions E7-E10 were concentrated together 
down to 1 ml and loaded on a gel filtration column. 
The resulting chromatogram showed a relatively broad peak that likely contained several 
sub-peaks (Figure 3-3 (A)). Collected fractions contained ntPE plus minor amounts of 
several discrete contaminants with molecular weight lower than ntPE (e.g. 45 kDa, 30 
kDa) (Figure 3-3 (B)). Due to the relatively negligible proportion of these contaminants 




compared to that of enriched full-length ntPE, fractions F10-G1 were combined and the 
purified protein was used for the following studies. 
    
Figure 3-2 – Initial enrichment of ntPE by AE chromatography. (A) Chromatogram 
obtained for AE separation. (B) Coomassie-stained SDS-PAGE of fractions 
corresponding to the UV peaks. E-labelled lanes in (B) correspond to arbitrary tray 
row and column reference on the fraction collector and are illustrated by the red 
dashes on (A). Fractions covered by the arrow in (A) indicate the complete range of 
fractions displayed in (B). The black dotted lines marked on both (A) and (B) 
indicate the fractions containing ntPE that were collected. 
 
Figure 3-3 – Further enrichment of ntPE by GF chromatography. (A) Chromatogram 
obtained for GF column separation. (B) Coomassie-stained SDS-PAGE of fractions 
corresponding to the UV peak. F- and G-labelled lanes in (B) correspond to arbitrary 
tray row and column reference on the fraction collector and are illustrated by the 
red dashes on (A). Fractions covered by the arrow in (A) indicate the complete 
range of fractions displayed in (B). The black dotted lines marked on both (A) and 
(B) indicate the fractions containing ntPE that were collected. 






The proteins described in this section were cloned by Dr Julia Mackay (engineering of the 
expression plasmids). Dr Emma Harvey contributed to their expression (isolation of 
inclusion bodies under supervision). 
ntPE GS TEV is a modified version of ntPE that was engineered to contain the poly glycine-
serine linker of SGSGSGSGS (5’-AGTGGTAGTGGTAGTGGTTCTGGTAGT-3’) between the 
protein and a C-terminal TEV cleavage sequence (ENLFQS). This flexible linker was added 
to increase cleavage efficiency by making the digestion site more accessible to the TEV 
enzyme. 
Five truncated versions of ntPE GS TEV were also produced: PE408 GS TEV, PE364 GS 
TEV, PE351 GS TEV, PE320 GS TEV and PE303 GS TEV. Numbers indicate the last amino 
acid of the truncated PE protein. 
Truncations were engineered so that for each mutant, one or several helices of domain II 
were removed (Figure 3-4). The shortest mutant (PE303 GS TEV) contains helices A and B, 
PE320 GS TEV terminates after helix C, PE351 GS TEV contains helices A-E and PE364 GS 
TEV comprises all six helices A-F. The last mutant, PE408 GS TEV, was composed of all 
three domains Ia, II and Ib. The molecular weight and isoelectric point of each version of 
ntPE GS TEV were calculated using ExPASy ProtParam (Table 3-1) [181]. 
 





Figure 3-4 – (A) Schematic representation of the different versions of ntPE GS TEV 
used in this study. Note the deletion of E553 in domain III that renders PE non-toxic 
(ntPE). (B) Ribbon representation of PE highlighting the various helices in domain 
II. The figure was generated using PyMOL [128]. Letters A-F refer to the six α-helices 
of domain II. 
 
Table 3-1 – Physicochemical properties of PE GS TEV truncated mutants. Both pI and 







ntPE GS TEV 5.28         66.7 
PE408 GS TEV 5.28        44.4 
PE364 GS TEV 5.86        40.1 
PE351 GS TEV 5.97        38.9 
PE320 GS TEV 6.33        35.6 
PE303 GS TEV 6.33        33.8 
 




While ntPE GS TEV was soluble, the truncated mutants were insoluble and had to be 
expressed as inclusion bodies, which are aggregates of misfolded protein, and 
subsequently refolded using a disulphide exchange shuffle buffer system (see below). A 
summary of the expression and purification outcomes is presented in Table 3-2. 








ntPE GS TEV Soluble Soluble IX, GF Good 
PE408 GS TEV Insoluble Inclusion bodies IX, GF Medium 
PE364 GS TEV Insoluble Inclusion bodies IX, GF Low 
PE351 GS TEV Insoluble Inclusion bodies IX, GF Low 
PE320 GS TEV Insoluble Inclusion bodies IX, GF Low 
PE303 GS TEV Insoluble Inclusion bodies IX, GF Medium 
 
Inclusion body formation results from the accumulation of partially folded proteins in the 
cytoplasm of E.	coli, but it can also arise from the reducing environment of the cytoplasm 
that does not allow for the formation of disulphide bonds, which can be crucial for a 
protein to adopt its native, soluble and biologically active conformation [213]. 
After their collection and washing by repeated centrifugation to reduce lipopolysaccharide 
content, inclusion bodies were solubilised in guanidine-HCl, which promotes complete 
protein unfolding by disrupting intermolecular interactions [214], and DTT, which 
reduces disulphide bonds by thiol disulphide exchange [215]. The amount of solubilised 
protein was assessed by Bradford assay.  A defined amount of total protein was then 
subjected to a di-sulphide shuffle buffer refolding method that utilized arginine and 
glutathione. Although its mechanism of action has not yet been elucidated, the presence of 
arginine seems to help protein refolding by reducing aggregation. It has been suggested 
that this amino acid could interact favourably with most amino acids’ side chains, thereby 
reducing intermolecular interactions (e.g. hydrogen bonds, ionic, and hydrophobic 
interactions) between proteins [216]. For instance, Tsumoto et	al (2004) reported that 
interaction between the guanidinium group of arginine and the side chain of tryptophan 
(which is normally buried in folded proteins but exposed to solvent in unfolded states) 




contributes to increasing protein solubility by preventing misfolding and protein 
aggregation mediated by hydrophobic interactions [217]. It has also been proposed that 
arginine in refolding solutions could act as a “neutral crowder” that can slow protein 
association and dissociation by being preferentially excluded from protein-protein 
encounter complexes, but not from dissociated protein molecules [217, 218]. Oxidised 
glutathione (GSSG) reportedly promotes the formation of correct disulphide bonds by 
encouraging rapid “reshuffling” of improper disulphide bonds [213]. In the protocol used, 
the protein was added drop-wise and maintained at low concentration (< 100 μg/ml) 
during refolding to further reduce the chance of aggregation. 
Following refolding, samples were dialysed in order to remove these low molecular 
weight compounds and purified using AE and GF chromatography. Presented below as 
examples are the chromatograms and an SDS-PAGE of column fractions obtained following 
purification of PE303 GS TEV. The protein was eluted from an AE column with a NaCl 
gradient. A single peak could be observed at 10-60% NaCl (= 0.1-0.6 M NaCl) (Figure 3-5 
(A)). 
   
Figure 3-5 – Initial enrichment of PE303 GS TEV by AE chromatography. (A) 
Chromatogram obtained for AE separation. (B) Coomassie-stained SDS-PAGE of 
fractions corresponding to the UV peaks. X- and F-labelled lanes in (B) correspond 
to arbitrary tray row and column reference on the fraction collector and are 
illustrated by the red dashes on (A). Fractions covered by the arrow in (A) indicate 
the complete range of fractions displayed in (B). The black dotted lines marked on 
both (A) and (B) indicate the fractions containing PE303 GS TEV that were collected. 
Fractions corresponding to this peak as well as the flow-through (molecules which were 
not retained by the column) were separated by SDS-PAGE (Figure 3-5 (B)). A band was 
observed for the flow-through at the same size as the protein. This band was relatively 
strong, and the presence of protein in the flow-through might have been due to column 




overloading.  In this case, the flow-through was re-run on the AE column. In the elution 
fractions, a single band was visible around 40 kDa for all fractions. These were 
concentrated together down to 1 ml for further purification by size exclusion 
chromatography (Figure 3-6 (A)).  
Following the second purification step, fractions corresponding to the UV-absorbing 
material were separated by SDS-PAGE. As the UV peak obtained was less well defined, an 
SDS-PAGE of individual column fractions was used to assess the amount and purity of the 
protein of interest, providing the rationale for fractions that were pooled; for example, 
PE303 GS TEV was collected from fractions M5-M11 (Figure 3-6 (B)). Analysis of the 
Coomassie-positive bands showed a dominant one visible at ~20 kDa in fractions M12-M14. 
Due to the presence of this contaminant, these fractions were not added to the final batch 
of enriched PE303 GS TEV. 
   
Figure 3-6 – Further enrichment of PE303 GS TEV by GF chromatography. (A) 
Chromatogram obtained for GF column separation. (B) Coomassie-stained SDS-
PAGE of fractions corresponding to the UV peak. M-labelled lanes in (B) correspond 
to arbitrary tray row and column reference on the fraction collector and are 
illustrated by the red dashes on (A). Fractions covered by the arrow in (A) indicate 
the complete range of fractions displayed in (B). The black dotted lines marked on 
both (A) and (B) indicate the fractions containing PE303 GS TEV that were collected.  
3.3.1.3 M40-1	expression	and	purification	
 
M40-1 is a monoclonal antibody which targets a region located between residues 264-308 
of the native protein and was expressed using mice hybridomas generated by Ogata et	al 
(1991) [153]. After collection and concentration, the cell culture medium was first filtered 
to remove the dead cells and loaded on a Protein G column to isolate the IgG. Elution with 
a linear gradient of glycine-HCl produced one peak of UV-absorbing material (~100 mAU), 




eluting at 42-63% glycine-HCl (= 0.042-0.063 M glycine-HCl) (Figure 3-7 (A)). As Protein G 
chromatography is a rather specific purification method, only IgG were likely to elute 
within this peak. Therefore, pooled fractions corresponding to the peak were concentrated 
to 1 ml and further purified using GF chromatography. One compound emerged in a single 
symmetrical peak at 14-16 ml (28-32 min) (Figure 3-7 (B)) and was examined by SDS-
PAGE with two main bands at ~50 kDa and 25 kDa being observed (Figure 3-8). These 
bands correspond to the heavy and light chains of the antibody, respectively, confirming 
the nature of the product collected. Furthermore, no contaminants could be seen on the 
gel, which suggested a relatively high purity of the antibody. This is largely due to the very 
specific interaction between the IgG and the Protein G column, which eliminates the main 
impurities present in the cell culture medium, including BSA from FBS.  
 
 
Figure 3-7 – Chromatograms obtained after purification of M40-1 by (A) Protein G 
and (B) size exclusion chromatography. Fractions covered by the arrow in (B) 
indicate the complete range of fractions displayed in Figure 3-8. The black dotted 
lines marked on both (A) and (B) indicate the fractions containing M40-1 that were 
collected. 





Figure 3-8 – Coomassie-stained SDS-PAGE of fractions collected after running M40-1 
on a GF column. Bands migrating at ~50 and 25 kDa correspond to the reduced 
heavy and light chains of the IgG, respectively. G-labelled lanes correspond to 
arbitrary tray row and column reference on the fraction collector and are 
illustrated by the red dashes on Figure 3-7 (B). The black dotted lines indicate the 
fractions containing M40-1 that were collected. 
The functionality and specificity of the M40-1 antibody were assessed by WB using ntPE 
as the antigen (Figure 3-9). One strong band could be detected after development at ~70 
kDa and corresponded to the native toxin, showing that the purified antibody did target 
ntPE. Furthermore, no band could be observed when blotting BSA with M40-1, confirming 
the specificity of the product. This therefore established that the product expressed from 
the hybridoma cells was able to selectively interact with ntPE. 
   
Figure 3-9 – WB analysis of the purified antibody (M40-1). 10 μg PE or BSA was 
studied by SDS-PAGE and transferred to PVDF membrane that was probed with the 
purified antibody diluted at 1 in 10,000 in TBS-T from a 1 mg/ml stock solution. 
The purified M40-1 antibody preparation was divided in two batches: one lot was stored 
at 1 mg/ml in 1:1 PBS: glycerol for Western blot, and the rest was stored in PBS at 12 
mg/ml for HPLC and crystallisation studies. The presence of glycerol helps preserve the 









In order to confirm that the protein expressed and used here presented the same pH-
dependent behaviour as described in the literature, the structural behaviour of ntPE in 
solution was probed by trypsin digestion. Like in many experiments described here, BSA 
was used as a control protein. In fact, the mature BSA is composed of 583 amino acids and 
was particularly appropriate as a control since its molecular weight (66.5 kDa vs. 66.8 
kDa) and calculated pI (5.6 vs. 5.3) are very close to the 613 amino acids of mature ntPE 
[181]. Different from PE, BSA has been reported to undergo structural transitions below 
pH 5.0 and above pH 7.5, but it appears to have a conserved conformation within the 
working pH range of 5.0-7.0 [219, 220]. Moreover, the isoelectric point of BSA in aqueous 
solution containing 0.15 M NaCl is ~4.7 which means that BSA should remain stable in 
solution over the studied pH range [221, 222]. 
BSA and ntPE were diluted in citrate-phosphate buffer at different pHs (5.8, 6.2 and 7.4) 
and digested by trypsin before being analysed by SDS-PAGE (Figure 3-10). In the case of 
BSA, no difference in the digestion pattern could be observed between the three pHs: one 
main band appeared at ~70 kDa, corresponding to the undigested protein, and one fainter 
secondary band could be seen at ~60 kDa. It showed that digestion of BSA by trypsin was 
minimal and pH-independent within the range studied. On the contrary, ntPE presented a 
different digestion pattern depending on the pH. At pH 7.4, one strong band appeared at 
~70 kDa and corresponded to the undigested protein, while a faint secondary band was 
visible at ~60 kDa. This indicated that enzymatic digestion of ntPE at pH 7.4 was minimal. 
When the pH was lowered to 6.2 and 5.8, a shift in the digestion pattern could be 
observed. The band at ~70 kDa disappeared and a band at ~50 kDa appeared instead, 
which progressively became the main digestion fragment. Trypsin activity is highest 
around pH 7.0, and therefore the increase in protein digestion at lower pH could not be 
explained by a change is enzyme efficacy [223]. Instead, it seemed that the site for trypsin 
cleavage became more accessible for enzyme digestion at pH 5.8. These results confirmed 
that when transferred to acidic pH, the ntPE expressed here undergoes a conversion from 
a native state in which trypsin cleavage is limited, to a second conformation in which the 
enzyme recognition sequence seems to be more exposed and thus available for digestion. 





Figure 3-10 – Trypsin digestion of ntPE but not BSA is pH-dependent. Coomassie-
stained SDS-PAGE of ntPE and BSA diluted in citrate-phosphate buffer at pH 5.8, 6.2 
and 7.4 and digested using 0.4 μg trypsin at 4 °C for 30 min. 
In order to refine the pH range where the conformational change occurred, the size of 
ntPE over the 5.8-7.4 pH interval was determined by dynamic light scattering (DLS). 
In Figure 3-11 (A), the determined mean hydrodynamic diameter is plotted against the pH 
of the solution. Statistical analysis of the results is presented in Figure 3-11 (B). On each 
graph, two distinct areas emerge: when pH > 6.2, ntPE presented an average tumbling 
volume of 9.5 nm and variations in size were small (± 0.4 nm, ~4.2%). When pH ≤ 6.2, the 
average protein size increased by ~12.0% to 10.8 ± 0.7 nm that suggested a slightly 
greater size variability of ~6.5%. Two sets of data collected over a three year-interval 
described the same trend, with the first set of data being collected by Dr Julia Mackay in 
May 2011 and the second in October 2014. Minimal variations in pH shift between the two 
curves could be explained by sample preparation method. While samples prepared in 
October 2014 were dialysed against buffer at the indicated pH (as described in Section 
2.11), in May 2011 the protein was diluted directly in buffer, thereby slightly increasing 
the pH by addition of PBS into the mixture. 
 





Figure 3-11 – (A) Measurement of the size of ntPE at different pH values in citrate-
phosphate buffer using DLS. (B) Statistical analysis of the results obtained in (A). 
Bars show mean ± SD for n = 6 independent experiments where *** P < 0.001, ** P < 
0.01 and * P < 0.05.  
To confirm these results, the ntPE preparations used for DLS measurements were 
separated by SDS-PAGE and Coomassie-stained (Figure 3-12). The conformational change 
could be observed as a progressive transition and pH 6.2 appeared as the conversion point 
between the two conformations. In fact, while the intensity of undigested protein (band 1, 
~70 kDa) slowly decreased with the pH, band 2 (~55 kDa) nearly entirely disappeared 
and band 3 (~47 kDa) began to emerge below pH 6.2. Furthermore, the amount of 
undigested material was much less at lower pH. 
 
Figure 3-12 – Determination of the transition point between two conformations by 
trypsin digestion. Coomassie-stained SDS-PAGE of DLS samples following digestion 
of 10 μg sample with 0.4 μg of trypsin at 4 °C for 30 min. 







































To rule out the possibility that the transition observed only reflected protein denaturation 
or hydrolysis due to exposure to acidic environment, reversibility of the conversion was 
assessed. ntPE was incubated in citrate-phosphate buffer, 0.1 M NaCl at pH 5.8 and the pH 
was reversed back to 7.4. The digestion pattern of the reversed sample (REV) was 
identical to the one of ntPE in buffer at pH 7.4 when analysed by SDS-PAGE (Figure 3-13), 
which suggests that the conformational transformation undergone by the protein was 
reversible when the pH was switched back to more physiological values. 
 
Figure 3-13 – pH-dependency of ntPE digestion by trypsin is reversible. Coomassie-
stained SDS-PAGE of ntPE in citrate-phosphate buffer at pH 5.8 or 7.4 and of a 
sample incubated at pH 5.8 for 5 min and returned to pH 7.4 by dialysis (REV). All 
samples were digested using 0.4 μg trypsin at 4 °C for 30 min. 
The apparent total reversibility observed in the trypsin digest studies suggests that ntPE 
does not go through a global reorganisation of structure when exposed to low pH values, 
as an extensive modification would be less likely to reverse so completely. Instead, it 
would seem more likely that the difference in trypsin sensitivity observed with pH would 
result from a subtler, local switch in conformation. DLS measurements and examination of 
protein cleavage by trypsin indicate that this switch takes place around pH 6.2 in the 




Characterisation of ntPE by size exclusion HPLC using 0.1 M potassium-phosphate buffer 
(kPB) containing 0.1 M NaCl at pH 7.4 or 5.8, showed that the protein eluted at 9.282 and 
9.383 min, respectively (Figure 3-14 (A)). By comparison, BSA, whose conformation has 
been shown to remain constant within studied pH range [219, 220], eluted at 9.061 and 




9.082 min at pHs 7.4 and 5.8, respectively (Figure 3-14 (B)). These results show that 
switching to a more acidic environment did not modify significantly the elution time of 
ntPE. This would support the idea that ntPE does not go through any global structural 
rearrangements (e.g. major unfolding or change of orientation of a whole domain) as the 
pH is lowered. 
If in fact ntPE did undergo a local rather than an overall conformational change, a 
complete reorientation of one domain relatively to the others would seem unlikely as this 
would involve extensive structure modifications. Instead subtle alterations of the protein’s 
structure, within or possibly at the interface between, one or several domains would 
appear to be more probable. Domain II has been demonstrated to be responsible for toxin 
translocation through the cells [200] and it is assumed that the conformational change 
described here is responsible for the re-routing of PE away from the lysosomal 
degradation pathway, towards the Golgi and eventually the cytosol. It could therefore be 
anticipated that the conformational change could occur within domain II [200, 224]. 
Supporting this hypothesis are the observations that replacing either or both domains I 
and III by an alternative protein does not alter the ability of PE to reach the cytosol of the 
target cell [145, 165]. 
 
 
Figure 3-14 – HPLC chromatograms of (A) ntPE and (B) BSA after elution on a HPLC 
GF column in kPB + 0.1M NaCl at pH 7.4 and 5.8 at 37 °C. UV measurements were 
performed at 254 nm. The chromatograms presented here were taken as 
representative of 6- and 3-run sets for ntPE and BSA, respectively. 







In order to better define the region in which this conformational change happens, a series 
of truncated proteins were cloned and expressed from PE. These truncated mutants were 
shortened up to the end of α-helix B and their ability to undergo the same conformational 
change as ntPE was examined by trypsin digestion. 
Truncated mutants of ntPE GS TEV were subjected to trypsin cleavage at either pH 5.8 or 
7.4 at 4 °C for 30 min and separated by SDS-PAGE. Gels were stained with Coomassie blue 
(Figure 3-15). 
 
Figure 3-15 – Trypsin digestion of PE GS TEV mutants. 10 μg protein was incubated 
with 0.4 μg trypsin for 30 min at 4 °C and analysed by SDS-PAGE. Undigested 
samples were incubated in PBS without trypsin. Top line indicates the mutant used; 
full-length (FL), PE408 GS TEV (408), PE364 GS TEV (364), PE351 GS TEV (351), 
PE320 GS TEV (320) or PE303 GS TEV (303). Bottom line indicates the conditions of 
the digestion in citrate-phosphate at pH 5.8 or 7.4 (CP5 and CP7, respectively), or 
undigested protein (UD). 
In the case of the full-length ntPE GS TEV (FL), the pattern observed was significantly 
different depending on the pH. At neutral pH, cleavage was scarce with only a band at ~55 
kDa detectable and most protein left undigested (~72 kDa band). This pattern is 
consistent with previous reports detailing cleavage of PE by trypsin after Arg490 [225]. In 
mildly acidic conditions (pH 5.8), protein cleavage was more extensive. A band 
corresponding to the unprocessed sample was still present though far less intense than at 
pH 7.4. Four main bands could be observed on the gel at approximately 45, 40, 30, and 20 
kDa. N-terminal sequencing revealed that both 20 and 30 kDa bands matched the N-
terminal end of the protein (AEEAF). This suggests that ntPE GS TEV was cut at two 
distinct positions, and that two pairs of bands were actually detected by SDS-PAGE (one 




cleavage, cleavage 1, C1, resulted in bands at 20 and 45 kDa while another, cleavage 2, C2, 
produced bands at 30 and 40 kDa). Further N-terminal sequencing (Alta Bioscience Ltd., 
Birmingham, UK) showed that the 40 kDa fragment starting sequence was GWEQL, 
therefore demonstrating that one of the trypsin digestion sites, most likely C2, 
corresponds to the furin cleavage site. This would be in agreement with previous reports 
showing that this region of the protein is exposed to enzymatic cleavage only under acidic 
conditions [162]. N-terminal sequencing of the 45 kDa band did not provide satisfactory 
results, and consequently the location of C1 could not be determined accurately. However, 
based on the approximate molecular weight of the fragments (~20 and 45 kDa) and the 
location of each residue (Figure 3-16), it could be assumed that the protease would most 
likely cleave after either Arg186 or Arg213 (Table 3-3). 
 
 
Figure 3-16 – Positions of the potential trypsin cleavage sites corresponding to the 
20 and 45 kDa fragments that were detected in Figure 3-15. (A) Schematic 
representation of the full-length PE and (B) Ribbon representation of PE domain I. 
Arg186 (R2) and Arg213 (R3) are both located on loops, while Arg154 (R1) and 
Arg226 (R4) are in the middle of β-strands. Disulphide bonds are indicated orange 
in (A). Figure (B) was generated using PyMOL [128]. 
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Table 3-3 – Potential trypsin cleavage sites corresponding to the 20 and 45 kDa 
fragments detected. ExPASy Peptide Cutter and ExPASy ProtParam were used to 
generate the fragments and calculate their molecular weight, respectively. Only 
100% probability cleavage sites are displayed.  
Position of cleavage site MW (fragment 1) (kDa) MW (fragment 2) (kDa) 
Arg154 16.9 49.9 
Arg186 20.5 46.4 
Arg213 23.6 43.3 
Arg226 25.2 41.7 
 
The bands detected after trypsin digestion of the truncated mutants denoted strikingly 
different behaviour compared to the FL protein; sensitivity to the protease was inversed 
compared to FL for all five. At pH 5.8, a ~20 kDa N-terminal band was detected and 
represented the main fragment. These results suggested C1 became the main cutting site 
in these truncated proteins. In some cases, bands possibly corresponding to the 30 kDa N-
terminus and the undigested sample (e.g. PE364 GS TEV and PE303 GS TEV) were also 
identifiable. Proteins seemed to be digested more at pH 7.4, with fewer fragments 
retrieved and a complete absence of uncleaved material. A ~20 kDa band could also be 
detected with reasonably strong intensity. These results suggested that the mutants 
examined in these studies were more extensively digested by trypsin, making them more 
difficult to detect by SDS-PAGE.  
These studies show that lowering the pH promotes a conformational change of the FL 
protein resulting in exposure of additional trypsin cutting sites, and that these same sites 
appear to be more exposed at neutral pH in all truncated mutants. This would imply that 
in native PE, domain III could conceal a cleavage site at pH 7.4, or might impose 
conformational constraints on the protein to prevent exposure of these sites. Removal of 
domain III seemed to lift these restrictions and reveal the additional cleavage sequences. 
The fact that all mutants still displayed a difference in their digestion patterns with the pH 
suggests not only that a conformational change still occurs, despite removal of III, but also 
that the origin/trigger of this conformational change is located, at least in part, somewhere 
between amino acids 1 and 303 (shortest mutant), i.e. either in domain I or, more 
probably, in the N-terminal half of domain II. 
The reversibility test previously performed on the FL protein was then applied to all 
mutants (Figure 3-17). The pattern observed for samples that had been diluted in buffer at 




pH 5.8 before being returned to neutral pH and digested with trypsin matched that 
obtained previously for samples cut at pH 7.4. Thus, the conformational change(s) 
undergone by the mutants, just like the FL protein, seemed to be completely reversible. 
This observation reinforced the idea that removing amino acids 304-613 did not prevent 
the conformational change from occurring in these truncated proteins, and that this 
process must originate from transformations in residues located before position 303. 
 
Figure 3-17 – Assessment of the reversibility of the pH-induced conformational 
change in PE GS TEV mutants. Coomassie-stained SDS-PAGE of PE GS TEV mutants 
incubated in citrate-phosphate buffer at pH 5.8 for 5 min and returned to pH 7.4 by 
dialysis. All samples were digested by 0.4 μg trypsin for 30 min at 4 °C. 
These results support the hypothesis that the pH-dependent conformational change 
undergone by ntPE is local and could occur within domain II, and that this change may be 
focused between amino acids 252 and 303. This segment contains a region rich in 
hydrophobic residues (amino acids 256-280: LAALTAHQACHLPLETFTRHRQPRG, 
hydrophobic residues are highlighted in bold) [154, 201] which, if subject to a 
conformational change, could be more or less exposed to solvent depending on the pH. To 
investigate the relative exposure of this region in acidic and neutral conditions, the overall 




ANS was used to further characterise ntPE conformational change by investigating the 
effect of pH on the protein surface hydrophobicity. The pKa of ANS is 0.37 [226], thus it 
was assumed that the dye was always present under its anionic form in the pH range 




studied (5.8-7.4). The hypothesis was that lowering the pH would trigger a change in the 
conformation of the protein and result in the exposure of buried (hydrophobic) residues. 
Fluorescence measurements were performed in citrate-phosphate buffer containing 0.1 M 
NaCl at pH 5.8 and 7.4. The fluorescence emission spectrum was scanned from 400 to 700 
nm (Figure 3-18), after what areas under the fluorescence curves (AUC) were calculated 
and values of λem,max were determined (Table 3-4). BSA was used as a control at the same 
concentration as ntPE. 
  
  
Figure 3-18 – Hydrophobic residues are exposed on the surface of ntPE when the 
protein is exposed to acidic pH. Fluorescence spectra of (A) ANS, (B) ANS + ntPE and 
(C) ANS + BSA at pH 5.8 (red) and 7.4 (black) for [ANS] = 100 μM and [ntPE] = [BSA] = 
1.52 μM. (D) Areas under the fluorescence curves of ntPE and BSA at both pHs. Black 
bars refer to left-hand y axis; red bars refer to right-hand y axis. Bars show mean ± 
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ANS + BSA 7.4
















































































































































Table 3-4 – Values of ΔF and λem,max collected by spectrofluorometry for samples 
composed of ANS, ANS + ntPE or ANS + BSA. 




ANS 5.8 517 
ANS + ntPE 7.4 
1.449 
483 
ANS + ntPE 5.8 475 
ANS + BSA 7.4 
0.938 
476 
ANS + BSA 5.8 475 
 
As expected, ANS in solution at 100 μM displayed minimal fluorescence, and no differences 
between the spectra collected at either pH could be observed (ΔF = 0.98, identical λem,max). 
Addition of ntPE at a concentration of 1.52 μM (0.1 mg/ml) to ANS in solution at pH 7.4 led 
to a 2.5-fold increase in total fluorescence intensity and a shift of λem,max from 518 to 483 
nm. When the pH was lowered to 5.8, the fluorescence intensity of ANS in presence of ntPE 
increased by 1.5-fold compared to ANS + ntPE at pH 7.4 and a blue shift in λem,max from 483 
to 475 nm could be observed. When BSA was mixed to ANS in solution, a significant 
increase in fluorescence could be observed compared to ANS alone, but λem,max were 
similar at both pHs and ΔF was equal to 0.938. 
These results suggest that in their native conformational state, both ntPE and BSA present 
surface hydrophobic residues that are accessible to solvent and thus available for 
interaction with ANS (Figure 3-19). The dramatic increase in ANS fluorescence for BSA 
suggested that this protein presented a significant number of surface hydrophobic sites. 
This would be in agreement with one of the major functions of serum albumins which bind 
to fatty acids in the blood, thereby increasing their solubility, and transport them through 
the plasma [227, 228]. In fact, hydrophobic interactions between fatty acids hydrocarbon 
tails and the uncharged side chains of amino acids lining the binding sites were previously 
reported to be important in the binding process [229-231]. When the pH of the protein 
samples was lowered to 5.8, the two proteins behaved in very dissimilar ways. The 
fluorescence spectrum of BSA remained identical to the one obtained at pH 7.4, with both 
fluorescence quantum yield (ΔF = 0.938) and λem,max unchanged, which was in agreement 
with the fact that the protein does not undergo any conformation change within this pH 
range. In contrast, results collected for ntPE suggested that the number of hydrophobic 




sites available for ANS binding was greater at acidic pH. These data suggest that at a more 
acidic pH, extra hydrophobic residues accessible to solvent appear on the surface of ntPE 
and that ANS could interact with them. This would support the earlier stated hypothesis 
that when the pH is lowered, ntPE would undergo a local conformational change, resulting 
in the unfolding of a specific region of the protein, and exposure of additional hydrophobic 
residues. 
  
Figure 3-19 – Surface hydrophobicity of (A) PE and (B) BSA at pH 7.4 (based upon 
crystal structure information). Red and white refer to hydrophobic and hydrophilic 
residues, respectively. Even in their native conformations, PE and BSA present 
solvent-exposed hydrophobic sites that could bind ANS. The figures were generated 




In order to test the hypothesis that unfolding of a specific region of the protein could 
account for the pH-dependent differences observed in ntPE, crystallisation of PE in acidic 
conditions would be ideal. However, several attempts to obtain ordered crystals for X-ray 
analysis have failed, likely due to the instability of the protein at slightly acidic pH. It was 
suggested that the region surrounding the furin cleavage site (amino acids 276-280) 
would be particularly suitable for the conformational change to take place due to its pH-
dependent exposure and hydrophobicity. 
The monoclonal antibody M40-1 was generated by Ogata et	al (1991) as part of a series of 
monoclonal antibodies (mAbs) designed to probe and gain a better understanding of the 
transformations that arise in PE’s structure under different sets of conditions. Although 
the exact residues required for binding remain unknown, M40-1 was reported to 
specifically target a site located within a 45 amino acid-long segment at the N-terminal end 




of domain II (amino acids 264-308). Therefore, its binding site could potentially envelope 
the proposed region of conformational flexibility. 
Several studies have reported the advantages of co-crystallisation between a protein and 
one of its ligands [232-235]. Here, it was proposed that the interaction between M40-1 
and PE at pH 5.8 could be used to stabilise the protein enough to obtain ordered crystals. 
3.3.6.1 M40-1	binding	properties	are	not	pH-dependent	
 
Before any attempt at crystallising the protein/antibody complex, the interaction between 
the two components had to be tested at both neutral and acidic pH to ensure that the 
antibody expressed here presented similar characteristics to the one described by Ogata et	
al [153].  
The monoclonal antibody M40-1 run on a HPLC GF column in potassium-phosphate buffer 
at 1 mg/ml came out as two main peaks which eluted at similar retention times at both 
pHs (Figure 3-20 and Table 3-5). The small difference observed between retention times 
was, as in the case of ntPE, non-significant. 
 
 
Figure 3-20 – The elution profile of M40-1 is not dramatically affected by changes in 
pH. Chromatograms were collected for M40-1 at either pH 7.4 or 5.8 using HPLC GF. 










Table 3-5 – Elution times and areas of main peaks obtained for M40-1 by HPLC GF at 
pH 5.8 and 7.4 and corresponding to Figure 3-20. 
 
Rt (Peak 1) 
(min) 
Rt (Peak 2) 
(min) 
Area (Peak 1) 
(AU) 
Area (Peak 2) 
(AU) 
pH 5.8 8.90 9.50 121,120 67,732 
pH 7.4 8.69 9.17 128,873 77,496 
 
ntPE was then diluted in 0.1 M potassium-phosphate buffer at pH 5.8 or 7.4 to a 
concentration of 1 mg/ml and M40-1 was added in a 2:1 or 4:1 molar ratio. 10 μl samples 
were separated by HPLC GF at 1 ml/min. The chromatograms obtained seemed to suggest 
that the protein-antibody interaction was  not affected by pH as in both 2:1 and 4:1 ratio 
samples the complex formed was eluted at the same retention time (6.80 min) whether at 
neutral or acidic pH (see Figure 3-21). 
 
 
Figure 3-21 – Elution profiles for solutions of ntPE and M40-1 in (A) 2:1 or (B) 4:1 
molar ratio. ntPE concentration was maintained constant at 1 mg/ml. 




Ogata et	 al (1991) reported that no changes in M40-1 binding to PE were observed 
between pH 5.0 and 7.4, indicating that pH variations within this range do not influence 
the binding affinity of the antibody for PE [153]. Assuming that the region surrounding the 
furin cleavage site is, in effect, key to the conformational change, these results could be 
explained by the fact that the antibody would interact with residues located in the second 
half of the proposed binding site (residues 264-308) (Figure 3-22). Therefore, its affinity 
for PE would not be affected by a localised modification in the first half of the sequence. 
However, it was also demonstrated that treatment of PE with both urea and DTT (which 
commonly lead to protein unfolding, exposure of the loop carrying the furin recognition 
site and reduction of the disulphide bond between Cys267-Cys285 [236]) resulted in a 
decrease in M40-1 reactivity for the protein. This suggests a transformation within the IgG 
binding site which would be more likely to occur in the region encompassed by the two 
cysteine residues rather than in α-helix B itself, and therefore include at least part of the 
loop connecting α-helices A and B. In this case, the absence of variation in binding affinity 
between M40-1 and PE when the pH is lowered could be due to a local variation in the 
protein’s 3D organisation that would be structurally small but functionally significant.  
 
Figure 3-22 – Ribbon representation of the region suggested as M40-1 binding site. 
The red arrow indicates the loop connecting helices A and B and carrying the furin 
cleavage site. Highlighted in white are the two cysteine residues (C265 and C287) 
which form a disulphide bond. The structure was generated using PyMOL [128]. 
Furthermore, these results seem to indicate that one molecule of antibody is able to bind 
two molecules of ntPE. In fact, no leftover protein or antibody could be detected in the 2:1 
ratio sample, whereas a peak could be observed at 8.99 min in the 4:1 ratio sample. This 




peak probably corresponds to the unbound antibody, for whose retention time was 
determined to be 8.69 and 8.90 min at pH 7.4 and 5.8, respectively. 
As a conclusion, the epitopes for M40-1 interaction with ntPE seem to be sufficiently 
accessible for binding at either pH. However, the whole IgG is a relatively large molecule 
(150 kDa), and thus too bulky for co-crystallisation. Therefore it was cleaved in order to 
generate fragments that could be used for crystallisation studies. 
3.3.6.2 Antibody	fragmentation	and	complex	isolation	
 
Antibody fragments such as Fab (antigen-binding fragments), Fv (variable fragments) or 
scFv (single-chain variable fragments), can be used as crystallisation chaperones (Figure 
3-23) [237]. They are specific and high-affinity protein-binding partners, and facilitate the 
formation of well-ordered crystals by reducing the conformational freedom of the target 
protein, enhancing solubility or, alternatively, helping crystallisation of proteins which are 
too soluble to form crystals [234, 235, 237-239]. Besides, antibody fragments are often 
able to match the size of the chaperone (15-50 kDa) to the specific target. 
 
Figure 3-23 – Schematic representation Fc, Fab, Fv and scFv fragments from whole 
IgG. 
The interaction between a fragment of M40-1 and PE at pH 5.8 could be enough to 
stabilise the protein in its conformation at low pH and allow crystallisation of the complex 
for further determination of the protein structure in acidic conditions. Therefore the 
antigen-binding portion of the antibody (Fab fragment) was generated and used for 
crystallisation studies. 
Fab fragments were generated by digestion of the whole IgG by the enzyme papain, whose 
cleavage site is located above the hinge region containing the disulphide bonds that link 
the heavy chains, but below the site of the disulphide bond joining the heavy and light 




chains. They were further isolated by elution on an immobilised protein A column, to 
which both undigested IgG and Fc fragments will bind via the Fc domain. 
After purification, 2.1 mg (4.2 x 10-8 mol) of Fab were collected. As 3.8 mg whole IgG (2.53 
x 10-8 mol) was initially used for fragmentation and one mole of IgG generates 2 moles of 
Fab, the final yield was calculated to be 83.0%. This result was confirmed by running 
samples eluted in PBS (Fab1 and Fab2, 3) and elution buffer (IgG1, IgG2 and IgG3) on SDS-
PAGE under denaturing and non-denaturing conditions (Figure 3-24). As expected, only 
reduced Fab fragments (25 kDa) and light chains (23 kDa) were present in the denatured 
flow-through fractions of Fab1 and Fab2, 3. The presence of a second pair of bands in the 
non-denatured lanes for these samples results from the partial denaturation of the Fab 
fragments due to incubation with reducing buffer at RT. Materials detached from the 
column by the elution buffer appeared as a single ~27 kDa band on the gel following 
reduction. When samples were only mixed with reducing buffer without being boiled, this 
band was located at ~45 kDa. These results are consistent with data previously described 
for analysis of M40-1 by SDS-PAGE (Figure 3-8). In both cases, only a very faint band could 
be observed > 130 kDa. The absence of bands at either ~50 kDa (denatured samples) or 
~150 kDa (non-denatured samples) suggests that no undigested IgG remained after 
fragmentation and that all material recovered in these samples after elution were Fc 
fragments. 
 
Figure 3-24 – Fragmentation of M40-1. Coomassie-stained SDS-PAGE of the fractions 
obtained after purification of the digested sample on immobilised protein A column. 
Fab and IgG samples were eluted with PBS and elution buffer, respectively. 
Subscripts indicate wash number. 
All Fab fragments were mixed with ntPE in a 1:1 molar ratio and the sample was run on a 
gel filtration column in order to isolate the protein-Fab complex from any unbound 
material present in solution.  




One main peak could be observed on the UV chromatogram (Figure 3-25 (A)), which 
corresponded to fractions J10 and J11 and contained the ntPE-Fab (M40-1) complex (Figure 
3-25 (B)). These fractions were therefore collected. Due to time constraints, crystallisation 
studies could not be initiated and the purified complex was handed out to Dr Julia MacKay 
who, in collaboration with Dr Jean van den Elsen, set up crystallisation studies of PE in 
acidic conditions. Unfortunately, at the time of writing, no results had been obtained yet. 
 
 
Figure 3-25 – Purification of the ntPE-Fab (M40-1) complex by GF. (A) 
Chromatogram and (B) Coomassie-stained SDS-PAGE of the fractions corresponding 
to the UV peaks. J-labelled lanes in (B) correspond to arbitrary tray row and column 
reference on the fraction collector and are illustrated by the red dashes on (A). 
Fractions covered by the arrow in (A) indicate the complete range of fractions 
displayed in (B). The black dotted lines marked on both (A) and (B) indicate the 
fractions containing the ntPE-Fab (M40-1) complex that were collected. 
3.4 General discussion 
 
In this chapter, the transformations undergone by PE upon lowering the pH of its 
environment have been examined. It is shown that ntPE undergoes a conformational 




change when the pH is dropped from 7.4 to 5.8. This confirmed earlier reports describing 
this transition [150, 154, 206, 240, 241]. However, in most of these studies, influence of pH 
on the protein’s behaviour was examined at pH 4.0 or lower, which is not in the 
physiological pH range. In fact, no cellular compartment of the endocytic pathway, which 
has been suggested for PE entry, reaches these acidic pH values. The most acidic 
compartments described being the late endosome and lysosome with respective pHs of 5.5 
and 4.7 [242]. Moreover, the isoelectric point of PE (the pH value where the protein bears 
no charge) has been reported to be ~5.0 [154, 241]. Above this value, PE carries an overall 
negative charge, whereas below it, the protein bears an overall positive charge. Therefore 
if an inversion of its polarity occurred, the protein would behave differently in solution. 
Such observations would not necessarily reflect physiologically relevant changes. Fryling 
et	al (1992) showed that protease cleavage of PE at pH < 5.5 was more extensive than at 
pH ≥ 5.5. However, in this case the recovery of defined fragments was diminished, 
suggesting that at pH < 5.5 the protein’s digestion pattern is different. This outcome could 
result  from further change(s) associated with exposure to a pH that is near its pI [210]. 
The results presented here suggested that the transition in conformation in response to an 
increasing acidity in its environment occurs around pH 6.2. Previous studies reported pH 
values for this conversion between 4.2 and 6.0 [139, 150, 154, 207, 241]. These 
discrepancies could derive from the various methods of detection (e.g. fluorescence, 
trypsin digestion, binding/insertion into membranes) and experimental conditions used 
by different groups (e.g. temperature, salt and denaturant concentrations). A shift 
occurring at pH 6.2 would imply that ntPE could undergo a conformational change in the 
early endosome (pH ~6.3) [242], which is the first compartment the toxin would enter in 
the endocytic pathway following receptor-mediated endocytosis. It has been 
demonstrated that the furin cleavage site is not accessible to the protease at neutral pH, 
and that PE needs to go through structural changes for it to take place [162]. As this 
activation step was suggested to happen within the endosomal compartment [210], this 
pH seems to be a reasonable value for the transition point. 
The change observed was apparently fully reversible when studied by trypsin digest as the 
same fragments where generated when compared to the native toxin at neutral pH. While 
findings by Farahbakhsh et	al (1987) are in agreement with these data [150], work by 
Idziorek et	 al	 (1990) only reported 80% reversibility in the protein structure [154]. 
However, their work was carried out at pH < 4.0 which could explain why the protein did 
not return to its original conformation (as a certain degree of protein denaturation cannot 
be excluded in such conditions). Therefore, additional studies such as assessment of ADP-




ribosylating activity and translocation would be needed to confirm these results. The 
apparent complete reversibility of the transition suggests that the conformational change 
experienced by ntPE might be more likely to involve a localised modification in the toxin’s 
structure rather than a major disruption of its molecular organisation. Indeed, 
intramolecular interactions such as hydrogen and disulphide bonds as well as electrostatic 
interactions would be harder to re-establish properly by solely re-increasing the pH after 
disruption. This notion was further supported by HPLC studies that monitored the elution 
time of the protein run either by itself or in complex with a monoclonal antibody. 
Importantly, the antibody used in these studies targeted a region of the toxin that 
encompassed the furin loop but wasn’t affected by changes in pH. 
Although studies by Méré et	al	(2005) would support the idea that the conformational 
change described here does not involve a global rearrangement of structure (since 
creation of a disulphide bond between residues 253 and 364 doesn’t affect translocation 
or cytotoxicity), the data presented in this chapter does not seem to promote the role of 
Asp358 as a pH sensor whose protonation would be the trigger to the conformational 
change [202]. In fact, the pKa value of aspartic acid (pKa = 3.65) makes this residue 
unlikely to become protonated within the pH range considered here. Furthermore, trypsin 
digestion on truncated mutants seemed to indicate that shortening the protein up to 
amino acid 303 did not prevent the conformational change from occurring, which would 
be unlikely if the interaction between Asp358 and Trp305 was critical for this process.  
Wedekind et	al (2001) determined a refined crystallographic structure of PE at a 1.62 Å 
resolution and suggested that residues located at the interface of the different structural 
domains might be responsible for inducing the observed pH-dependent conformational 
change [243]. Their work highlighted specific donor/acceptor interactions that might 
control (or at least play a role in) conformational change(s) due to their involvement in 
the formation of salt bridges (= combination of two non-covalent interactions, hydrogen 
bonding and electrostatic interaction) at lower pH. This is shown in Figure 3-26.  
After examining the pKa values of amino acids’ side chains (Table 3-6) and relating them 
to the determined transition pH (pH = 6.2), it appeared that histidine would constitute the 
most likely residue involved in the shift. Its pKa is the only one between 5.0 and 7.4 and 
makes it the most probable amino acid susceptible to see its protonation state modified 
within this pH range. 
Three possible histidine residues were indicated as potential salt bridge partners; His249, 
His262 and His275. All three amino acids are fairly close to the loop carrying the furin-
cleavage site (Arg276-Gly280) within PE’s primary sequence. As previously mentioned, 




this loop has been described as inaccessible to the enzyme at neutral pH [162]. On the 
contrary, in more acidic environments and supposedly following the protein’s 
conformational change, it becomes exposed to solvent and accessible for cleavage. 
Therefore it would seem reasonable to believe that the switch triggering the 
conformational change could be localised in the vicinity of this loop. 
 
Figure 3-26 – Interactions between Histidine (His) and Glutamic acid (Glu) residues. 
At neutral pH, only an H-bond is formed between the two amino acids’ side chains. 
When the pH is lowered below pKa (His), one of the nitrogen atoms becomes 
protonated, leading to an additional (electrostatic) interaction between His and Glu 
and resulting in the formation of a salt bridge. 
Table 3-6 – Three-letter abbreviations and list of the pKa for amino acids’ side 
chains. Data obtained from [244]. 
Amino acid Abbreviation pKa (side chain) 
Arginine Arg 12.48 
Aspartic acid Asp 3.65 
Cysteine Cys 8.18 
Glutamic acid Glu 4.25 
Histidine His 6.00 
Lysine Lys 10.53 
Tyrosine Tyr 10.07 




ExPASy ProtScale [181] was used to calculate, for each amino acid in the structure, the 
degree of solvent concealment (in terms of % buried), the degree of accessibility (% 
accessible) and the flexibility (Figure 3-27). The region extending from cysteine 265 to 
proline 290, which includes the loop between α-helices A and B and thus the mentioned 
His residues, was revealed as particularly interesting. In fact, this section is one of the least 
buried segments of the protein (% buried as low as 0.25), but is also scored as one of the 
least accessible areas in the structure (% accessible is 0.38-0.5). Moreover, this zone 
seems to be especially flexible compared to the average protein flexibility. These 
observations suggest that this region, which is neither excessively buried nor accessible at 
neutral pH, but is fairly flexible, has the potential to become solvent-exposed following a 
minor change in the protein structure. They also confirm that His249, His262 and His275 
could be potential candidates involved in the conformational change. 
The protein sequence of PE was then run into FlexPred in order to examine the individual 
flexibility of each of the amino acids involved in these three salt bridges [196]. FlexPred 
attributes a value between 0 and 1 to each residue depending on their likelihood to be 
involved in protein conformational switches, and only amino acids with scores > 0.75 are 
considered as reasonably flexible [197]. It occurred that amongst the six residues involved 
in the salt bridges of interest, all His249, His262, Asp366 and Glu391 displayed low scores 
(Table 3-7). On the contrary, Glu80 could be categorised as flexible and His275 is clearly 
more flexible than the average amino acid as its score nears the 0.75 threshold. These two 
residues would thus be more likely to trigger the conformational change upon lowering 
the pH. 
 





Figure 3-27 – Graphic representation of the relative degree of amino acid flexibility, 
accessibility and concealment from the surface. Dotted lines represent the 
respective average values for each curve. (Data were generated using ExPASy 
ProtScale [181]). 
Table 3-7 – Relative individual flexibility of the residues involved in the formation 
of salt bridges with His. (Scores were calculated using FlexPred [196]). 
Acceptor residue Flexibility score Donor residue Flexibility score 
Glu80 0.8680 His275 0.7302 
Asp366 0.4120 His249 0.4210 
Glu391 0.5374 His262 0.2952 
 
These results can be explained by looking at the relative arrangement of the residues on 
the protein tertiary structure. His262, which presented the lowest flexibility score, is fairly 
close to the furin site but located in the middle of the α-helix A, while Glu391 is in the 
centre of a β-strand and its side chain completely solvent inaccessible. Wedekind et	al 
suggested that the protonation of His262 might trigger an untethering of the loop carrying 
the furin-cleavage site and, potentially, result in a more global disruption of the protein’ 
structure [243].  
His249 is located just at the interface of domains I and II, on a loop preceding the α-helix, 
and Asp366 is positioned at the beginning of domain Ib. They are also part of a larger set 
of interactions involving His246, Arg247, Asp384 and Asp387 [243]. Brinkmann et	 al 



















(1992) mentioned that when the trio His246, Arg247 and His249 was mutated to glutamic 
acid, the resulting protein did not need activation by DTT and urea to express ADP-
ribosylation activity [225]. Chaudhary et	al (1990) had previously demonstrated that the 
same mutations resulted in a loss of toxicity on 3T3 cells. However, when all three amino 
acids were mutated to lysine, which retained their positive charge and hydrogen atoms, 
toxicity remained unchanged [245]. This could possibly indicate that, due to a lack of 
hydrogen or electrostatic interactions between Glu and Asp, the protein was unfolded to a 
greater degree than its native counterpart, and that His249 could play a role in 
maintaining a “close” conformation in which the loop would be kept from solvent 
exposure at neutral pH. To confirm the specific role of His249, individual mutations of 
each of these three amino acids would be required. 
His275 is the first residue on the loop connecting α-helices A and B. It is relatively flexible, 
adjacent to the furin cleavage site, and its position on the loop would thus make it fairly 
inaccessible to solvent at neutral pH (but possibly exposed under more acidic conditions). 
Furthermore, Glu80 is also located on a rather long loop which explains its flexibility. 
Kasturi et	 al (1992) reported that mutation of His275 into Ala (H275A) resulted in a 
decrease in toxicity in L929 and A431 cells [246]. However, the mutant protein retained 
its ADP-ribosylating activity, even in the absence of DTT and urea, which are normally 
required for activation of the native toxin in	vitro. Moreover, the H275A mutant of PE was 
much more sensitive to chymotrypsin action but less sensitive to trypsin at neutral pH 
than native PE. A possible explanation could be that the mutated protein was folded 
differently compared to PE due to the absence of interaction between the Ala and Glu 
residues at neutral pH. The increased sensitivity to chymotrypsin could suggest that the 
mutant protein was more unfolded than its native counterpart, in such a way that the loop 
would be more accessible, and thus protease-induced cleavage increased. Finally, α-helix A 
is short and protonation of one residue might be enough to destabilise the entire helix. 
These observations support the role of His275 as an N-cap residue, which protonation 
would contribute to the exposure of the furin-cleavage site and thus activation of the toxin.  
Studies describing trypsin digestion of the PE mutants truncated at various positions in 
domain II revealed that removal of domain III changes the protein’s sensitivity to the 
protease. Therefore, as previously discussed, domain III could be imposing structural 
constraints on the molecule that would contribute to preventing its early activation by 
furin cleavage. On the other hand, even after removing amino acids 304-613, the protein 
still seems to undergo a pH-induced and reversible conformational switch. Therefore, one 
or several residues located prior to this position are likely to be involved in this transition. 




Finally, fluorescence techniques were used in this chapter to demonstrate that upon 
lowering the pH, additional non-polar residues are exposed to solvent and made available 
for binding to a hydrophobic probe. The region 256-280 is rich in hydrophobic residues 
[154]. In particular, the last amino acid present on the loop carrying the furin-cleavage site 
is tryptophan 281 (Trp281). Therefore, the exposure of the loop between helices A and B 
and of this tryptophan residue following a drop in pH would be in agreement with the 
increase in hydrophobicity described here by the fluorescence assay. Moreover, it was 
shown that mutation of Trp281 into alanine increased the toxin’s sensitivity to trypsin but 
completely inhibited its cytotoxic activity on three cell lines [246]. Similarly, replacement 
of this tryptophan residue by a methionine slightly enhanced intracellular furin cleavage 
but reduced toxicity by about 100-fold [138]. In this last case, the authors suggested that 
the observed loss of catalytic activity on cells could be due to a defect in translocation 
caused by a change in protein conformation. These reports reinforce the idea that 
exposure of this residue, and more generally of the loop on which it is positioned, are 
crucial for protein translocation. 
Localised modifications which result in small but functionally significant protein 
conformational changes have been described elsewhere for viral and bacterial proteins 
[152, 247-251]: glycoprotein B from Herpes simplex virus type 1 (gB) constitutes a 
particularly interesting case. Crystallisation of gB at pH 8.5 and 5.5 showed that this 
protein undergoes a pH-induced conformational change which does not affect its overall 
conformation [252]. Instead, it was suggested that a histidine residue would become 
protonated upon lowering the pH and act as a “switch” by creating new electrostatic 
interactions that would force the side chain to move out. This seemingly minor change 
would actually result in a significant conformational transformation by pulling the second 
fusion loop F2 out. However, the difference between the two conformations (neutral and 
acidic pHs) could only be characterised following crystallisation, which reinforces the 
need to find suitable conditions for crystallisation of PE at pH 6.0. A similar mechanism 
has also been proposed to explain the membrane-insertion process of another ADP-
ribosylating toxin, DT. Conformational change from a membrane-incompetent state to a 
membrane-competent state was suggested to originate from the protonation of six 
histidine residues, which would disrupt several salt bridges between different helices. In 
particular, Kurnikov et	al (2013) hypothesised that following protonation, the repulsion 
between His223 and His257, whose side chains are facing each other, would lead to the 
destabilisation of one α-helix of DT followed by exposure of a hydrophobic helical hairpin, 
important for membrane insertion [253].  




These results seem to strongly suggest the involvement of histidine residues in the 
conformation switch undergone by PE under acidic conditions. While the furin-cleavage 
site remains concealed from the protease at neutral pH to prevent early activation, a 
decrease in pH in the early endosome would lead to protonation of histidine residues and 
result in the creation of salt bridges. His249 and His275 appear to be strong contenders 
for the role, and it cannot be discounted that a combination of their respective 
protonation’s effects might be required to complete the conformational switch. In fact, 
evidence suggests that mutation of His249 to a negatively-charged residue could lead to 
early protein activation and defect in translocation activity [245]. Similarly, point 
mutation of His275 to an uncharged amino acid seems to trigger a defect in toxin 
translocation [246]. 
The conformational change undergone by PE in acidic conditions is thus suggested to 
contribute to protein diversion from the lysosomal degradation pathway towards the 
Golgi and eventually either the cytosol of non-polarised cells or basal side of polarised 
cells. In fact, this conformational change could decrease the affinity of PE for the LRP1 
receptor, leading to the dissociation of the complex. While the receptor would then recycle 
to the plasma membrane, the protein would then be free to bind another receptor in the 
endosome, whose role would be to lead the protein away from the lysosomal pathway. 
  




4 RESULTS 2 – ROLE OF GM1 IN 




Monosialoganglioside GM1 belongs to the family of gangliosides. It bears two hydrocarbon 
chains, which constitute the ceramide moiety and are connected to a hydrophilic sugar 
head composed of two galactose rings (II and IV) and one of each glucose (I), N-
acetylgalactosamine (III) and sialic acid (V) moieties (Figure 4-1 (A)). GM1 has an 
important role in the physiology of the brain [254-256] and is also the host receptor used 
by cholera toxin (CT), one of the virulence factors secreted by the intestinal pathogen 
Vibrio	cholerae. CT binds to GM1 on the apical surface of polarised epithelial cells and is 
internalised via receptor-mediated endocytosis [257]. Similarly, other toxins penetrate 
their target cells following interactions with cell surface lipids [102], which then mediate 
their transport to the ER in a retrograde manner [104, 111, 258, 259]. PE appears to be an 
exception, as its endocytosis in non-polarised cells is mediated by a surface protein 
receptor, the α-2-macroglobulin receptor/low density lipoprotein receptor-related 
protein (LRP1 aka CD91), rather than a lipid receptor [108], and because the intracellular 
pathway it exploits to reach the ER has been shown to vary from those of the lipid-binding 
proteins [142, 143]. One study has suggested that LRP1 may be involved in the uptake of 
PE by polarised cells that results in epithelial transcytosis [164]. 




However, preliminary studies performed by Dr Thomas Hunter (personal communication) 
using bio-layer interferometry (BLI) have shown that PE can interact moderately and 
reversibly with GM1, and that the binding affinity was greater at mildly acidic rather 
slightly alkaline pH. These results were complemented by HPLC studies that demonstrated 
incubation of PE with asialoGM1 instead of GM1 did not result in complex formation, 
suggesting the protein interacts with the sialic acid moiety of the ganglioside. 
Furthermore, Carter (2014) suggested that GM1 could be involved in the transcytosis of 
PE, as addition of CT considerably reduced the transport of fluorescent PE across a 
monolayer of polarised epithelial cells [27]. These results suggest that interaction between 
the protein and the ganglioside might be required for efficient transcytosis. However, 
neither the location, nor the role of this interaction in the trafficking of PE in polarised or 
non-polarised systems, has been elucidated. 
In this chapter, the role of GM1 in the uptake and early trafficking of PE was investigated 
in non-polarised epithelial cells. First, BLI was employed to quantify the interaction 
between the protein and the ganglioside at different pH values. The location of the binding 
site on PE was then examined by spectrofluorometry. Finally, the role of GM1 in the 
internalisation and intracellular transport of PE was studied using a fluorescently-labelled 
protein. 
   















































































Determination of the critical micellar concentration of lysoGM1 using the dye 
micellisation method 
LysoGM1 is a version of GM1 lacking one of the two hydrophobic chains (Figure 4-1 (B)) 
[260] that was used in spectrofluorometry studies to investigate the location of the GM1 
binding site on PE. Its critical micellar concentration (CMC) was determined using the dye 
micellisation method with eosin Y [261]. Eosin Y (Figure 4-2) is a dye which maximum 
absorption occurs at 518 nm in the absence of micelles. Due to encapsulation of the dye 
into surfactant micelles, increasing the surfactant concentration results in a progressive 
shift of the maximum absorption wavelength from 518 nm to 538 nm. It has been reported 
that the variation can be better followed at 542 nm (A542) and that the inflection point on 
the A542 = f ([lysoGM1]) or λmax = f ([lysoGM1]) curves corresponds to the CMC [261]. 
 
Figure 4-2 – Molecular structure of eosin Y. 
5 μl lysoGM1 samples were prepared in phosphate buffer (PB) 5.8 containing 0.1 M NaCl 
at concentrations ranging from 1 x10-9 to 1 mM and eosin Y was added to each sample to a 
final concentration of 0.19 mM. Absorbance data were collected at 542 nm (A542) using a 
NanoDropTM 2000c on pedestal setting [261]. 




In order to quantify the interaction between PE and GM1 in both acidic and neutral 
conditions using BLI, ntPE was biotinylated to be immobilised on the biosensor tip via 
biotin-streptavidin interactions, and GM1 was used as the analyte in solution in buffer. 
Characterising the strength of the interaction between the protein and its receptor at 




different pHs is essential to determine at which stage the interaction between PE and GM1 
is most prone to take place. 
4.3.1.1 Preparation	of	biotin-labelled	PE	
 
In order to obtain biotinylated protein, the C-terminal TEV sequence of ntPE GS TEV was 
digested with a commercial AcTEV protease; 1.28 mg (19 nmol) of cleaved ntPE GS TEV 
was collected in 3.5 ml PBS and incubated in presence of 50-molar excess sulfhydryl-
reactive EZ-Link® Maleimide-PEG2-Biotin reagent (950 nmol ≡ 0.5 mg) for 3 h at RT 
(Figure 4-3). Following desalting, buffer exchange and concentration, 200 μl of ntPE-biotin 
at 3.5 mg/ml were collected in PBS. 
 




BLI was used here to characterise the interaction between PE and GM1 in neutral and 
mildly acidic conditions. Measurements were performed in collaboration with Dr Thomas 
Hunter who had access to a BLI instrument. 
Experiments were conducted at 37 °C in 0.1 M potassium-phosphate buffer at pH 5.5 or 
7.5. The plate layout used is presented in Figure 4-4. The biosensor tip was first dipped in 
buffer in order to establish a baseline (Equilibration, Column 1). Biotinylated ntPE was 
then loaded on the sensing surface (Loading, Column 2). A second baseline step was 




performed to remove unbound ligand from the biosensor and assess for possible drifts 
caused by non-specific binding (Baseline, Column 3). The association between GM1 and 
ntPE was then monitored in real time (Association, Column 4). Finally, the biosensor was 
dipped into buffer one last time and dissociation was observed (Dissociation, Column 5). A 
summary of the kinetics assay step times is presented in Table 4-1 and the sensorgrams 
obtained for each condition are displayed in Figure 4-5. For each pH, a reference well, 
devoid of attached ligand but exposed to the same ganglioside concentration, was used to 
measure non-specific binding of GM1 to the sensor surface (Lanes G and H). 
 
 
Figure 4-4 – Plate layout diagram for the kinetics assay. 
 
Table 4-1 – Summary of kinetics assay procedure. 
Step # Step name Time (sec) 
Sample plate 
column 
1 Equilibration 60 1 
2 Loading 120 2 
3 Baseline 35 3 
4 Association 120 4 











    
Figure 4-5 – Kinetic characterisation of the interaction between ntPE and GM1. 
Sensorgrams obtained following interaction of GM1 and immobilised, biotin-
labelled ntPE at pH 5.5 and 7.5. 
Observation of the sensorgrams revealed that the curves were biphasic, especially at 
lower pH. This indicates that more than one interaction was taking place. As a result, data 
were fitted to a 2:1 heterogeneous ligand binding model (Figure 4-5) as described in 
Equation 4-1, where A is the analyte in solution, and B1 and B2 represent two different 
ligands on the surface [262]. KD is the dissociation constant (expressed in M) and ka and kd 
are the association and dissociation constant rates, respectively. This model is used when 
one molecule of analyte can bind to two different ligands immobilised on the surface. It 
also assumes that there are no cooperative interactions and that the analyte in solution is 
a single species. The observed binding is then the sum of the interaction with the two 
different ligands. This is an appropriate model for samples in which the ligand is not 
homogeneous or fully active, e.g. when the ligand prepared contains a small amount of 
misfolded protein which could still bind to the analyte or when the immobilisation of the 
ligand on the surface can alter its activity. The fact that the heterogeneous ligand binding 
model provided a best fit for the data collected here, especially at pH 5.5 (r² = 0.996), 
could be related to the instability and dynamic behaviour of PE in mildly acidic conditions, 
as previously described in Chapter 3. In fact, if the conformation adopted by ntPE in acidic 
conditions is unstable, then the protein could bind to GM1 as two different entities.  A 
summary of the parameters obtained following data fitting is presented in Table 4-2. 
 




Equation 4-1 – 2:1 heterogeneous ligand model. 
 
 
Table 4-2 – Summary of the parameters obtained by fitting experimental data to a 
heterogeneous ligand binding model. Parameters are the average of three 
individual lanes. 





kd1 (s-1) kd2 (s-1) r2 
7.5 7.06 x10-6 7.06 x10-6 4.43 x102 4.43 x102 2.60 x10-3 2.60 x10-3 0.711 
5.5 < 1 x10-12 3.01 x10-9 6.72 x105 1.33 x107 < 1 x10-7 3.70 x10-2 0.996 
 
The calculated KD values indicate that ntPE binds to GM1 at pH 5.5 and 7.5 with relatively 
high affinities as in both cases KD < 10-5 M. However, the protein and receptor complex 
constitutes a higher affinity pair in acidic conditions (KD5.5 < 10-9 M). The results obtained 
following data fitting confirmed that while the protein was immobilised under one state 
only at pH 7.5 (KD1 = KD2), more than one species of ntPE was attached to the tip surface at 
pH 5.5 (KD1 ≠ KD2). Since both samples originated from the same batch of protein, this 
discrepancy likely reflects the dynamicity of ntPE in acidic conditions mentioned above, 
and its presence under different conformations on the tip surface. One of these 
conformations interacted much more tightly with GM1 (KD1 < 1 x10-12 M and kd1 < 1 x10-7 s-1) 
than the other (KD2 = 3.01 x10-9 M and kd2 = 3.70 x10-2 s-1). This could suggest that the pair 
showing the highest binding affinity involved a protein which had fully undergone its 
conformational change, while the other species could be a protein which was either still in 
transition, unable to reach its final state, or even kept alternating between the two states. 
It was shown in Chapter 3 that following internalisation, ntPE undergoes a conformational 
change, which is likely to occur in the early endosomal compartment. Together with the 
results presented here, data seem to indicate that the pH-dependent difference in binding 
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affinity observed for ntPE interactions with GM1 could be due to a difference in binding 
site exposure reflecting an ntPE-associated conformational change. Moreover, it was 
previously concluded that the rearrangement in the toxin’s structure is likely to occur 
within domain II, particularly between amino acids 252 and 303, and that it results in the 
exposure of formerly buried hydrophobic residues. Therefore, it is possible for GM1 to 
interact, at least partially, with the region of changing hydrophobicity revealed by ANS 
studies (Section 3.3.5). Consequently, if GM1 was added in solution to ntPE, and did 
interact with a hydrophobic region of the protein, it would then prevent contact between 
the dye and these exposed residues and inhibit any increase in fluorescence at pH 5.8. 
Spectrofluorometry was therefore employed in an attempt to further characterise the 
interaction(s) of GM1 with ntPE. 
4.3.2 Investigation	of	the	GM1	binding	site	by	spectrofluorometry	
 
ANS was employed here to determine whether the GM1 binding site is located in a region 
of variable hydrophobicity, possibly within domain II. Such studies are complicated by the 
fact that GM1, as a ganglioside, contains a highly hydrophobic tail that is prone to ANS 
binding and thereby would increase the dye’s fluorescence in solution (Figure 4-6). 
 
Figure 4-6 – ANS readily binds to GM1 in solution. Fluorescence spectra of ANS and 
ANS + GM1 at pH 7.4 or 5.8 with [ANS] = 100 μM and [GM1] = 2.5 μM. 
In order to reduce this effect, GM1 was substituted in these experiments by lysoGM1, 
which is a version of GM1 lacking one of the two hydrophobic chains, which dramatically 
decreases its hydrophobicity (Figure 4-1). The hypothesis underlying this work was that 
the interaction between protein and ganglioside occurred via the sialic acid moiety of the 
head group, and therefore substituting GM1 by lysoGM1 should not affect the ability to 




accurately test this hypothesis since it would not affect the nature of the ganglioside 
binding properties being studied. 
For these studies, it was important to maintain lysoGM1 concentration below its CMC, as 
the steric hindrance due to the formation of ganglioside micelles could affect the protein-
receptor interaction. Unfortunately, CMC information for lysoGM1 could not be found in 
the literature. Therefore, this data was determined empirically for the conditions to be 
used in subsequent studies.  
4.3.2.1 Determination	of	lysoGM1	CMC	
 
Eosin Y was employed to record the appearance of lysoGM1 micelles using the dye 
micellisation method. The shift from monomeric to micellar form was monitored by 
changes in maximum absorption wavelength (λmax) as a function of lysoGM1 
concentration. Figure 4-7 illustrates lysoGM1 CMC determined by the shift in λmax as the 
concentration of ganglioside was increased from 1 x10-9 to 1 mM. Three phases could be 
observed: i) when [lysoGM1] < 0.05 mM, λmax remained stable at 518 ± 2 nm, 
characterising the concentration range where the ganglioside was present as a monomer 
and the dye was free in solution. ii) A second stable zone could be observed as λmax reached 
528 ± 1 nm when [lysoGM1] ≥ 0.2 mM. The majority of the ganglioside was then present 
under micellar form and most of the dye was encapsulated into these micelles. Between i) 
and ii) was a region of rapid transition in λmax, characteristic of the progressive 
encapsulation of the dye into the lysoGM1 micelles as these started to form. This zone was 
characterised by the presence of lysoGM1 under both monomeric and micellar form. 
Figure 4-8 depicts the three phases of the micelle formation process. 





Figure 4-7 – Critical micellar concentration determination of lysoGM1 using the dye 
micellisation method. λmax values were determined over a concentration range of 
the ganglioside. Eosin concentration was 0,19 mM. Bars represent mean ± SD for n = 
3 independent samples. The plain black line represents a sigmoidal fit of the data. 
The red dashed line indicates the coordinates of the inflection point to the sigmoidal 
curve. 
A sigmoidal curve could be fitted to the experimental data (r² = 0.9647) (Equation 4-2) 
and determination of the inflexion point allowed for an evaluation of the critical micelle 
concentration of lysoGM1. Using this method, the CMC was calculated to be 0.09 mM. This 
value is in agreement with the graphic data which suggested that micelle formation was 
initiated for [lysoGM1] ≥ 0.05 mM. 
 







































































Figure 4-8 – Micelle formation process with increasing concentrations of lysoGM1. 
The dye micellisation technique using eosin Y was shown to procure CMC values 
comparable to those obtained by surface tension measurements and could thus be 
considered a reliable method for determination of surfactant CMC [261]. Here, it was used 
to determine an approximate CMC for the ganglioside lysoGM1, in order to ensure that 
further fluorescence studies would be performed on the monomeric form of this 
compound. It was concluded that for any concentration below 0.09 mM, lysoGM1 would 
not form micelles in the particular conditions used here. CMC data for gangliosides, 
including GM1, remain controversial. While some reports suggest that the critical micellar 
concentration for GM1 is of the order of 10-8 M [263-265], others have determined that 
GM1 only forms micelles at micromolar [266] or even higher concentrations [267]. The 
discrepancy in these data might be due to variations in experimental conditions as 
solvents (aqueous or partly organic) and techniques used (conductivity, surface tension 
and spectrophotometry) typically differ in most of these studies; challenges that are 
further complicated by the fact that the degree of purity of the gangliosides has a 
significant impact on the end result and these are likely different between studies [261]. 
The greater CMC value for lysoGM1 compared to GM1 was expected as the propensity to 
form micelles would be dependent upon the reduced hydrophobic character resulting 
from the presence of one versus two acyl chains [268]. In that respect, the values 
determined here with the dye micellisation technique seem coherent. 
 






It was previously shown that as the pH decreases, PE undergoes a conformational change 
which both results in exposure of hydrophobic residues and increased GM1 binding. To 
investigate a potential connection between these two events and the possibility that the 
newly exposed hydrophobic sites might be part of the GM1 binding site, displacement 
studies were performed using ANS fluorescence. ANS fluorescence is increased at lower 
pH due to interaction with additional hydrophobic residues. However, if these residues are 
involved in GM1 binding to PE, ANS should not be able to interact with these sites and no 
increase in fluorescence should be observed [191, 269]. 
As mentioned earlier, GM1 was replaced by lysoGM1 in order to minimise binding of ANS 
to the ganglioside’s ceramide moiety. To test for specificity and ensure that the remaining 
hydrophobic tail of the ganglioside did not interfere with ANS fluorescence measurements, 
N-acetylneuraminic acid (NANA) (sialic acid) was used as a control. Measurements were 
also performed after replacing lysoGM1 by sucrose to investigate whether potential 
interactions would be sugar-specific (Figure 4-9). 
 
Figure 4-9 – Molecular structures of N-acetyl neuraminic acid (sialic acid) and 
sucrose. 
Each sample was corrected with either the intrinsic fluorescence of ANS or that of ANS in 
the presence of lysoGM1 or one of its substitutes, and values of AUC, ΔF and λem,max were 
determined (Table 4-3). The study of the influence of each lysoGM1, NANA and sucrose on 
the fluorescence of ANS revealed that none of these components had a significant effect on 
the dye fluorescence spectrum within the 400-700 nm range that was used for analysis in 
these studies. In fact, the AUC were similar and λem,max remained unchanged (Table 4-3 and 
Figure 4-10 (A)). Moreover, no pH-induced difference could be observed between the 
fluorescence spectra of ANS in presence of each of these compounds (Figure 4-10, (A), (C), 
(E), (G)). Therefore, none of these compounds seemed to affect ANS fluorescence in the 
present experimental conditions. 




When ntPE was added to ANS in solution, only the variation between AUC5.8(ANS + ntPE) 
and AUC5.8(ANS + ntPE + lysoGM1) was recorded as statically significant (Figure 4-11 (B)). 
However, the ratios ΔF between ANS + ntPE and ANS + ntPE + lysoGM1 were not 
significantly different (Figure 4-11 (C)), suggesting that the addition of lysoGM1 did not 
affect the fluorescence of ANS in the presence of ntPE at either pH. Similarly, the 
fluorescence of the protein and ANS solution was unaffected by the presence of NANA or 
sucrose. 
Overall, these data revealed that the presence of lysoGM1 in solution did not affect the 
exposure of hydrophobic residues available for ANS binding on the surface of ntPE at 
either pH. These results did not support the hypothesis that lysoGM1 binding to ntPE 
could occur through a hydrophobic surface area exposed due to conformational change(s) 
induced at acidic pH. This finding would be coherent with the hypothesis that GM1 and 
lysoGM1 interact with PE via their sialic acid moiety as NANA is a fairly polar group (Log P 
= -3.56 [226]). However, to ensure that the absence of variation was due to the lack of ANS 
displacement, a positive control with a molecule known to dislocate ANS from one of its 



















Table 4-3 – Values of ΔF and λem,max collected by spectrofluorometry for different 
mixtures of ANS, ntPE and lysoGM1 or one of its substitutes. 




ANS 5.8 518 
ANS + lysoGM1 7.4 
0.952 
520 
ANS + lysoGM1 5.8 518 
ANS + NANA 7.4 
1.020 
515 
ANS + NANA 5.8 516 
ANS + sucrose 7.4 
0.964 
516 
ANS + sucrose 5.8 518 
ANS + ntPE 7.4 
1.449 
483 
ANS + ntPE 5.8 475 
ANS + ntPE + lysoGM1 7.4 
1.526 
488 
ANS + ntPE + lysoGM1 5.8 479 
ANS + ntPE + NANA 7.4 
1.432 
483 
ANS + ntPE + NANA 5.8 480 
ANS + ntPE + sucrose 7.4 
1.506 
489 
ANS + ntPE + sucrose 5.8 478 





Figure 4-10 – Fluorescence spectra of (A) ANS, (B) ANS + ntPE, (C) ANS + lysoGM1, 
(D) ANS + ntPE  + lysoGM1, (E) ANS + NANA, (F) ANS + ntPE + NANA, (G) ANS + 
sucrose and (H) ANS + ntPE + sucrose in CP 5.8 (red) and 7.4 (black). For all 
measurements, [ANS] = 100 μM, [ntPE] = 1.52 μM and [lysoGM1] = [NANA] = 
[sucrose] = 2 μM. 
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ANS + ntPE + NANA 7.4











































































ANS + ntPE + lysoGM1 7.4









































































ANS + ntPE 7.4













































































































































ANS + lysoGM1 7.4






































































ANS + NANA 7.4






































































ANS + sucrose 7.4








































































Figure 4-11 – Statistical analysis of the areas under the curves of (A) ANS and (B) 
ANS + ntPE in presence of lysoGM1, NANA and sucrose and (C) Variations in ΔF in 
different samples. In (A) and (B) data at pH 7.4 are represented in black and data at 
pH 5.8 are displayed in red. Bars show mean ± SD for n = 3 independent samples 




In non-polarised (NP) cells, internalisation of PE has been reported to occur by 
endocytosis following binding to LRP1 as a cell-surface receptor [108]. However, BLI 




















































































































































































































































interaction is stronger in mildly acidic conditions. This could suggest a role for GM1 as a 
PE receptor not only inside the cell (endosomal compartment), but also on the cell surface, 
where the pH is closer to physiological values. The involvement of GM1 in the uptake and 
early intracellular trafficking of PE by NP cells was therefore examined using a 
fluorescently-labelled protein. Further, the individual and combined effects of 
neuraminidase treatment on the cells and addition of cholera toxin B subunit (CTB) to the 
protein mixture were also analysed. 
4.3.3.1 Coupling	of	PE	to	a	fluorescent	tag	
 
All coupling experiments were performed and purified using the same protocol. As an 
example, coupling of full-length ntPE GS TEV to Alexa Fluor® 568 is described below. 
After cleavage of the C-terminal TEV sequence with a commercial AcTEV protease, ntPE GS 
TEV was incubated with a maleimide-functionalised Alexa Fluor® 568 tag (ntPE-A568). In 
order to separate the tagged protein from unreacted materials (uncoupled tag), the 
sample was loaded on a size exclusion column and purified by FPLC. The different 
components were eluted with PBS, and the fractions corresponding to the UV-absorbing 
peaks were separated by SDS-PAGE (Figure 4-12). 
Purification by GF chromatography resulted in the separation of two main UV-absorbing 
compounds. While the first peak (fractions M12-N1) corresponded to a band at ~70 kDa on 
Coomassie-stained gel, no bands corresponding to the second peak (fractions N5-N9) could 
be observed. This shows that the coupled ntPE-A568 and unbound dye were eluted in 
fractions M12-N1 and N7-N9, respectively. In fact, the dye is a very small molecule (MW = 
880.9 Da [270]) and thus could not be seen on the gel, whose MW range was between ~17 
and 100 kDa. The absence of secondary bands revealed that the coupled material was, as 
expected, very pure. Thus, fractions M14-M15 were concentrated together for further use. 
 





Figure 4-12 – Enrichment of ntPE-A568 by GF chromatography. (A) Chromatogram 
obtained for GF column separation. (B) Coomassie-stained SDS-PAGE of fractions 
containing the UV-absorbing material. M-, N- and O-labelled lanes in (B) correspond 
to arbitrary tray row and column reference on the fraction collector and are 
illustrated by the red dashes on (A). Fractions covered by the arrow in (A) indicate 
the complete range of fractions displayed in (B). The black dotted lines marked on 
both (A) and (B) indicate the fractions containing ntPE-A568 that were collected. 
4.3.3.2 Uptake	of	PE	by	non-polarised	epithelial	cells	
 
Non-confluent, non-polarised (NP) Caco-2 cells seeded on glass coverslips were incubated 
with 20 μg ntPE labelled with a fluorescent tag (ntPE-A568) diluted in 100 µl complete 
growth medium (= 3 µM final protein concentration). After 2 h, ntPE-A568 could be 
observed inside these NP cells, localising to individual spots at the periphery of the nuclei 
(Figure 4-13). Next, the effect of neuraminidase on protein entry was tested; NP cells were 
treated with the enzyme using several experimental formats. Initially, the effect of cell pre-
treatment with neuraminidase on the fate of added ntPE-A568 was examined. The pattern 
of intracellular fluorescence was observed to be similar for untreated NP Caco-2 cells 
compared to those following a 15-min pre-treatment with 1 U/ml neuraminidase. On the 
other hand, when the length of pre-treatment was extended to 2 h, a net increase in the 
amount of internalised protein could be detected, suggesting that removal of sialic acid 




residues by the action of neuraminidase resulted in increased ntPE-A568 internalisation. 
To explore this possibility further, NP Caco-2 cells were subjected to the same treatment 
and 3.5 µM cholera toxin B subunit (CTB), which selectively binds to sialic acid residues of 
the ganglioside GM1, was added to ntPE-A568 during incubation. In this case, hardly any 
intracellular fluorescence could be detected. Similarly addition of 3.5 µM CTB to ntPE-
A568 in the absence of neuraminidase (Figure 4-13; bottom) decreased the amount of 
fluorescent material that could be observed inside the cells compared to ntPE-A568 alone 
(Figure 4-13; top). Although no co-localisation studies were performed to determine 
exactly which final intracellular compartment the internalised ntPE-A568 reached, 
observation of the fluorescence patterns were consistent with the possibility that the 
protein could have travelled to the Golgi and/or possibly the ER. Importantly, the pattern 
of ntPE-A568 was inconsistent with EE or lysosome compartments as these are not 
typically adjacent to the nuclei of NP Caco-2 cells.  
Neuraminidase is an enzyme that cleaves sialic acid (SA) groups from glycoproteins and 
glycolipids [271]. In particular, gangliosides are progressively transformed from di-, tri- 
and tetrasialogangliosides to mono- and asialogangliosides by neuraminidase. Although 
the enzyme used here originated from Clostridium	 perfringens, neuraminidase is also 
secreted by bacteria, such as Pseudomonas	aeruginosa and Vibrio	cholerae [272, 273]. The 
role of bacterial neuraminidase isn’t well defined, but it has been suggested that one of its 
functions might be to prepare the cell surface for microbial attack. In fact, mucosal 
surfaces are heavily glycosylated [274] and neuraminidase could participate in the 
intoxication process by clearing the way to the epithelium through cleavage of SA groups 
from surface glycolipids and glycoproteins [275]. In the case of Pseudomonas	aeruginosa, 
Soong et	al (2006) suggested that neuraminidase might facilitate infection by taking part 
in the formation of biofilms [276]. In fact, the enzyme would modify the surface of 
epithelial cells in order to facilitate bacterial attachment; an event that might be 
exaggerated in cystic fibrosis patients, whose airway epithelia are more prone to 
modification than that of healthy patients. 
Another potential role for this enzyme could be to expose cell-surface receptors for 
bacterial toxins, thereby increasing their internalisation and facilitating the subsequent 
cell intoxication process. This mode of neuraminidase action has been mentioned in the 
case of cholera toxin (CT). It was suggested that following its release from the bacteria, the 
enzyme could digest SA groups from surface glycolipids and especially gangliosides, which 
would be transformed into additional monosialoganglioside molecules. GM1 is the host 
cell receptor for CT [109, 155, 156] and was proven to be resistant to Vibrio	cholerae-




secreted neuraminidase [277]. Its cleavage into asialoGM1 by the enzyme is thus limited. 
With more GM1 molecules unmasked on the cell surface by the removal of sialic acid from 
non-ganglioside molecules, the uptake of CT would be promoted and cell intoxication 
increased [277-279]. However, findings by Galen et	at (1992) revealed that neuraminidase 
was not essential for CT action, and that the enzyme might actually be an accessory 
virulence factor whose action and enhancement of pathogenicity would be noticeable only 
if conditions for the uptake of CT were not optimal [277]. 
Here, pre-treating the cells with neuraminidase aimed at clearing cell-surface SA groups 
on non-ganglioside molecules before applying ntPE [271]. The data collected showed that 
neuraminidase treatment was not compulsory for protein internalisation but indicated 
that pre-incubating the cells for 2 h in the presence of the enzyme enhanced protein entry. 
This effect could be due to removal of cell-surface SA groups unrelated to GM1 that could 
act to distract an interaction between ntPE and the SA group of GM1. Thus, removing the 
bulk of surface SA could promote ntPE internalisation. On the contrary, nearly no protein 
could be observed in the cells following addition of CTB (whether the cells were exposed 
to neuraminidase or not), implying that targeted GM1 blocking greatly reduced the 
cellular uptake of ntPE and supporting the likelihood that interaction with GM1 may play a 
role in ntPE internalisation. 
As neuraminidase action seemed to be both optional and beneficial to protein uptake, but 
specific GM1 blocking appeared detrimental to this process, these results suggest that this 
ganglioside functions in the internalisation of PE and P.	 aeruginosa-secreted 
neuraminidase could play a role in such a process by helping the toxin efficiently access 
the receptor. Although neuraminidase treatment should remove SA moieties from most 
surface proteins and lipids simultaneously, the recycling rate of lipids is much faster than 
that of proteins (minutes compared to hours) [280-282]. In fact, one of the lipid metabolic 
pathways allows for membrane lipids to be directed from the early endosome to the Golgi 
apparatus, where additional glycosylation can take place before the lipid is recycled back 
to the plasma membrane [281]. On the contrary, most proteins have to be entirely 
resynthesized (although the proportion of direct reglycosylation and recycling through the 
TGN compared to de	 novo synthesis depends both on the cell line and the protein 
considered) [283-285]. As a consequence, monosialated gangliosides would be recycled to 
the cell surface long before the bulk of sialated proteins were restored. Moreover, 
although the overall number of functional surface GM1 molecules might be reduced 
compared to untreated cells, the remaining gangliosides would be more accessible for 
binding by the toxin, which would itself be less distracted by surrounding sialated surface 




proteins. Finally, it would not be impossible for neuraminidases secreted by Vibrio 
cholerae and Pseudomonas	aeruginosa to present comparable characteristics, and for the 
enzyme secreted by the latter to be unable to cleave the SA moiety from 
monosialiogangliosides. As a conclusion, neuraminidase could improve GM1 binding by a 
combination of effects that would reduce the non-specific interaction between PE and 
sialated surface proteins and increase the potential for enhanced interactions with 
exposed GM1 molecules concomitantly. The studies presented here indicate that removal 
of the bulk of sialated protein from the cell surface could improve the GM1-associated 









Figure 4-13 – Neuraminidase and CTB affect the entry of PE in NP epithelial cells. 
Fluorescent images of NP Caco-2 cells incubated for 2 h with 3 µM ntPE-A568 under 
various conditions, including cell treatment with 1 U/ml neuraminidase for the 
indicated duration and/or addition of 3.5 µM CTB in solution with ntPE-A568. Cell 
nuclei were stained with DAPI (blue). Images are representative of three 
independent experiments. 




4.4 General discussion 
 
In this chapter, the interaction between PE and GM1 was characterised at neutral and 
acidic pH and the role of GM1 in the uptake and early endocytic pathway of PE was 
investigated in non-polarised (NP) epithelial cells. BLI was used to show that the 
ganglioside binds to ntPE with relatively high affinity at the neutral pH of 7.5, and that the 
interaction is even stronger at the mildly acidic pH of 5.5. By relating these results with 
data described in Chapter 3, it was hypothesised that the increased binding observed in 
mildly acidic conditions could be due to an improved exposure of the GM1 binding site on 
PE following a conformational change of the protein. It was therefore suggested that the 
ganglioside binding site(s) on PE could be located within or near the region of the protein 
undergoing this localised structure rearrangement (domain II), although 
spectrofluorometry studies did not allow confirmation or rejection of this hypothesis. Such 
a configuration could allow the protein to bind simultaneously to LRP1 and GM1 (Figure 
4-14). 
The fact that ntPE could interact with GM1 at neutral pH seems to indicate that binding 
could take place at the cell surface. This was confirmed by uptake assays in NP intestinal 
epithelial cells. GM1 is the host cell-membrane receptor for CT [109, 155, 156] and 
addition of CTB following neuraminidase treatment greatly decreased the amount of 
fluorescent protein detected in the cells. Moreover, it was revealed that the action of 
neuraminidase increased the uptake of ntPE most likely by removing the bulk of sialic acid 
moieties on the cell surface, thereby enhancing the specific binding of ntPE to GM1 and 
increasing its internalisation into cells. It was concluded that this enzyme could be acting 
as an accessory virulence factor, which would be released by the bacteria, and which 
action would be required only when conditions are not optimal for toxin uptake at the cell 
membrane [277]. 





Figure 4-14 – Proposed mechanism for the interaction of PE with GM1 both at the 
plasma membrane and in the endosome. PM, plasma membrane; EE, early 
endosome. 
Several pathways may be involved in the entry and early trafficking of PE in non-polarised 
Caco-2 cells. This possibility was mentioned previously by Smith et	al (2006), whose work 
indicated that PE could exploit two independent trafficking pathways to reach the ER in 
HeLa cells (Figure 4-15) [142]. The first route proposed is the KDEL receptor-mediated 
pathway, which is characterised by protein endocytosis mediated by LRP1 and subsequent 
trafficking from the EE to the LE, and further to the TGN, in a Rab9-dependent manner. In 
the TGN, KDEL receptors would interact with the C-terminal KDEL-like sequence of PE, 
leading the toxin to the ER in a retrograde manner. The alternative pathway considered by 
these authors is Rab6-dependent and involves the recruitment of LRP1 in detergent-
resistant membrane (DRM) micro-domains, which are highly ordered plasma membrane 
domains rich in glycosphingolipids and cholesterol [286]. Following internalisation, PE 
would traffic directly from the EE to the Golgi and then the ER following a lipid-dependent 
sorting pathway. A similar pathway has been described for shiga toxin intoxication [287, 
288]. The relative contribution of each pathway to the intracellular transport of PE was 
shown to vary in a cell-type specific manner [142]. 





Figure 4-15 – PE can exploit multiple pathways to traffic from the plasma membrane 
to the ER in HeLa cells. PM, plasma membrane; DRM, detergent-resistant membrane 
micro-domain; EE, early endosome; LE, late endosome; L, lysosome; TGN, Trans 
Golgi network; ER, endoplasmic reticulum; KDEL-R, KDEL receptor. Adapted from 
[142]. 
Data obtained in (NP) Caco-2 cells seemed to support and perhaps complete this 
hypothesis. It is proposed here that in untreated cells, specific interaction between PE and 
GM1 is prevented at the plasma membrane by the mass of sialated surface components 
and the toxin would therefore enter the cells by LRP1-mediated endocytosis. A fairly small 
amount of protein would then be internalised. However, due to the high potency of the 
toxin, only a few molecules need to reach the cytosol to intoxicate the cells [289, 290]. 
Activation of this sole pathway might therefore be enough for the virulence factor to carry 
out its catalytic activity and lead to the arrest of protein synthesis following infection by 
Pseudomonas	aeruginosa. 
Application of neuraminidase to the NP cells likely resulted in the cleavage of sialic acid 
groups from glycoproteins and glycolipids at the plasma membrane [271]. The faster 


































GM1 molecules available for specific binding to PE being greater than in untreated cells. 
Protein binding to the ganglioside would then result in the opening of a second pathway 
and in the subsequent increased uptake of PE by the cells. GM1 has been shown to be fairly 
evenly distributed on the cell membrane [291], but can also be also concentrated in 
structures including, but not limited to, caveolae [292, 293], clathrin-coated pits [292, 
293] and DRM domains [294]. However, it has been suggested that only DRM-associated 
GM1 molecules could efficiently mediate the transport of CT to the ER via the Golgi and 
thereby cause toxicity [295]. This could explain why molecules of GM1 located near LRP1 
but not associated with DRM did not trigger protein endocytosis following this pathway. 
As a conclusion and as suggested by Smith et	al [142], the second pathway exploited by PE 
could be initiated by protein associated with DRM domains.  
Upon addition of CTB and ntPE, the two proteins would compete for GM1 binding on the 
cell surface. Because the affinity of CTB for GM1 (KD = 4.61 x 10-12 M at pH 7.5 [296]) is 
greater than that of PE (KD = 7.06 x10-6 M at pH 7.5), the binding of CTB would dominate 
and as a result, the amount of PE internalised by the DRM-associated pathway would be 
reduced. Moreover, the small amount of PE that managed to enter the cell via this pathway 
would also have to compete for GM1 binding upon any conformational change that 
occurred in the EE. This could further reduce the amount of PE trafficking to the Golgi and 
possibly redirect it to the lysosome for degradation. 
CT has been shown to also exploit different pathways to enter the cells depending on the 
cell line [257, 297]. In particular, CT can be internalised via clathrin-dependent and 
clathrin-independent mechanisms following GM1 binding; the respective fractions of each 
pathway varying with the cell line considered [257]. Furthermore, although the A subunit 
of CT bears a C-terminal KDEL sequence, this has been demonstrated to not be required 
for transport to the ER as its absence slows down, but does not inhibit, the action of CT on 
cells [295, 298]. Instead, evidence strongly suggests that following internalisation, CT 
remains bound to GM1 molecules associated with lipid rafts, and that the ganglioside leads 
the toxin from the plasma membrane to the ER via the Golgi apparatus [295]. Moreover, 
the A subunit is not required for transport from the plasma membrane to the ER via the 
Golgi apparatus [295]. Therefore, as in the case of PE, the KDEL sequence might not be a 
requirement for transport to the ER but it might help to retain CT in the ER in order to 
increase the fraction of A1 subunit transporting to the cytosol [295]. It is an interesting 
possibility that the previously described Rab6-dependent pathway used by PE to reach the 
Golgi [142] might be associated with GM1 binding at the cell surface and in the endosome, 




and that this trafficking route might resemble the lipid transport pathway suggested for 
CT intracellular transport [299]. 
The two pathways of PE cellular trafficking described in this chapter seem to vary mainly 
in the way the protein enters the cells. However, it would be possible for them to be 
connected in the cell, perhaps in the early endosome. Independent of its entry mechanism, 
PE could dissociate from LRP1 and fully interact with GM1 following a pH-dependent 
structural rearrangement. This could allow all internalised PE to traffic to the Golgi using a 
lipid transport pathway, and would explain why even in untreated cells the addition of 
CTB seemed to reduce the amount of fluorescent PE detected inside the cells. 
Based on the results presented here and by making comparisons with CT, a mechanism for 
the entry and early intracellular pathway of PE can be proposed (Figure 4-16). This 
mechanism correlates with previous reports from Smith et	 al (2006) and seems to 
complement their hypothesis [142]. Two different processes could be involved in the 
entry of PE into non-polarised epithelial cells. The first one involves protein endocytosis 
following binding to the LRP1 receptor and its subsequent transport to the EE. The second 
mechanism proposed here would involve protein binding to the DRM-associated GM1 
ganglioside present on the plasma membrane and transport to the EE. Whether this 
binding would occur in conjunction to LRP1 binding is unknown. However, previous 
reports showed that PE is able to recruit a fraction of the LRP1 receptors in DRM [142], 
and data presented in this chapter suggests that the toxin might interact with GM1 via its 
second domain. It is therefore possible that protein endocytosis from DRM would involve 
simultaneous binding to LRP1 (via domain I) and GM1 (via domain II). The two pathways 
could then either carry on separately to the ER or connect in the EE, where independently 
of how it was internalised, PE would dissociate from LRP1 and bind completely to GM1. 
The ganglioside would then lead the protein to the ER through the Golgi. Alternatively, a 
fraction of the protein could transport from the EE to the Golgi via the LE before carrying 
on to the ER following binding to KDEL receptors, as previously suggested [142]. 
Physiologically, the lipid transport pathway used by PE to reach the ER might not be the 
main trafficking pathway, as the studies presented here have suggested that that the 
exposure of GM1 might need to be increased for specific protein binding and activation of 
this trafficking route. Thus, the toxin might utilise this route only when conditions for 
transport via the KDEL-dependent pathway are not optimal. In this case, neuraminidase 
secreted by the bacteria upon infection would clear the cell surface from SA groups 
thereby enhancing toxin binding to GM1, a sialic acid-expressing ganglioside. This would 
result in the initiation of this secondary pathway and in the increase in the amount of PE 




penetrating the cells. It is important to point out that these findings were obtained in	vitro 
using NP Caco-2 cells; more discrimination in	vivo between these various internalisation 




Figure 4-16 – PE can exploit a lipid transport pathway as well as a KDEL-dependent 
pathway to traffic to the ER. PM, plasma membrane; DRM, detergent-resistant 
membrane micro-domain; EE, early endosome; LE, late endosome; L, lysosome; TGN, 
Trans Golgi network; ER, endoplasmic reticulum; KDEL-R, KDEL receptor. 
As a conclusion, it is proposed that efficient binding and transport of at least a fraction of 
PE to the ER are mediated by interaction with DRM-associated GM1 molecules. The 
different routes exploited by the protein to reach its intracellular target have been studied 
here, and by others, using the native toxin [108, 139, 142, 300]. Understanding the 
characteristics and requirements of the protein for efficient uptake and translocation is 
essential if PE is to be used as a drug carrier. Similarly, it is crucial to appreciate how the 
addition of a cargo macromolecule may impact the intracellular trafficking of PE in order 































5 RESULTS 3 – PE AS A DRUG 
DELIVERY VEHICLE: 
STRUCTURAL REQUIREMENTS 




In the last 20 years, the use of bacterial toxins such as PE and DT as therapeutic tools has 
been widely explored by replacing their receptor-binding domain with a cell-specific 
antibody, thereby transforming these natural cell killers into highly potent immunotoxins 
for the treatment of cancer [120]. Recently, Mohammed et	al (2012) exploited PE’s ability 
to reach the cell cytosol following internalisation, and showed that fusion of a cell-
penetrating peptide (CPP) sequence to the N-terminus of domain II of PE facilitated the 
cytosolic delivery of a cargo protein [165]. Moreover, these toxins are characterised by 
their remarkable ability to translocate across the polarised cells of mucosal surfaces 
without causing any obvious damage to the epithelium, but to subsequently target and kill 
antigen-presenting cells located in the submucosal space [164]. Carter (2014) showed that 
PE could not only deliver siRNA into macrophages to elicit a knockdown effect, but also 





transport the siRNA cargo across polarised cells and deliver it into macrophages of the 
underlying mucosa [27]. 
Altogether, these observations suggest that PE could represent a highly efficient delivery 
system for transport of drugs across epithelial barriers such as those present in the lung 
or intestine. This would allow oral administration of macromolecular drugs, which 
currently have to be delivered by injection. Importantly, the crystal structure of PE and 
information regarding functional properties of various regions of the molecule suggest 
that this protein is organised in a carrier-cargo format: domain I and II appear to be 
required for protein transport and responsible for carrying domain III across polarised 
cells and delivering it to non-polarised cells where it can incite cell death. Thus, removal of 
domain III should not prevent transcytosis, and this cytotoxic domain could potentially be 
replaced by a therapeutic payload (protein, siRNA, etc.) that could be carried across 
epithelial barriers.  
The use of PE as a drug carrier following the replacement of domain III with a therapeutic 
protein would exhibit various advantages over currently existing delivery systems for 
macromolecules. First, it would allow the drug to be transported across the epithelium 
without causing any damage to the mucosa, which would represent a major advance 
compared to the current systems used to improve epithelial absorption of macromolecular 
drugs.  Moreover, several studies have reported that there is no competition between PE 
and other LRP1 ligands for the binding of the LRP1 receptor [301-303]. Therefore, cellular 
uptake of the PE-cargo drug complex would not be limited by the presence of endogenous 
LRP1 ligands, as is currently the case for other delivery systems that involve competition 
with endogenous ligands [304, 305]. Finally, removal of PE domain III, which carries the 
cytotoxic activity, should decrease the immunogenic potential of this delivery system. 
This chapter describes an attempt at characterising a non-toxic form of PE (ntPE) as a 
delivery system for protein therapeutics. First, truncated mutants of the toxin were used 
to investigate the minimal protein length required for uptake into non-polarised cells; a 
fluorescent cargo protein was then attached to these versions of PE and the resulting 
fusion proteins were employed to determine the impact of such an addition on 
internalisation and transcytosis events in	 vitro. This fluorescent element was then 
replaced by a therapeutic cargo, and transepithelial transport of this compound was 
studied in	 vivo. Finally, the role of the ganglioside GM1 in the uptake of truncated PE 
mutants by non-polarised cells was examined. 







Co-localisation analysis using Image J 
Each image was visually inspected and co-localisation of GFP (green) and GM130 (red) 
was qualitatively tested using the Image Correlation J [306] and Colocalization [307] 
plugins on Image J [308] in order to establish, for each image, a scatter plot and a mask 
image, respectively. The latter was generated from the overlay of two masks 
encompassing the fluorescent signal for the labelled protein and GM130 
immunofluorescence, respectively. The sites of co-localisation appear in white on the final 
image. 
5.3 Results and discussion 
5.3.1 Cloning,	expression	and	purification	of	PE364-hGH	
 
Cloning of PE364-hGH 
Human growth hormone (hGH) was amplified from pHGH107 by PCR using a set of 
different buffers (GC buffer, GC buffer + DMSO or HF buffer) and primers containing the 
AflII and EcoRI restriction sites. While use of HF buffer results in a lower error rate of 
Phusion polymerase, GC buffer is more adapted to primers with GC-rich content and 
presence of DMSO can help in the denaturation of such templates [309]. Amplification in 
each of these conditions produced bands at ~0.6 kbp of comparable intensities (Figure 5-1 
(A)). As HF is the recommended buffer for high-fidelity amplification, the PCR was scaled 
up using this buffer, and the insert was digested by AflII and EcoRI-HF® restriction 
enzymes. 
In parallel, pPE364-GFP was digested at the AflII and EcoRI restriction sites in order to 
release the GFP fragment (Figure 5-1 (B)). Digestion products were separated by agarose 
gel electrophoresis, and three bands were observed: one strong band ~4 kbp (undigested 
plasmid) and two very faint bands at ~3 kbp (digested plasmid) and 0.7 kbp (GFP). The 
strong intensity of the 4 kbp band compared to the other bands shows that digestion was 
not very effective, and only a small amount of the original DNA was cleaved. However, by 
scaling up the reaction, enough of the digested plasmid was collected to proceed to the 
next steps. 





   
Figure 5-1 – (A) Amplification of hGH by PCR. Lane 1 contains the fragment 
amplified in GC + DMSO, and lanes 2 and 3 correspond to GC and HF buffers, 
respectively. (B) Fragments obtained following digestion of pPE364-GFP by AflII and 
EcoRI-HF®. 
The plasmid obtained after ligation of the insert (hGH) and the digested plasmid and 
transformation on competent DH5α cells was named pPE364-hGH (DH5α). Confirmation 
of the nature of the plasmid was obtained by sequencing (Sanger sequencing, Source 
BioScience, Oxford, UK). This plasmid was further transformed in competent BL21 cells to 
obtain pPE364-hGH (BL21) for protein expression.  
 
Expression and purification of PE364-hGH 
PE364-hGH was insoluble when expressed in E.	 coli, as shown in Figure 5-2: after 
centrifugation of bacterial cells, virtually no protein was present in the supernatant, while 
the pellets were loaded with protein. 
 
Figure 5-2 – PE364-hGH is insoluble when expressed in E. coli. S364, sample 
containing the soluble protein fractions (supernatant) and P364, sample containing 
the insoluble protein fractions (pellet). 





As a consequence, PE364-hGH was expressed as inclusion bodies from pPE364-hGH 
(BL21). Despite the presence of an N-terminal His tag, the expressed protein was not 
retained on His column (Figure 5-3). This could be due to column degradation, or 
alternatively the tag could have been masked during protein refolding and therefore could 
be unable to interact with nickel groups on the column. As a result, PE364-hGH was 
purified using AE and GF chromatography. First, PE364-hGH was eluted from an AE 
column with a NaCl gradient. A single peak could be observed at 15-55% NaCl (= 0.15-0.55 
M NaCl) (Figure 5-4 (A)). 
Fractions corresponding to this peak as well as the flow-through were separated by SDS-
PAGE (Figure 5-4 (B)). A single band at ~70 kDa was detected in fractions D3-D7 which 
corresponds to PE364-hGH (Section 2.4.5 and Appendix 1). As the band observed in the 
flow-through fraction (X6) was relatively faint compared to bands detected in fractions D3-
D7, these fractions were concentrated together down to 1 ml for further purification by 
size exclusion chromatography (Figure 5-5) and X6 was discarded. 
Following this second purification step, fractions corresponding to the UV-absorbing 
material were separated by SDS-PAGE. As the UV peak obtained was less well defined, an 
SDS-PAGE of individual column fractions was used to assess the amount and purity of the 
protein of interest, providing the rationale for fractions that were pooled; PE364-hGH was 
collected from fractions J6-J12 (Figure 5-5 (B)). Analysis of the Coomassie-positive bands 
showed a dominant one visible at ~37 KDa in fractions J13-J15. This band could correspond 











Figure 5-3 – Despite carrying an N-terminal His tag, PE364-hGH was not retained on 
a His column. (A) WB of the purified PE364-hGH. 10 μg of protein was separated by 
SDS-PAGE and transferred to PVDF membrane that was probed with an anti-His 
antibody diluted at 1 in 3,500 in TBS-T. PE-tev is a version of PE carrying a C-
terminal His tag and was used as a positive control. BSA was used as a negative 
control. (B) Chromatogram obtained following elution of PE364-hGH on a Ni2+-
functionalised column. 
  
Figure 5-4 – Initial enrichment of PE364-hGH by AE chromatography. (A) 
Chromatogram obtained for AE separation. (B) Coomassie-stained SDS-PAGE of 
fractions corresponding to the UV peaks. X- and D-labelled lanes in (B) correspond 
to arbitrary tray row and column reference on the fraction collector and are 
illustrated by the red dashes on (A). Fractions covered by the arrow in (A) indicate 
the complete range of fractions displayed in (B). The black dotted lines marked on 
both (A) and (B) indicate the fractions containing PE364-hGH that were collected. 






 Figure 5-5 – Further enrichment of PE364-hGH using GF chromatography. (A) 
Chromatogram obtained for GF column separation. (B) Coomassie-stained SDS-
PAGE of fractions corresponding to the UV peaks. J-labelled lanes in (B) correspond 
to arbitrary tray row and column reference on the fraction collector and are 
illustrated by the red dashes on (A). Fractions covered by the arrow in (A) indicate 
the complete range of fractions displayed in (B). The black dotted lines marked on 
both (A) and (B) indicate the fractions containing PE364-hGH that were collected. 
5.3.2 Properties	of	PE-GFP	mutants	
 
A series of six PE-GFP versions was cloned and expressed in collaboration with Dr Julia 
MacKay. ntPE-GFP is a fusion protein that is constituted of full-length ntPE GS TEV 
connected to a C-terminal GFP molecule and was isolated by IMAC. Five truncated versions 
of ntPE-GFP were also produced, corresponding to the PE GS TEV protein series: PE408-
GFP, PE364-GFP, PE351-GFP, PE320-GFP and PE303-GFP. Numbers indicate the last 
amino acid of the truncated protein. Physiochemical properties of these proteins are 
presented in Table 5-1. 







Figure 5-6 – (A) Ribbon representation of ntPE-GFP structure. ntPE GS TEV was 
fused to a C-terminal GFP molecule. The figure was generated using PyMOL [128]. 
(B) Schematic representation of the different versions of PE-GFP used in this study. 
Note the deletion of E553 in domain III that renders PE non-toxic (ntPE). Letters A-F 
refer to the six α-helices of domain II. 
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Table 5-1 – Physicochemical properties of PE-GFP truncated mutants. Both pI and 







ntPE-GFP 5.34 93.2 
PE408-GFP 5.36 71.4 
PE364-GFP 5.33 69.2 
PE351-GFP 5.41 67.6 
PE320-GFP 5.53 64.4 




It is proposed that utilising the internalisation mechanism and intracellular trafficking 
used by PE would be an effective method for the delivery of biopharmaceuticals. This 
concept involves the use of domains I and II that appear to be specifically involved in these 
internalisation and trafficking processes; domain III could be eliminated. In an attempt to 
better understand the requirements of domain II in these processes, PE was genetically 
truncated at residues 303 or 364 and modified at the new C-terminus with a sequence of 
amino acids that could be specifically cleaved by tobacco etch virus (TEV) protease and 
that allowed for a site-selective chemical coupling with the fluorescent Alexa Fluor® tag 
568 (A568). The two PE-derived materials, denoted as PE303 GS TEV (short-length 
mutant) and PE364 GS TEV (medium-length mutant), respectively, were evaluated for 
their internalisation and trafficking properties in NP epithelial cells in	vitro.  
NP Caco-2 cells seeded on coverslips were incubated with 20 μg of each fluorescently-
tagged protein diluted into 100 µl complete growth medium (concentration of ntPE-A568 
= 3.0 µM, PE364-A568 = 5.0 µM, and PE303-A568 = 5.9 µM, respectively) for 2 h at 37 °C 
before being fixed and stained with DAPI (Figure 5-7). 
Importantly, fluorescent images obtained by confocal microscopy showed that both 
truncated PE proteins retained their ability to be taken up by NP cells in	vitro. However, 





the intracellular distribution of PE364-A568 and PE303-A568 may have been somewhat 
distinct. No co-localisation studies were performed here and therefore the proposed 
intracellular location of each protein remains purely speculative at this time. In the 
absence of these co-localisation studies, it appears that full-length ntPE-A568 could be 
detected primarily in a compartment that might correspond to the ER/Golgi apparatus 
(Figure 5-7; top, green arrow). In the case of PE364-A568, the protein was found as well-
defined fluorescent dots surrounding the nuclei in some cells (white arrow), while in 
others it was present as a single fluorescent spot close to the nucleus (green arrow). The 
pattern observed for PE303-A568 is less clear and only small and poorly-defined 
fluorescent protein dots around cell nuclei could be identified. These observations could 
suggest that while some of PE364-A568 might have reached the Golgi/ER (similar pattern 
to ntPE-A568), a substantial fraction of the protein might have remained inside endocytic 
vesicles or alternatively, trafficked to the lysosome. It appeared that PE303-A568 may 
have reached these peri-nuclear locations less efficiently than PE364-A568 or with a 
slightly different pattern of intracellular distribution. Rigorous co-localisation studies 
involving intracellular markers for the Golgi (GM130, TGN46), EE (Rab4, EEA1), LE (Rab7, 
Rab9a) or lysosome (LAMP1) would be required to accurately determine the intracellular 
localisation of ntPE-A568, PE364-A568, and PE303-A568 [310-312]. 






Figure 5-7 – Truncated forms of PE are internalised by NP epithelial cells. 
Fluorescent images of NP Caco-2 cells incubated for 2 h with 20 μg of protein tagged 
with Alexa Fluor® 568 and diluted in 100 µl complete growth medium (red). Final 
protein concentrations were 3.0 µM ntPE-A568, 5.0 µM PE364-A568 and 5.9 µM 
PE303-A568. Cell nuclei were stained with DAPI (blue). Arrows indicate protein 
suggested, but not demonstrated, to be localised in endocytic vesicles (white) and 
Golgi network (green). Images are representative of three independent 
experiments. 
It was reported that following receptor-mediated endocytosis, the intoxication pathway of 
PE in NP cells involves vesicular transport through the endocytic pathway to the Golgi 
[145]. In Chapter 4 two trafficking routes were proposed as exploitation strategies used by 
the toxin to reach the ER, and it was suggested that the dominant pathway in untreated 





cells could involve interaction with KDEL receptors in the Golgi via the protein’s C-
terminal REDL sequence and further transport to the ER in a retrograde manner (Section 
4.4). In the studies presented above, the REDL sequence of full-length ntPE-A568 is not 
accessible to KDEL receptors due to attachment of the C-terminal fluorescent tag. 
Therefore, the protein’s capacity to reach the ER in a retrograde manner should be greatly 
decreased, and the toxin should not be able to transport further than the Golgi apparatus. 
The fluorescence pattern observed for full-length ntPE-A568 could be in agreement with 
this assumption as it appeared to be restricted to a peri-nuclear vesicular structure (green 
arrow) rather than diffusely distributed in the cytosol, where the protein would retro-
translocate to after reaching the ER [145]. Again, this hypothesis would need to be 
confirmed by co-localisation studies. 
If PE364-A568 was shown to be present in the Golgi and inside endocytic vesicles 
simultaneously, this could indicate that a fraction of the protein was redirected to the 
lysosome for degradation after trafficking to the Golgi. In fact, quality control in the 
secretory pathway allows properly folded proteins to traffic from the ER to the Golgi and 
subsequent compartments, while incompletely folded or misfolded proteins which escape 
to the Golgi are recycled back to the ER using their ER-retrieval sequence (KDEL-like 
sequences) [313]. Here however, none of the proteins used carried any accessible ER-
retrieval sequence. Therefore, it would be possible for truncated proteins to be perceived 
as misfolded in the Golgi apparatus and subsequently redirected to the lysosome for 
degradation. In this case, it would be plausible that quality control mechanisms in the 
Golgi were quicker to perceive PE303 compared to PE364 as misfolded, resulting in its 
faster redirection to the lysosome. Thus, it would be interesting to determine if there are 
differences in the extent of PE364-A568 or PE303-A568 that traffic to lysosomes versus 
the Golgi apparatus. 
As a conclusion, all three versions of PE tested here (full-, medium- and short-length) 
seemed able to enter into NP cells. Observation suggested that these proteins could have 
different intracellular fates and could therefore imply that truncation might affect the 
proteins’ capacity to traffic through the endocytic pathway. Further studies are required to 
determine the nature and extent of these differences in intracellular fate. 
 
 







In order to determine the ability of truncated forms of PE to transport a cargo protein 
inside the cells, fusion proteins carrying a C-terminal green fluorescent protein (GFP) 
molecule were cloned. This system presents the advantage of having each mutant 
conveying a cargo protein that has approximately the same molecular weight as PE 
domain III and is fluorescent, hence easy to detect. 20 μg of a truncated PE-GFP protein 
diluted in 100 µl complete growth medium was applied to NP Caco-2 cells and incubated 
at 37 °C for 2 h. Final molar concentrations for all proteins applied are given in Table 5-2. 
Cells were then fixed with PFA, labelled with an anti-GM130 antibody and prepared for 
confocal microscopy. GM130 belongs to the Golgin family of proteins, which are present 
specifically in the Golgi matrix [314]. Confocal images showed that although a limited 
amount of ntPE-GFP seemed to have entered the cells, the internalised protein was 
frequently co-localised with GM130 labelling (Figure 5-9; top). Therefore a full-length 
ntPE carrying a cargo molecule of GFP conserved its ability to be taken up by NP cells and 
to be trafficked, at least partially, to the Golgi apparatus. The low fraction of internalised 
material is consistent with data obtained in Chapter 4, which demonstrated that only a 
minor fraction of ntPE applied to untreated NP Caco-2 cells could be taken up (Section 
4.3.3.2). Conversely, none of the five truncated versions of PE-GFP seemed able to enter 
NP Caco-2 cells. 
Studies presented in Chapter 4 suggested that increasing the number of accessible GM1 
molecules on the surface of NP cells greatly enhanced the efficiency of toxin uptake. 
Therefore, cells were pre-treated with 1 U/ml neuraminidase for 2 h. Following this, 20 μg 
of protein diluted in 100 µl complete growth medium containing 1 U/ml neuraminidase 












Table 5-2 – Molar equivalent of 20 μg protein for the PE-GFP mutant series and 
concentrations used in uptake assays in NP Caco-2 cells. 
Protein 
designation 
Molar equivalent of 20 μg 
protein (nmol) 
Protein concentration in 
100 µl medium (µM) 
ntPE-GFP 0.21 2.1  
PE408-GFP 0.28 2.8 
PE364-GFP 0.29 2.9 
PE351-GFP 0.29 2.9 
PE320-GFP 0.31 3.1 
PE303-GFP 0.32 3.2 
 
 
Figure 5-8 – Fluorescence of PE-GFP mutant proteins. Fluorescence intensity of 20 
μg of fusion protein in HBSS (λex = 480 nm, λem = 520 nm). Corresponding molar 
concentrations are presented in Table 5-2. Data are presented as mean ± SD for 
each sample, for n = 3 microplate wells. 
All proteins appeared to be internalised when administered in conjunction with 
neuraminidase treatment. However, they seemed to show little co-localisation with 
GM130, indicating that most of the internalised material observed was not in the Golgi, as 
shown in Table 9-4 and Appendix 4. This was striking as even the ntPE-GPF, which 
showed some Golgi apparatus co-localisation when initially tested, lost that co-localisation 
behaviour when administered with neuraminidase. On the other hand, the fluorescence 
pattern observed in neuraminidase-treated cells did not strongly suggest lysosomal 
degradation either. This could thus imply that, following cell penetration, the proteins 
might have remained held within endosomal compartments, were unable to escape, and 



































possibly underwent constant cycling between the early and recycling endosomes. This 
hypothesis would need to be tested by carrying out co-localisation studies using organelle 
markers such as EEA1 or Rab11, which target the early and recycling endosomes, 
respectively [315]. 
In order to determine if the internalisation and trafficking of PE-GFP truncated mutants 
was affected by treatments such as neuraminidase and addition of CTB that could alter the 
availability of SA moieties, proteins were applied to NP Caco-2 in the presence of 3.5 µM 
CTB with or without a 1 U/ml neuraminidase treatment. Fluorescence signals inside 
treated cells were greatly decreased for all PE-GFP mutants following CTB addition in the 
presence (Figure 5-11) or absence of neuraminidase treatment (Figure 5-12). The results 
suggest that the PE-GFP truncations behaved similarly to ntPE-GFP with regards to the 
actions of treatment that could affect SA levels in cells. Importantly, the carrier protein 
length did not seem to affect the internalisation process in NP cells; none of the truncated 
mutants described here appeared to be internalised in the absence of neuraminidase 
treatment while addition of this enzyme dramatically increased the uptake of all six 
proteins.  
Interestingly, the A568-tagged counterparts of PE364-GFP and PE303-GFP seemed to be 
internalised, even in untreated cells (Section 5.3.3). Therefore, the observation that the 
full-length form, but not truncated forms of PE-GFP, was readily internalised, was 
surprising. It is possible that addition of a medium-sized cargo protein (MWGFP = 27 kDa) 
to the C-terminal end of truncated forms of PE could have affected the intracellular fate of 
these materials relative to those tagged with a fluorescent molecule, altering their 
engagement with the lipid-associated pathway described in Section 4.4. Due to the 
inability to quantitatively compare the A568- and GFP-tagged proteins these observations 
are restricted to qualitative assessments. Alternatively, the GFP cargo protein might have 
been cleaved from the carrier domain before cell entry, which could account for the lack of 
intracellular fluorescence. This latter possibility seems unlikely, as there is no obvious 
reason for GFP to be cleaved off the truncated mutants but not the full-length protein.  
The discrepancies observed between the estimated intracellular locations of A568-tagged 
and GFP-labelled versions of PE364 and PE303 following application to untreated cells 
could also be explained by differences in fluorophore stability. In fact, GFP is used here as 
a cargo protein as well as a fluorescent reporter. However, its nature makes it more 
sensitive to enzymatic degradation than the fluorescent tag A568, and perturbations of its 
tertiary structure are likely to cause a loss of fluorescence. As a consequence, it is possible 





that even if a small amount of protein entered NP Caco-2 cells and was re-routed to the 
lysosome, variations in fluorophore stability would have led to A568-tagged molecules 
being visualised in the lysosomes, while the GFP-labelled mutants would have been 
undetected due to a more rapid inhibition of the fluorescence of GFP. 
It is also possible that attachment of a cargo protein, such as GFP, could affect the 
intracellular destination of truncated forms of PE, possibly accelerating or enhancing 
routing to the lysosome (Section 5.3.3). While results from Chapter 4 suggested that 
neuraminidase treatment did not impact the intracellular protein location of A568-
labelled ntPE, this same treatment seemed to have striking effects on the fate of ntPE-GFP. 
One possible interpretation of these data is that the protein could be caught in a trafficking 
loop possibly located between early and recycling endosomes. 
Finally, in the hypothesis that GM1 is indeed involved in PE protein uptake, these findings 
complement earlier studies and suggest that the ganglioside binding site might be located 
between amino acids 1 and 303, as even the shortest fusion protein (PE303-GFP) entered 
the cells upon addition of neuraminidase. These results would be in agreement with 
conclusions drawn in Chapter 4 concerning the location of the GM1 binding site on PE 
domain II. However, this hypothesis relies on mere observation and would need 
confirmation by rigorous fluorescence quantification in each sample and additional 
truncation mutants. 






Figure 5-9 – PE-GFP mutant proteins are not internalised by NP epithelial cells. 
Fluorescent images of NP Caco-2 cells incubated for 2 h with 20 μg protein diluted in 
100 µl complete growth medium. Molar concentrations are detailed in Table 5-2. 
Cell nuclei were stained with DAPI (blue) and expression of GM130 (red) was used 
to visualise the Golgi network. Images are representative of three independent 
experiments. 






Figure 5-10 – Treating the cells with neuraminidase increases the uptake of PE-GFP 
mutants by NP epithelial cells. Fluorescent images of NP Caco-2 cells pre-incubated 
for 2 h with 1 U/ml neuraminidase followed by a further 2 h-incubation with 20 μg 
of protein diluted in 100 µl complete growth medium in the presence of 1 U/ml 
neuraminidase. Molar concentrations are detailed in Table 5-2. Cell nuclei were 
stained with DAPI (blue) and expression of GM130 (red) was used to visualise the 
Golgi network. Images are representative of three independent experiments. 






Figure 5-11 – CTB inhibits the internalisation of PE-GFP proteins by NP epithelial 
cells treated with neuraminidase. Fluorescent images of NP Caco-2 cells pre-
incubated for 2 h with 1 U/ml neuraminidase before applying 20 μg of each protein 
diluted in 100 µl complete growth medium and 3.5 µM CTB in the presence of 1 
U/ml neuraminidase for 2 h. Molar concentrations are detailed in Table 5-2. Cell 
nuclei were stained with DAPI (blue) and expression of GM130 (red) was used to 
visualise the Golgi network. Images are representative of three independent 
experiments. 






Figure 5-12 – CTB specifically inhibits the internalisation of PE-GFP mutants in NP 
cells. Fluorescent images of NP Caco-2 cells incubated for 2 h with 20 μg of each 
protein diluted in 100 µl complete growth medium and 3.5 µM CTB. Molar 
concentrations are detailed in Table 5-2. Cell nuclei were stained with DAPI (blue) 
and expression of GM130 (red) was used to visualise the Golgi network. Images are 
representative of three independent experiments. 







Data obtained in the previous section showed that all six PE-GFP mutants were 
internalised by NP epithelial cells following neuraminidase treatment. However, the 
characteristics of polarised cells constituting the intestinal epithelium are different from 
those of their NP counterparts. This is highlighted by the fact that native, enzymatically 
active PE intoxicates and kills NP cells while it can transport across epithelial barriers 
without causing any perceptible cell damage. In order to determine the entry and 
transport characteristics of ntPE in polarised systems, Caco-2 cells were cultured on semi-
permeable filters (Transwell®) to a confluent and polarised state. The Transwell® filters 
used in these studies were coated with a rat-tail Type I collagen matrix, which has been 
proposed to decrease the time needed for the cells to polarise by promoting cell 
attachment and cell growth [316]. The cells used here are the Caco-2 C2BBe1 clone 
(ATCC), which were reported to display a more homogeneous brush border expression 
and are therefore comparable to human enterocytes found in the small intestine [177, 317, 
318]. When the cells became polarised following monolayer formation, a fluorescent 
protein was applied onto their apical surface, and transport across the monolayer was 
assessed by quantifying fluorescence in samples collected from the basolateral 
compartment (Figure 5-13). Functional monolayer integrity was evaluated by measuring 
both transepithelial electrical resistance (TEER) and dextran permeability through the 












Figure 5-13 – Diagram for the Transwell® filter system for assessing protein 
transport across polarised cells. Cells are seeded on a semi-permeable membrane in 
the inner well and, once they polarise, protein is applied to their apical surface. 
Medium from the basolateral compartment is sampled at regular time intervals to 
assess the amount of protein that has crossed the cell monolayer. A non-permeable 
macromolecular marker, such as 4 kDa fluorescent dextran, added to the apical 
compartment can be used to monitor non-selective apical to basal flux. 
First, 0.1 µM, 0.5 µM and 1.0 µM of full-length ntPE-A568 were applied to the apical 
surface of polarised cells (= 2, 10 and 20 μg diluted in 300 µl HBSS, respectively). Samples 
removed from the basolateral compartment at t = 15, 30, 60, 120 and 240 min were 
assayed for fluorescent content. Figure 5-14 represents the accumulation of total 
fluorescence collected from the basolateral compartment with time. It shows that 
transport of as little as 0.1 µM toxin could be detected and quantified by fluorescence. 
Furthermore, the total amount of protein transported increased linearly with incubation 
time for all three concentrations. Linearity of the fluorescence intensity with increasing 
amounts of protein was verified in the 0.001-0.1 mg/ml range (Figure 5-15). This implies 
that the saturation point of the system, and therefore the maximum transport rate, had not 
been reached. Measurements of dextran permeability indicated that between 8.2 and 
16.2% of FITC-labelled 4 kDa dextran crossed the monolayer compared to the blank well. 
TEER values measured at the start and end of the assay (TEER > 350 Ω·cm2) demonstrate 
that monolayer integrity was maintained throughout the experiment. 
 







Figure 5-14 – Transport of full-length ntPE-A568 across polarised epithelial cells. 
(A) Normalised total fluorescence of 1.0 µM, 0.5 µM and 0.1 µM of ntPE-A68 present 
in the basolateral compartment over 240 min following initial application to the 
apical surface of Caco-2 monolayers. Data are presented as mean ± SD for each time 
point, for n = 3 independent samples. (B) Amount of FITC-labelled 4 kDa dextran 
present in the basolateral compartment 30 min after application to Transwell® 
filters (Blank) compared to Transwell® filters supporting a monolayer of polarised 
Caco-2 cells which were incubated with various amounts of ntPE-A568 for 240 min. 
Data are presented as mean ± SD for each sample, for n = 3 independent samples 
(*** P < 0.001). 

















































































































































































































Figure 5-15 – Fluorescence intensity is linear in the 0.001-0.1 mg/ml range. 
Solutions of full-length ntPE-A568 at 0.1, 0.05, 0.02, 0.01, 0.005, 0.002 and 0.001 
mg/ml were obtained by serial dilutions in HBSS from a 4.3 mg/ml stock solution in 
PBS. Data are presented as mean ± SD for each concentration, for n = 3 microplate 
wells. 
Data here establishes that ntPE has the ability to transport a fluorescent tag across 
polarised cells without damaging the epithelium, as illustrated by conservation of the 
monolayer integrity throughout the assay. Furthermore, the tight intercellular contacts 
which prevent paracellular diffusion of 4 kDa dextran suggest that, due to its rather large 
molecular weight (66 kDa), the protein couldn’t have permeated the monolayer via this 
pathway. As passive transcellular diffusion is also very unlikely, it would be safe to assume 
that ntPE transported across the cells by transcytosis, thereby confirming the presence of 
functional receptor(s) on the cell surface. This assay validates the potential of ntPE to 
transport across polarised monolayers in the experimental conditions described here. 
In an attempt to test and compare the transport characteristics of several PE truncated 
mutants to those of the full-length protein, the assay was repeated with the PE-GFP 
protein series. However, the fluorescence detected in the basolateral compartment after 
240 min was minimal, suggesting that no protein had transcytosed across the cells (Figure 
5-16 and Table 5-3). ntPE-A568 was applied as a control, but did not seem to transport 
either. After several attempts to reproduce the results previously obtained for full-length 
ntPE-A568, no protein could be detected in the basolateral side. A series of tests were 
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performed in order to determine if this lack of transport was caused by the protein itself 
or instead a dysfunction of the cells. 
 
Figure 5-16 – (A) Amounts of PE-GFP mutants present in the apical (black) and 
basolateral (red) compartments after 240 min, following the application of 20 μg of 
protein in 300 µl HBSS to the apical surface of Caco-2 monolayers. Final molar 
concentrations for all proteins applied are given in Table 5-3. (B) Amounts of FITC-
labelled 4 kDa dextran present in the basolateral compartment 30 min after apical 
application to Transwell® filters (blank) compared to Transwell® filters supporting 
a monolayer of polarised Caco-2 cells which were incubated with 20 μg protein for 
240 min. Data presented as mean ± SD, for n = 3 wells, where *** P < 0.001. 
Table 5-3 – Molar equivalent of 20 μg protein for the PE-GFP mutant series 
concentrations used in transport assays in polarised Caco-2 cells. 
Protein 
designation 
Molar equivalent of 20 μg 
protein (nmol) 
Protein concentration in 
300 µl medium (µM) 
ntPE-GFP 0.21 0.70 
PE408-GFP 0.28 0.93 
PE364-GFP 0.29 0.97 
PE351-GFP 0.29 0.97 
PE320-GFP 0.31 1.03 
PE303-GFP 0.32 1.07 
 
Investigation of full-length ntPE functionality was carried out using different formats of 






































































































































































































































































































A488, GFP). This strategy should have reduced the possibility that there might be a flaw in 
the protein being tested. For instance, it is possible that the protein could have been folded 
improperly or that the chemical coupling could have altered the protein; both events could 
have reduced its capacity to bind to receptors essential for transcytosis. Similarly, the use 
of two different fluorescent tags provided some assurance that detection was not the 
issue. Despite these efforts, neither ntPE-A568 nor ntPE-GFP was observed to transport 
across polarised monolayers of Caco-2 cells in	vitro (Figure 5-17). The observation that 
two different full-length ntPE proteins carrying distinct fluorescent tags demonstrated 
undetectable transcytosis rates in the studied system suggests that they could be fully 
functional, and that the factor(s) preventing their transport across epithelial monolayers 
might be cell-related instead. This concept is supported by the fact that previous studies 
had shown efficient ntPE transcytosis (Figure 5-14). As a consequence, other tests were 
then performed on the cells themselves in an attempt to understand the nature of how 
their properties or status might affect ntPE transcytosis. 
  
Figure 5-17 – (A) Amounts of ntPE-A568 and ntPE-GFP present in the apical and 
basolateral compartments after 240 min, following the application of 1.0 µM ntPE-
A568 and 0.7 µM ntPE-GFP to the apical surface of Caco-2 monolayers. (B) Amounts 
of FITC-labelled 4 kDa dextran present in the basolateral compartment 30 min after 
apical application to Transwell® filters (blank) compared to Transwell® filters 
supporting a monolayer of polarised Caco-2 cells which were incubated with 1.0 µM 
ntPE-A568 or 0.7 µM ntPE-GFP for 240 min. Data presented as mean ± SD, for n = 3 
wells, where *** P < 0.001. 
Rat-tail collagen has been used in various laboratories to pre-coat Transwell® filters prior 
to the seeding of Caco-2 cells to facilitate their maturation into confluent, polarised cell 















































































































[320] and used to coat Transwell® filters. This was compared to Transwell® filters coated 
with a commercial preparation of rat-tail collagen and Transwell® filters with no collagen 
coating. In all three cases, we failed to observe transport of full-length ntPE across Caco-2 
monolayers. 
We next tested if the medium used in the transport assay had an effect. Usually, cells were 
transferred from complete growth medium to HBSS 30 minutes before a transport study 
was initiated. Cells were either left in growth medium for the duration of the experiment 
or transferred to HBSS prior to addition of the full-length ntPE protein, in order to try to 
decrease or alternatively increase stress levels caused by medium change on the cells, 
respectively. Still no transport could be detected. 
Conditions were then modified so that the cells were incubated in the presence of full-
length ntPE protein at mildly acidic pH given that pH at the cell surface in diseased tissue 
during Pseudomonas	 aeruginosa infection is lower than in healthy systems [321]. In 
parallel, a mixture of various protease and phosphatase inhibitors (PI) was added to the 
cells in addition to the full-length ntPE protein to prevent potential degradation, which 
could hinder internalisation. While no transport could be detected at pH 5.88, a small 
increase in fluorescence intensity in the basolateral compartment was observed in 
presence of the PI. However, evaluation of dextran permeability indicated that the 
integrity of the monolayer had been partly compromised and therefore the observed 
increase in transport was probably due to protein leaking via the paracellular route rather 
than by transcytosis. 
The proteins used here (ntPE-A568 and ntPE-GFP) appeared to be taken up by NP Caco-2 
cells (Chapter 4 and Section 5.3.4), thereby implying that they were able to interact with 
their cell-surface receptor(s) in this system. Next, other cell lines were used for the 
transport assay: Calu-3 and MDCK that cells are lung adenocarcinoma and canine kidney 
epithelial cells, respectively. As LRP1 is located on the basolateral surface of MDCK cells, 
protein was added to the basolateral compartment of these cells and samples were taken 
out of the apical well [322]. However, neither protein seemed able to cross these cells 
better than they transported across Caco-2 monolayers. These results suggested that the 
problem was not caused by the polarised cell system used. Therefore the detection 
method was tested. 
Samples were usually removed from the basolateral compartment and fluorescence 
intensity assessed using a microplate reader as detailed in Section 2.16.1 and Table 2-5. 
Here, Calu-3 cells were seeded in the inner well to polarise, and NP Caco-2 cells seeded on 





coverslips as described in Section 2.14 were placed in the basolateral compartment. Any 
protein transporting across the Calu-3 monolayer should reach and enter the underlying 
NP cells, and therefore could be observed under confocal microscopy even if fluorescence 
measurements by the plate reader were faulty. However, no toxin could be detected in the 
NP Caco-2 cells. Then, protein was added to either the apical or basolateral side of cells in 
case cell polarity had shifted due to the presence or absence of cellular components [323]. 
Finally, new Caco-2 cells were acquired in case the line previously used had been passaged 
too far and their phenotypic characteristics had mutated [317]. In parallel, cells were 
grown on filters by another group (Prof. M. Gumbleton, Cardiff University). None of these 
conditions resulted in the transport of full-length ntPE protein. Some of the results 
described above are presented in Figure 5-18. 
    
Figure 5-18 – (A) Amounts of ntPE-A568 or CTB-A488 collected from the apical and 
basolateral compartments after 240 min, following the application of 0.30 nmol 
ntPE-A568 or 0.35 nmol CTB-A488 to the apical (black) or basolateral (red) surface 
of Caco-2 monolayers. (B) Amount of FITC-labelled 4 kDa dextran present in the 
basolateral compartment 30 min after apical application to Transwell® filters 
(blank) compared to Transwell® filters supporting a monolayer of polarised Caco-2 
cells incubated with either protein for 240 min. Data presented as mean ± SD for n = 
3 wells. 
Altogether, these results indicate that while the protein could be internalised by NP Caco-2 
cells, its entry and transport in polarised monolayers was inconsistent for the in	 vitro 














































































































































































































































































































































































































































































































Caco-2 model. The fact that full-length ntPE protein and several truncated forms appeared 
to be taken up by NP cells suggests that it could still interact with its surface receptor(s). 
Tests aiming to eliminate experimental factors causing zero interaction did not prove 
conclusive either, since modifying the incubation conditions or even switching the system 
to new cells or different cell lines did not result in protein transport. CTB, which binds to 
the monosialoganglioside GM1 and can be used as a positive control for receptor-mediated 
endocytosis and transcytosis, was not able to cross or even traffic effectively in polarised 
Caco-2 cell monolayers (Figure 5-18 and Figure 5-19). If GM1 plays as important a role in 
the internalisation and potentially the transport of PE as was suggested by previous data 
(Chapter 4), its inability to traffic from the apical membrane would explain why 
transcytosis of ntPE across Caco-2 monolayers was not observed. How and why GM1 
would be retained at the apical surface is unclear.  
 
Figure 5-19 – CTB does not transport across polarised epithelial cells. Z-stack image 
of a Caco-2 monolayer 240 min after application of 0.35 nmol CTB-A488 (green) to 
the apical surface. Cell nuclei were stained with DAPI (blue). 
5.3.6 In	vivo	transport	of	PE364-hGH	
 
Results described in this chapter have shown that several truncated versions of PE linked 
to a C-terminal GFP molecule were internalised by NP cells in	 vitro. Moreover, it was 
demonstrated that full-length ntPE could carry a fluorescent tag across a polarised 
monolayer of intestinal epithelial cells. However, no data were obtained regarding the 
transport of a cargo protein across polarised cells, which is essential with regards to oral 
protein delivery, possibly due to problems that may be related to the in	vitro system. To 
determine if this could be achieved, the uptake and trafficking of a truncated version of PE 
(PE364) carrying a molecule of human growth hormone (hGH) were studied in	 vivo 
(Figure 5-20 (A)). hGH was selected as a model protein drug because its molecular weight 
is comparable to that of PE domain III, and because the mature protein is a non-
glycosylated monomer and could therefore be expressed in E.	coli (Figure 5-20 (B)).  
PE364-hGH diluted in PBS was first injected directly into the lumen of a rat’s small 
intestine. A sample segment was collected 15 min after administration and tissues were 





processed and immunostained as described in Section 2.17.2. PE364 and hGH were 
individually detected with antibodies targeting each protein, used in conjunction with 
corresponding fluorescent secondary antibodies. The white light channel was used to 
visualise individual villi as well as the borders of epithelial cells composing them. Controls 
(naïve tissue) are presented in Appendix 5. 
The fluorescence pattern observed in Figure 5-21 showed that both PE364 (red) and hGH 
(green) were present inside the enterocytes lining the villi. Moreover, the detection of 
yellow fluorescence patches revealed that the two proteins co-localised within these 
polarised cells in both apical and basal regions. Further, some cells in the submucosa 
showed internal labelling for both PE364 and hGH, suggesting that these materials 
completed the transcytosis process and were internalised by some of these cells. On the 
contrary, other cells present in the submucosal space displayed only red or green labelling, 
suggesting that in some instances, the carrier and cargo proteins could have separated 
following transepithelial transport. 
It has been shown in various cell types that following interaction with plasma membrane 
receptors, hGH is internalised by endocytosis [324]. The protein-receptor complex does 
not dissociate at low pH and is directed towards either the lysosome for degradation 
(degradative pathway, ~75%) or recycled to the cell surface, where intact hGH is released 
(non-degradative pathway, ~25%) [325]. As a consequence, the presence of intracellular 
hGH suggests that, in all likelihood, this protein was still attached to PE364. This idea is 
supported by the detection of both proteins at the basal pole of enterocytes, which implies 
that transcytosis occurred and that PE364 acted as a carrier and transported hGH within 
the cells, away from degradation or recycling pathways. 
Detection of yellow fluorescence in the submucosal space suggests that the fusion protein 
transported across the enterocytes and reached cells present in the underlying mucosa. In 
fact, it has been shown that these cells share some of their cell-surface receptors with 
polarised enterocytes and are able to internalise PE [27]. The observed fluorescence 
pattern would therefore be consistent with the administered material undergoing 
transepithelial transport before being internalised by some cell populations in the 
submucosal space. Targeted co-localisation studies would need to be performed in order 
to identify which cell types may have internalised the transported material (e.g. 
macrophages, dendritic cells). 





These findings demonstrate that neither truncation of PE down to residue 364, nor 
replacement of domain III by a different cargo protein, eliminated the protein’s ability to 
transcytose across polarised enterocytes in	vivo. 
Although the protein was injected at high dose directly at the site of absorption, the in	vivo 
model used here incorporates dynamic components such as blood circulation and 
gastrointestinal transit which can affect protein absorption and are not considered in the 
Caco-2 polarised system [318, 326]. Moreover, studies by Lennernäs et	al (1995) reported 
lower expression of membrane-associated carrier proteins in Caco-2 monolayers than in	
vivo, possibly resulting in saturation of the carrier and leading to significantly lower 
effective permeability in	 vitro [327]. If this were applicable to membrane receptors, 
reduced LRP1 and/or GM1 expression in Caco-2 cells might explain why no transcytosis 
was observed in	 vitro (Section 5.3.5), whereas PE364 appears to effectively transport 
across polarised epithelial cells in	vivo. 
 
 
Figure 5-20 – Ribbon representations of (A) PE364-hGH and (B) human growth 
hormone (hGH) (PDB_ID: 1HGU). The mature hGH is a monomer composed of four α-
helices and is non-glycosylated. α-helices and loops are displayed in red and green, 
respectively.  Structures were generated using PyMOL [128].  
 








Figure 5-21 – Transport of PE364-hGH across rat small intestinal cells. (A) A section 
of rat intestinal tissue (5 μm) was indirectly immunostained with antibodies to PE 
(red) and hGH (green).  Cell nuclei were stained with DAPI (blue). (B) Higher 
magnification of white rectangle from merge of image (A). 





5.4 General discussion 
 
This chapter describes efforts to characterise the properties of PE as a device for oral 
delivery of macromolecular drugs. Previous reports suggested that the three structural 
domains of PE may have independent functions [159] and that PE domain III was not 
required for cellular uptake or transcytosis of the protein in polarised epithelial cells 
[328]. To further investigate these concepts, six fusion proteins were used in the studies 
reported here, in addition to the PE GS TEV constructs. Each of them was composed of a 
carrier domain of variable length (one of the PE GS TEV proteins) linked to a C-terminal 
cargo molecule (GFP). The internalisation and transport properties of these proteins were 
studied in polarised and non-polarised cells. In addition to this, the transepithelial 
transport of a fusion protein composed of PE364 genetically linked to hGH was 
investigated in	vivo. 
Caco-2 cells have been widely described as a model for human intestinal absorption as 
they differentiate into monolayers of polarised enterocyte-like cells, characterised by the 
presence of a brush border, metabolic enzymes and tight junctions that establish cell-cell 
contacts [329, 330]. Caco-2 cells were used here to investigate protein uptake and 
transcytosis across intestinal epithelial cells. In	vitro uptake assays in NP cells showed that 
two of PE’s shorter mutants, truncated either at the end or middle of domain II and 
carrying a fluorescent Alexa Fluor® tag (PE364-A568 and PE303-A568, respectively), 
seemed to be internalised by NP Caco-2 cells. This is consistent with earlier reports 
indicating that the catalytic domain is dispensable for cell entry [328] and suggests that 
half of domain II might also be removed without affecting the protein’s ability to be taken 
up by cells. Fluorescence patterns observed for each of the three versions of PE tested 
appeared to differ, suggesting that truncation of the carrier domain could interfere with 
PE’s trafficking properties in NP cells. This could be due to truncated proteins being 
perceived as misfolded by quality control sensors, and therefore being redirected to the 
lysosome for degradation. Alternatively, a fraction of the protein could remain trapped 
within endosomal compartments. However no co-localisation studies were carried out, 
and therefore no conclusions can be drawn regarding the destination of these proteins or 
the extent of this truncation effect. 
As a conclusion, truncation of PE did not seem to affect its ability to enter NP cells in this 
study. This is consistent with the attribution of binding activity to PE domain I, which 
remained intact in the truncated proteins that were prepared and tested. However, the 





data described could also point to the possibility that excessive shortening of the protein 
might result in its premature clearance and degradation by intracellular quality control 
systems. 
Similar uptake assays were performed on NP Caco-2 cells using the PE-GFP mutants in 
order to investigate the impact of a cargo protein on internalisation. Following the 
application of each protein to untreated cells, intracellular fluorescence could only be 
visualised for the full-length ntPE, suggesting that none of the five shorter mutants were 
able to be internalised by the cells. This could be due to the presence of the cargo protein 
at the C-terminal end of PE. As previous results highlighted the importance of specific PE-
GM1 interactions for uptake, the role of GM1 in the entry process of the PE-GFP protein 
series was examined here using the same set of experiments that were used for the full-
length ntPE in Chapter 4. Results denoted the same dependency upon GM1 for efficient 
entry of PE-GFP proteins in NP cells as was observed for full-length ntPE-A568. Therefore, 
it could be assumed that the mechanism used by the PE-GFP mutants to enter the cells was 
similar to the one used by full-length ntPE. In this case, the fact that all truncated proteins 
seemed to enter the cells implies that the presence of a cargo domain which is different 
from domain III, but of similar size, did not affect receptor-mediated endocytosis. 
Furthermore, as all proteins showed a marked improvement in internalisation following 
neuraminidase treatment, these studies appear to confirm results from Chapter 4 and 
support the hypothesis that the GM1 binding site could be located between amino acids 1 
and 303 of PE. 
These results establish that PE would constitute a suitable carrier for protein delivery in 
NP cells. However, this system does not completely reflect the mechanisms observed in 
polarised cells. For instance, polarised cells can display different endocytic mechanisms 
depending on whether the uptake occurs from their apical or basolateral membranes 
[311, 331], and the population of surface lipids, proteins and receptors also reflects the 
asymmetric cell organisation [332, 333]. As the intestinal epithelial barrier is composed of 
polarised cells, understanding transport mechanisms in these cells is necessary to 
evaluate the potential of PE as a carrier for oral protein delivery. Therefore, uptake and 
transcytosis of PE were assessed using polarised Caco-2 cell monolayers. Using this model, 
the ability of a fluorescently-tagged full-length ntPE to cross intact epithelial barriers was 
established. However, no information could be obtained about the transport 
characteristics of the PE-GFP protein series due to the collapse of the model for transport 
outcomes. Therefore, both the individual and combined impacts of truncation and 
presence of a cargo on transcytosis in	 vitro remain unknown. To further assess the 





effect(s) of these factors, the transepithelial transport of PE364-hGH was then investigated 
in	vivo. Results showed that following direct injection in the intestinal lumen, the fusion 
protein appeared to be internalised by enterocytes, translocated across these cells, and 
possibly taken up by some cells of the submucosal space. These findings therefore 
establish that replacement of PE domain III by a protein drug such as hGH does not block 
transcytosis of a truncated form of PE in	vivo and that the cargo protein can be delivered to 
the underlying mucosa.  
In conclusion, these results confirm that truncated forms of PE may provide a promising 
system for intracellular as well as oral delivery of biologics. Although shorter versions of 
PE carrying a C-terminal cargo protein did not seem able to be internalised by untreated 
NP cells, uptake of all mutants could be restored by activation of the DRM-mediated 
transport pathway (Section 4.4). Moreover, removal of domain III did not seem to alter 
protein trafficking and cargo delivery in	vivo. Shortening the length of the carrier domain 
could therefore represent a significant advantage as it could dramatically decrease 
immune response upon administration. It must be underlined that the use of PE as a 
carrier for protein therapeutics would overcome the poor permeability of the intestinal 
epithelium, but would not protect the drug against the other obstacles encountered during 
oral delivery. Therefore, PE and its cargo protein would need to be associated with other 
protection devices, e.g. enzyme inhibitor or pH-dependent coating, to avoid degradation in 
the GIT, and potentially supplemented by adherent systems to bring it closer to the 
intestinal mucosa and ensure maximum effect. 
  










6 RESULTS 4 – CHOLIX 
6.1 Introduction 
 
Jørgensen et	al (2008) characterised the ADP-ribosylating protein that can be secreted by 
Vibrio	cholerae, a protein that has been named cholix toxin (Cho) [105]. Cholix (70.4 kDa) 
structurally resembles PE, as it is a single polypeptide chain of 634 amino acids divided 
into three distinct domains, which appear to have the same respective functions as that of 
PE (Figure 6-1). Cho contains the same furin cleavage site required for activation 
(Arg292), has a C-terminal KDEL sequence, and has disulphide bridges that are positioned 
in an alignment similar to PE (C11-C15, C208-C225, C278-C300, C394-C401) [113]. 
Importantly, the cell intoxication produced by PE and Cho is a result of targeting the same 
residue on eEF2 [105]. Residue Glu581 has been identified as the equivalent of Glu553 for 
PE since mutant proteins carrying an Alanine residue at position 581 showed little or no 
activity in mouse fibroblasts [105]. Although cholix also recognises the LRP receptor 
[105], it uses a different receptor to enter CHO cells [27] and no evidence has yet been 
found that it uses the same intracellular pathway as PE [145]. Overall, sequence alignment 
between PE and cholix shows that the two proteins share only 33% sequence identity 
[105], yet alignment of their X-ray crystal structures are nearly superimposable (see 
Appendix 6 and Figure 6-1). 
 
 





Figure 6-1 – The structure of cholix presents striking similarities with that of PE. (A) 
Schematic representation of PE and cholix structures. Both proteins are divided into 
distinct domains: Ia is responsible for cell recognition and receptor binding, domain 
II controls protein translocation and contains the furin-cleavage site, and domain III 
is the enzymatic domain of the toxin. The function of domain Ib, which is positioned 
between domains II and III, has yet to be elucidated. Disulphide bonds are 
represented orange and amino acids at the limit of each domain are indicated 
below. The furin cleavage site is indicated by an arrow. Note the deletions of PE-
E553 and Cho-E581 in domain III that render PE and cholix non-toxic (ntPE and 
ntCho). (B) Ribbon representation of PE and cholix structures highlighting their 
similarity. The figure was generated using PyMOL [128]. 
The great structural and functional similarities between PE and cholix suggest that these 
two toxins could possibly use comparable mechanisms to both intoxicate non-polarised 
cells and transport across polarised monolayers. Therefore, the following chapter 
describes an effort to characterise the intracellular behaviour of cholix using some of the 
techniques that have previously been employed to investigate the properties of PE. In 
particular, the behaviour of cholix at acidic pH, its interaction with GM1, and its potential 
as a drug delivery system were examined. 
 






Determination of trypsin cleavage sites from digestion fragments 
Following digestion of Cho GS TEV mutants by trypsin, the size of the resulting fragments 
was used to estimate potential cleavage sites. The protein sequence used (PDB_ID: 2Q5T) 
contains an N-terminal 6X His tag which was removed for calculations. The remaining 
sequence was run into PeptideCutter and only digestion sites with a 100% cleavage 
probability were displayed [183]. The molecular weight of the resulting fragments was 
then calculated with ProtParam [181]. 




In this chapter, the behaviour of truncated versions of Cho GS TEV and Cho-GFP were 
studied. The expression and purification outcomes of these proteins, as well as their 

















Table 6-1 – Summary of expression and purification outcomes for both Cho GS TEV 







ntCho GS TEV Soluble Soluble IX, GF Good 
Cho428 GS TEV Insoluble Inclusion bodies IX, GF None 
Cho386 GS TEV Insoluble Inclusion bodies IX, GF Good 
Cho368 GS TEV Insoluble Inclusion bodies IX, GF Good 
Cho332 GS TEV Insoluble Inclusion bodies IX, GF Good 
Cho313 GS TEV Insoluble Inclusion bodies IX, GF Good 
ntCho-GFP Soluble Soluble IMAC, GF Good 
Cho428-GFP Soluble Soluble IMAC, GF Good 
Cho386-GFP Insoluble Inclusion bodies IMAC, GF Low 
Cho368-GFP Insoluble Inclusion bodies IMAC, GF Low 
Cho332-GFP Insoluble Inclusion bodies IMAC, GF Low 
Cho313-GFP Insoluble Inclusion bodies IMAC, GF Low 















Table 6-2 – Physicochemical properties of Cho GS TEV and Cho-GFP mutants and of 








ntCho GS TEV 5.31 71.8 
Cho428 GS TEV 5.31 48.0 
Cho386 GS TEV 5.42 43.7 
Cho368 GS TEV 5.37 41.6 
Cho332 GS TEV 5.65 37.5 
Cho313 GS TEV 5.59 35.4 
ntCho-GFP 5.21 97.9 
Cho428-GFP 5.18 74.9 
Cho386-GFP 5.12 71.6 
Cho368-GFP 5.08 69.7 
Cho332-GFP 5.16 65.3 
Cho313-GFP 5.19 63.1 




Truncated versions of ntCho GS TEV were expressed following the same procedure as for 
PE GS TEV mutants. Only ntCho GS TEV was soluble. The other five proteins were 
insoluble and expressed as inclusion bodies. Below are presented, as an example, the 
chromatograms and Coomassie-stained SDS-PAGE obtained after purification of Cho386 
GS TEV. 
Following expression in inclusion bodies, Cho386 GS TEV was loaded on an AE column and 
eluted with a NaCl gradient. A single peak could be observed at 20-60% NaCl (= 0.2-0.6 M 
NaCl) (Figure 6-2 (A)). 




   
Figure 6-2 – Initial enrichment of Cho386 GS TEV by AE chromatography. (A) 
Chromatogram obtained for AE separation. (B) Coomassie-stained SDS-PAGE of AE 
fractions shown in (A) containing the flow-through and protein peaks. X- and A-
labelled lanes in (B) correspond to arbitrary tray row and column reference on the 
fraction collector and are illustrated by the red dashes on (A). Fractions covered by 
the arrow in (A) indicate the complete range of fractions displayed in (B). The black 
dotted lines marked on both (A) and (B) indicate the fractions containing Cho386 GS 
TEV that were collected. 
Fractions corresponding to the peak and flow-through were separated by SDS-PAGE 
(Figure 6-2 (B)). Although a very faint band the same size as the protein (~45 kDa) could 
be seen, the amount of Cho386 GS TEV present in the flow-through was negligible. On the 
contrary, fractions A4-A6 contained a large amount of protein which was collected, 
concentrated to a 1 ml volume, and further purified by size exclusion chromatography 
(Figure 6-3 (A)).  
Fractions corresponding to the UV-absorbing material were separated by SDS-PAGE 
(Figure 6-3 (B)). Cho386 GS TEV was present in the combined fractions D5-D14 and its 
purity was assessed to be acceptable for the following studies. 
 





Figure 6-3 – Further enrichment of Cho386 GS TEV by GF chromatography. (A) 
Chromatogram obtained for GF column separation. (B) Coomassie-stained SDS-
PAGE of fractions corresponding to the UV peak. D-labelled lanes in (B) correspond 
to arbitrary tray row and column reference on the fraction collector and are 
illustrated by the red dashes on (A). Fractions covered by the arrow in (A) indicate 
the complete range of fractions displayed in (B). The black dotted lines marked on 




The proteins described in this section were cloned in collaboration with Dr Julia Mackay, 
who also assisted with their expression. 
ntCho-GFP is a fusion protein where full-length Cho lacking residue E581 is connected by 
the previously described poly glycine-serine flexible linker to a C-terminal GFP molecule 
(Figure 6-4). The resulting protein carries an N-terminal 6X His tag which allows ntCho-
GFP to be purified by IMAC. 
 





Figure 6-4 – Ribbon representation of ntCho-GFP structure. Cholix was fused with a 
C-terminal molecule of GFP. The figure was generated using PyMOL [128]. 
Five truncated versions of Cho-GFP were also produced, corresponding to the Cho GS TEV 
protein series: Cho428-GFP, Cho386-GFP, Cho368-GFP, Cho332-GFP and Cho313-GFP. 
Numbers indicate the last amino acid of the truncated Cho protein. Some physiochemical 
properties of these proteins are presented in Table 6-2.  
While ntCho-GFP and Cho428-GFP were soluble and directly secreted by E.	coli, the four 
shorter proteins were insoluble and therefore expressed as inclusion bodies. The presence 
of a GFP molecule and the resulting green colour facilitated the evaluation of soluble 
protein content following expression. A summary of the expression and purification 
outcomes is presented in Table 6-1. As the expression yield for the shortest mutants was 
fairly low, only ntCho-GFP purification details are provided below as an example. 
Enrichment of His-tagged Cho protein was achieved using a nickel column that was eluted 
using an imidazole gradient. Two peaks of UV-absorbing material could be detected: the 
first peak (~400 mAU) corresponded to the flow-through (fraction X4). The second peak 
(~175 mAU, fractions A2-A5) was a smaller peak eluting from 63 to 215 mM imidazole (9-
41%) (Figure 6-5). This elution peak was well defined and, due to the specificity of IMAC, 
fractions A2-A5 were collected and enriched further using GF chromatography. The protein 
was eluted with PBS and only the content of fluorescent fractions (A12-A14) was separated 
by SDS-PAGE (Figure 6-6). The resulting Coomassie-stained gel revealed that these 
fractions did contain the protein of interest, and were therefore collected for future use. 





Figure 6-5 – Initial enrichment of ntCho-GFP by IMAC. X- and A-labelled lanes 
correspond to arbitrary tray row and column reference on the fraction collector and 
are illustrated by the red dashes. Fractions covered by the arrow indicate the 
complete range of fractions mentioned. The black dotted lines indicate the fractions 
containing ntCho-GFP that were collected. 
  
Figure 6-6 – Further enrichment of ntCho-GFP by GF chromatography. (A) 
Chromatogram obtained for GF column separation. (B) Coomassie-stained SDS-
PAGE of UV peak fractions. A-labelled lanes in (B) correspond to arbitrary tray row 
and column reference on the fraction collector and are illustrated by the red dashes 
on (A). Fractions covered by the arrow in (A) indicate the complete range of 
fractions displayed in (B). The black dotted lines marked on both (A) and (B) 
indicate the fractions containing ntCho-GFP that were collected. 
 






Cloning of Cho386-hGH 
Cho386 was amplified from pETCHO, a vector containing the full length non-toxic cholix 
(Figure 9-1), using the three same buffers which were used for amplification of hGH (GC, 
GC + DMSO and HF) (Figure 6-7 (A) and (B)). The primers included the NdeI and SpeI 
restriction sites. PCR using GC + DMSO produced only a very faint band at ~1.2 kbp, which 
would correspond to Cho386. However, amplification using either GC buffer or HF buffer 
produced a stronger band of correct size. For all three conditions, two other bands could 
be observed at ~3 and ~9 kbp, which could result from the aggregation of several inserts. 
As HF is the recommended buffer for high-fidelity amplification, the PCR was scaled up 
using this buffer with the resulting Cho386 being digested by NdeI and SpeI-HF®. In 
parallel, pPE364-hGH (DH5α) was digested at these same restriction sites in order to 
release PE364 (~1.2 kbp) (Figure 6-7 (C)). The ~4 kbp band corresponding to the 
remaining plasmid was purified on agarose gel. 
  
Figure 6-7 – Amplification of Cho386 by PCR in (A) GC buffer + DMSO or (B) GC or HF 
buffer only (Lanes 1 and 2, respectively). (C) Fragments obtained following 
digestion of pPE364-hGH by NdeI and SpeI-HF®. 
pCho386-hGH (DH5α) was obtained after ligation of Cho386 and digested pPE364-hGH 
(DH5α) and further transformation of the resulting plasmid in competent DH5α cells. The 
presence of both Cho386 and hGH were confirmed by sequencing. pCho386-hGH (DH5α) 
was finally transferred into competent Shuffle cells to obtain pCho386-hGH (Shuffle), the 








Expression and purification of Cho386-hGH 
Cho386-hGH was insoluble when expressed in E.	 coli, as shown in Figure 6-8: after 
expression and centrifugation of bacterial cells, little protein was present in the 
supernatant, while pellets were loaded with protein. 
 
Figure 6-8 – Cho386-hGH is insoluble when expressed in E. coli. S386, sample 
containing the soluble protein fractions (supernatant) and P386, sample containing 
the insoluble protein fractions (pellet). 
As a consequence, Cho386-hGH was expressed as inclusion bodies. Despite the presence of 
an N-terminal His tag, the expressed protein was not retained on a His column (Figure 
6-9). It was therefore purified using AE and GF chromatography. First, Cho386-hGH was 
eluted from an AE column with a NaCl gradient. A single peak could be observed at 15-
55% NaCl (0.15-0.55 M NaCl) (Figure 6-10 (A)). Fractions corresponding to this peak as 
well as the flow-through were separated by SDS-PAGE (Figure 6-10 (B)). A single band at 
~72 kDa was detected in fractions H4-H8. As the band observed in the flow-through 
fraction (X1) was very faint compared to bands detected in fractions H4-H8, these fractions 
were combined and were concentrated to 1 ml for further purification by size exclusion 
chromatography (Figure 6-11 (A)). 
Following this second purification step, fractions corresponding to the UV-absorbing 
material were separated by SDS-PAGE. As the UV peak obtained was less well defined, an 
SDS-PAGE of individual column fractions was used to assess the amount and purity of the 
protein of interest in order to select fractions that were pooled; Cho386-hGH was collected 
from fractions D5-D12 (Figure 6-11 (B)). Analysis of the Coomassie dye staining on the gel 
showed one dominant band visible at ~40 kDa in fractions D13-D14. This band could have 
corresponded to incompletely expressed Cho386-hGH. 




            
Figure 6-9 – Despite carrying an N-terminal His tag, Cho386-hGH was not retained 
on a His column. (A) WB of the purified Cho386-hGH. 10 μg protein was separated 
by SDS-PAGE and transferred to a PVDF membrane that was probed with an anti-His 
antibody diluted at 1 in 3,500 in TBS-T. PE-tev is a version of PE carrying a C-
terminal His tag that was used as a positive control. BSA was used as a negative 
control. (B) Chromatogram obtained following elution of Cho386-hGH on a Ni2+-
functionalised column. 
   
Figure 6-10 – Initial enrichment of Cho386-hGH by AE chromatography. (A) 
Chromatogram obtained for AE separation. (B) Coomassie-stained SDS-PAGE of 
fractions corresponding to the UV peaks. X- and H-labelled lanes in (B) correspond 
to arbitrary tray row and column reference on the fraction collector and are 
illustrated by the red dashes on (A). Fractions covered by the arrow in (A) indicate 
the complete range of fractions displayed in (B). The black dotted lines marked on 
both (A) and (B) indicate the fractions containing Cho386-hGH that were collected. 





Figure 6-11 – Further enrichment of Cho386-hGH by GF chromatography. (A) 
Chromatogram obtained for GF column separation. (B) Coomassie-stained SDS-
PAGE of fractions corresponding to the UV peaks. D-labelled lanes in (B) correspond 
to arbitrary tray row and column reference on the fraction collector and are 
illustrated by the red dashes on (A). Fractions covered by the arrow in (A) indicate 
the complete range of fractions displayed in (B). The black dotted lines marked on 
both (A) and (B) indicate the fractions containing Cho386-hGH that were collected. 
6.3.1.5 Coupling	of	cholix	to	a	fluorescent	tag	
 
All couplings were performed and purified using the same protocol. As an example, 
coupling of full-length cholix to Alexa Fluor® 568 is described below. 
After cleavage of the C-terminal TEV sequence with a commercial AcTEV protease, ntCho 
GS TEV was incubated with a maleimide-functionalised Alexa Fluor® 568 tag (ntCho-
A568). In order to separate the tagged protein from unreacted materials (uncoupled tag), 
the sample was loaded on a size exclusion column and purified by FPLC (Figure 6-12 (A)). 
The different components were eluted with PBS and the fractions corresponding to the 
UV-absorbing peaks were separated by SDS-PAGE (Figure 6-12 (B)). 
Purification by GF chromatography resulted in the elution of one main UV-absorbing 
compound (fractions M10-M14) corresponding to a ~72 kDa band on Coomassie-stained 
gel. The very small peak eluting in fractions N4-N7 is likely to have contained the unbound 
dye. Only one very faint secondary band could be detected at ~55 kDa, indicating that the 
level of purity of the coupled material was satisfactory, and fractions M10-M14 were thus 
concentrated together for further use. 





Figure 6-12 – Enrichment of ntCho-A568 by GF chromatography. (A) Chromatogram 
obtained for GF column separation. (B) Coomassie-stained SDS-PAGE of the 
fractions corresponding to the UV peak. M-labelled lanes in (B) correspond to 
arbitrary tray row and column reference on the fraction collector and are 
illustrated by the red dashes on (A). Fractions covered by the arrow in (A) indicate 
the complete range of fractions mentioned. The black dotted lines marked on both 
(A) and (B) indicate the fractions containing ntCho-A568 that were collected. 
6.3.1.6 Preparation	of	biotin-labelled	cholix	
 
In order to obtain a biotinylated version of the protein, the C-terminal TEV sequence of 
ntCho GS TEV was digested with a commercial AcTEV protease; 1.09 mg (15 nmol) of 
cleaved ntCho GS TEV was collected in 3.5 ml PBS and incubated in the presence of 50-
molar excess sulfhydryl-reactive EZ-Link® Maleimide-PEG2-Biotin reagent (950 nmol ≡ 0.5 
mg) for 3 h at RT. Following desalting, buffer exchange and concentration, 150 μl of ntCho-




In order to investigate the behaviour of cholix at mildly acidic pH, a set of experiments 
including trypsin digestion on the full-length protein and truncated mutants, size 
measurement using DLS and HPLC, and assessment of relative surface hydrophobicity by 
spectrofluorometry were performed. 
 






In order to determine whether cholix presented the same pH-dependency as PE, the 
protein was digested with trypsin as previously described (Section 3.3.1). Analysis by SDS-
PAGE revealed that the digestion pattern differed significantly depending on the pH 
(Figure 6-13). In fact, at physiological pH ntCho was hardly cleaved, as indicated by the 
presence of a strong band at ~72 kDa corresponding to the undigested protein (Figure 
6-19). Two secondary bands could be detected at ~55 kDa and 50 kDa. This suggests that 
the major enzyme cleavage site was not fully exposed at pH 7.4. On the contrary, the 
pattern obtained at pH 5.8 revealed that virtually no undigested protein remained, and 
four main bands were seen at ~57, 53, 47 and 25 kDa. Moreover, the change proved 
completely reversible (REV sample) when the sample was adjusted from pH 5.8 to pH 7.4 
(Figure 6-13). 
These results suggest that cholix presents a pH-dependent behaviour similar to that 
observed for PE; the protein being increasingly digested as the pH is lowered due to a 
reversible conformational change. As in the case of PE, this complete reversibility suggests 
that the protein does not undergo major structural changes during this pH-dependent 
conformational switch, and implies a more local variation in structure. 
 
Figure 6-13 – pH-dependency of cholix digestion by trypsin is reversible. Coomassie-
stained SDS-PAGE of ntCho GS TEV in citrate-phosphate buffer at pH 5.8 or 7.4 and of 
a sample incubated at pH 5.8 for 5 min and returned to pH 7.4 by dialysis (REV). All 
samples were digested using 0.4 μg trypsin at 4 °C for 30 min. SDS-PAGE of the 
undigested protein sample appears in Figure 6-19 (B). 
 






In an effort to refine the pH range where the pH-dependent conformational changes might 
occur, the size of ntCho over the 5.8-7.4 range was determined by DLS. Variations in the 
protein’s hydrodynamic diameter at various pH values and the statistical analysis used to 
assess that information are presented in Figure 6-14 (A) and (B), respectively. Statistical 
analysis revealed that only values at pH 6.2 and 7.4 were significantly different from other 
size measurements. Three distinct zones could be observed: when pH ≥ 6.4, a progressive 
decrease in protein size from12.1 ± 0.5 nm to 10.1 ± 0.3 nm (~16.5%) could be observed 
as the pH was lowered. When 6.0 < pH < 6.4, protein size seemed to re-increase to a 
maximum at 12.1 ± 1.0 nm. Finally, when the pH was ≤ 6.0, the hydrodynamic diameter of 
Cho seemed to stabilise around 10.7 ± 0.5 nm. 
Samples used for DLS measurements were digested with trypsin and separated by SDS-
PAGE. The gel was successively Coomassie- and silver-stained (Figure 6-15) and revealed 
that the conformational change occurred as a continuous transition between pH 7.4 and 
5.8.  In fact, band 1 (~72 kDa, ntCho) constituted the main band at pH 7.4 and 6.8, but 
gradually decreased in intensity until it completely disappeared at pH 5.8. The opposite 
progression could be observed for both bands 2 and 4 (~47 and 26 kDa, respectively). 
Finally, band 3 (~34 kDa) seemed to follow a similar transition but its intensity at pH 5.8 
was significantly decreased. These results suggest that lowering the pH results in the 
progressive exposure of the trypsin cleavage sites, which only become completely 
accessible below pH 6.0. Using these four bands’ relative intensities, three areas could be 
observed on these gels: when the pH was ≥ 6.8, the amount of digested protein remained 
minimal. However, when the pH was between 6.0 and 6.4 the protein became increasingly 
digested and maximum cleavage occurred at pH < 6.0. The significant increase in digestion 
observed at pH 5.8 could be due to protein denaturation, but this seems unlikely as it was 
previously shown that the conformational change at this pH was completely reversible. 
These results indicate that as the pH decreases, cholix undergoes a progressive 
conformational change from a state in which the protein is resistant to trypsin cleavage to 
a state where its degradation by this protease is much more pronounced. This suggests 
that Cho presents at least one cleavage site in acidic conditions that is not present at 
neutral pH, with more cleavage sites becoming accessible following the initial trypsin cut. 
The three pH zones observed varied slightly depending on the technique used (DLS or 
trypsin digestion), but they confirmed that the transition between the two conformations 
adopted by cholix occurred in the pH region of 5.8-6.2. The marked increase in size 




observed at pH 6.2 could imply that during its rearrangement from one conformation to 
the other, the protein might acquire different shapes of similar sizes. However, this 
conformational change did not tremendously affect the size of cholix, suggesting again that 
it might not be a global rearrangement of the protein’s tertiary structure. In order to 
investigate further the extent of the unfolding and its impact on the protein’s overall size, 
cholix was run on HPLC GF.  
  
Figure 6-14 – (A) Measurement of the size of ntCho GS TEV at different pH values in 
citrate-phosphate buffer using DLS. (B) Statistical analysis of the results obtained in 
(A). Bars show mean ± SD for n = 6 independent samples where *** P < 0.001. 
 
Figure 6-15 – Determination of the transition point between the two protein 
conformations by trypsin digestion. (A) Coomassie-stained and (B) silver-stained 
SDS-PAGE of DLS samples following digestion of 10 μg sample with 0.4 μg of trypsin 




A preparation of cholix was separated using an HPLC GF column in potassium-phosphate 
buffer (kPB) containing 0.1 M NaCl at pH 5.8 and 7.4. The main peak eluted from the 




column at ~8.9 min, which is in agreement with the retention times determined for PE 
(~9.3-9.4 min). PE is smaller than cholix and therefore elutes slightly later from the 
column. Chromatograms collected for cholix at different pH values (Figure 6-16) showed 
that the two conformations of the protein eluted at very close retention times (8.936 and 
8.870 min at pH 7.4 and 5.8, respectively). This suggested that their overall sizes and 
shapes were very similar, and therefore that no major structure alterations occurred upon 
lowering the pH. This supported the idea that, just as in the case of PE, the pH-dependent 
conformational change that occurred in Cho was consistent with a local change in 
structure.  
 
Figure 6-16 – HPLC chromatograms of cholix after elution on a GF column in 0.1 M 
kPB containing 0.1 M NaCl at pH 7.4 and 5.8 at 37 °C. UV measurements were 
performed at 254 nm. The chromatograms presented here were taken as 
representatives of 6 and 3 runs for pH 5.8 and 7.4, respectively. 
6.3.2.4 Cholix	conformational	change	results	in	the	exposure	of	hydrophobic	residues	
 
In an attempt to further characterise the conformational change made by cholix in mildly 
acidic conditions, the surface hydrophobicity of the protein at different pH values was 
probed by measuring the variations in ANS fluorescence. The hypothesis to be tested was 
as follows: pH-dependent conformation changes in ntCho would result in alterations in 
surface accessible hydrophobic regions of the protein. This hypothesis was tested using a 
fluorescent dye and a protocol described previously for ntPE.  
Fluorescence measurements were performed in citrate-phosphate buffer containing 0.1 M 
NaCl. The fluorescence emission spectrum was scanned between 400 and 700 nm, AUC 
values were calculated and values of λem,max were determined (Figure 6-17 and Table 6-3). 
The same ANS blank and BSA controls as for PE were used in this study. Addition of 1.52 
μM ntCho to 100 μM ANS at pH 7.4 resulted in a 1.25-fold increase in total fluorescence 




compared to ANS alone and a blue shift in λem,max  from 518 to 507 nm. Upon lowering the 
pH, this shift became more pronounced with λem,max  further displaced at 498 nm and the 
fluorescence between ANS + ntCho 7.4 and ANS + ntCho 5.8 multiplied by ΔF = 2.143. 
These observations suggested that, as in the case of ntPE, ANS was able to bind to solvent-
exposed hydrophobic areas on the ntCho protein used in these studies. This was 
consistent with a molecular representation of cholix surface hydrophobicity, on which it 
was clear that hydrophobic residues were present on the protein surface at physiological 
pH (Figure 6-18). However, fluorescence intensity was much lower for cholix, suggesting 
that this toxin bears less surface exposed hydrophobic sites in its native state than PE. The 
dramatic increase in ΔF upon lowering the pH could indicate that following the 
conformational change(s) associated with the altered trypsin sensitivity, additional 
hydrophobic residues became exposed to the surface and available to bind the ANS dye. 
 
 
Figure 6-17 – Hydrophobic residues are exposed on the surface of cholix when the 
protein is exposed to acidic pH. Fluorescence spectra of (A) ANS, (B) ANS + ntCho 
and (C) ANS + BSA at pH 5.8 (red) and 7.4 (black) for [ANS] = 100 μM and [ntCho] = 
[BSA] = 1.52 μM. (D) Areas under the fluorescence curves of ntCho and BSA at both 
pH values. Black bars legend on left y axis, red bars legend on right y axis. Bars show 
mean ± SD from n = 3 independent samples where * P < 0.05 and NS is non-
significant. 
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Table 6-3 – Values of ΔF and λem,max collected by spectrofluorometry for samples 
composed of ANS, ANS + ntCho or ANS + BSA. 




ANS 5.8 517 
ANS + ntCho 7.4 
2.143 
507 
ANS + ntCho 5.8 498 
ANS + BSA 7.4 
0.938 
476 
ANS + BSA 5.8 475 
 
 
Figure 6-18 – Surface hydrophobicity of cholix at pH 7.4 (based upon crystal 
structure information). Red and white refer to hydrophobic and hydrophilic 
residues, respectively. Even at neutral pH, cholix presents a significant number of 
surface-exposed hydrophobic sites which could bind ANS. The figure was generated 
using PyMOL [128]. 
6.3.2.5 Truncation	of	cholix	results	in	the	increased	exposure	of	trypsin	cleavage	sites	
 
All six Cho GS TEV protein mutants were individually digested with trypsin at 4 °C for 30 
min at pH 5.8 and 7.4. Samples were separated by SDS-PAGE and stained with Coomassie 
blue (Figure 6-19).  





Figure 6-19 – Trypsin digestion of Cho GS TEV mutants. 10 μg of protein was 
incubated with 0.4 μg trypsin for 30 min at 4 °C and separated by SDS-PAGE. 
Undigested samples were incubated in PBS without trypsin. Top line indicates the 
mutant used: full-length ntCho GS TEV (FL), Cho428 GS TEV (428), Cho386 GS TEV 
(386), Cho368 GS TEV (368), Cho332 GS TEV (332) or Cho313 GS TEV (313). Bottom 
line indicates the conditions of the digestion: in citrate-phosphate at pH 5.8 or 7.4 
(CP5 and CP7, respectively) or undigested protein (UD). 
As previously described, the digestion pattern observed for the full-length (FL) non-toxic 
cholix was significantly different depending on the pH. Cleavage at neutral pH produced 
only very faint bands at ~57 and 47 kDa, and most of the protein remained undigested. 
These bands are similar to those obtained following trypsin digestion of native PE at 
Arg490 [225]. Sequence alignment between the two proteins suggests that Arg519 would 
be the equivalent amino acid in cholix. Cleavage at this position would create two 
fragments of 57.9 and 12.8 kDa, respectively [181, 183], which would be consistent with 
the observations reported above, and with the absence of the lowest band on the gel. 
Cleavage at pH 5.8 was much more pronounced, producing four bands of ~57, 53, 47 and 
25 kDa. Virtually no undigested protein remained after incubation with the enzyme for 30 
min at 4 °C. N-terminal sequencing of the different bands did not prove successful, but 
assuming that digestion of PE and cholix occurred in similar ways, it could be conjectured 
that cholix was cut at several distinct positions, and that the 25 kDa fragment observed 
here corresponded to the N-terminal end of the protein following one of these cleavages. 
Trypsin digestion of PE was proposed to occur after Arg186 or Arg213 (Cleavage 1, C1) 
and Arg279 (Cleavage 2, C2, main cutting site) (Section 3.3.4). Sequence alignment with 
cholix revealed that corresponding sites could be identified at positions Arg197 and 
Arg292. The latter would match cholix’s furin-cleavage site but would generate two 
fragments of 32.9 and 37.9 kDa respectively, which would not coincide with the detected 
gel bands. Therefore, unlike PE, it would seem improbable that the main trypsin cleavage 
occurred at this position. Based on the approximate molecular weight of the fragments 




detected, four cleavage sites are proposed here; Lys128, Arg138 or Lys145 and Arg197 
(see Table 6-4 and Figure 6-20). While the latter would give the two 47 and 25 kDa 
observed on the gel, the three other cleavage sites would only produce one ~55 kDa 
visible band each, the other being too small and running off the gel.  
 
 
Figure 6-20 – Positions of the potential trypsin cleavage sites corresponding to the 
25 and 47 kDa fragments that were detected in Figure 6-19. (A) Schematic 
representation of full-length cholix and (B) Ribbon representation of Cho domain I. 
Arg138 (R1) and Lys145 (K2) are both located on loops, while Lys128 (K1) is in the 
middle of a β-strand and Arg197 (R2) is located within a α-helix. Disulphide bonds 




Ia II Ib III
1 264 386 423 634
R1K2 R2 A




Table 6-4 – Potential trypsin cleavage sites corresponding to the 25 and 47 kDa 
fragments detected in Figure 6-19. ExPASy Peptide Cutter and ExPASy ProtParam 
were used to generate the fragments and calculate their molecular weight, 
respectively [181, 183]. Only 100% probability cleavage sites are displayed. 
Position of cleavage site MW (fragment 1) (kDa) MW (fragment 2) (kDa) 
Arg77 8.6 62.2 
Lys128 14.3 56.4 
Arg138 15.5 55.2 
Lys145 16.3 54.5 
Lys160 18.1 52.6 
Lys186 21.0 49.7 
Arg197 22.3 48.5 
Lys244 27.6 43.2 
 
Trypsin digestion of the five truncated mutants revealed that four of them (Cho386 GS 
TEV, Cho368 GS TEV, Cho332 GS TEV and Cho313 GS TEV) presented very similar patterns 
at both pHs, with cleavage being slightly more pronounced at pH 7.4. No undigested 
material remained in any case. The ~25 kDa band previously described for ntCho GS TEV 
appeared for all mutants at both pHs and represented the main fragment. This supports 
the idea that it corresponds to an N-terminal digestion fragment, as any C-terminal 
fragment would see its size vary due to protein truncation. For some reason which 
remains unexplained, digested fragments of Cho428 GS TEV were difficult to detect and 
even the undigested protein was not readily observed. 
These results appear very similar to those obtained following digestion of the PE GS TEV 
protein series by trypsin. Again, the patterns observed suggest that additional trypsin 
cleavage sites were revealed in full-length ntCho upon lowering of the pH. On the contrary, 
the truncated proteins did not seem to need acidification of their environment to be 
cleaved by the protease, and the similarity between the patterns obtained at both pHs 
suggests that exposure of the cleavage sites were comparable in either conditions. This 
could imply that, as was previously proposed for PE, domain III (residues 423-634) could 
either conceal trypsin cleavage sites at neutral pH, or impose constraints on the protein 
structure that would prevent the enzyme from accessing these sites. The second 
possibility would seem more likely as, according to earlier observations, the 
conformational change experienced by cholix at mildly acidic pH remains local and 
therefore would be unlikely to trigger a change in position of the whole third domain to 




reveal the hidden cleavage sites. Although the difference here is much more subtle than 
what was observed for ntPE, digestion was not completely identical at pH 7.4 and 5.8. This 
implies that the truncated mutants might still undergo a change in conformation when the 
pH is lowered, although not as extensive as that which occurs on the FL protein. It is 
therefore possible that the trigger for this conformational switch is located between amino 
acids 1 and 313. 
Reversibility of the conformational change in the truncated mutants was tested as 
previously described for the full-length protein. As Cho428 GS TEV did not seem to 
provide any useful results after several attempts, it was not used here. Samples were 
incubated at pH 5.8 and returned to physiological pH by dialysis before being digested 
with trypsin and separated by SDS-PAGE (Figure 6-21). The pattern observed suggested 
that any conformational change(s) experienced by the truncated mutants was/were 
reversible, similar to that observed for the FL protein. This suggests that removal of 
residues 314-634 may not impede conformational change(s), nor prevent the remainder 
of the protein from returning to its original conformation. Therefore, it seems likely that 
the origin of this reversible pH-dependent conformational change is located prior to amino 
acid 313. 
 
Figure 6-21 – Assessment of the reversibility of the pH-induced conformational 
change in Cho GS TEV mutants. Coomassie-stained SDS-PAGE of Cho GS TEV mutants 
incubated in citrate-phosphate buffer at pH 5.8 for 5 min and returned to pH 7.4 by 
dialysis. All samples were digested using 0.4 μg trypsin for 30 min at 4 °C. 
6.3.3 Interaction	of	cholix	with	GM1	
 
Studies reported above seem to suggest that cholix undergoes a conformational change 
whose characteristics are very similar to those described earlier for ntPE (Chapter 3). 




Carter (2014) reported however that cholix does not interact with LRP1 at the surface of 
CHO cells, as the absence of this receptor does not prevent toxin internalisation by non-
polarised cells [27]. Therefore, it is likely that in most cell lines PE and cholix use different 
receptors to gain entry into cells. Moreover, addition of CTB affected the transcytosis 
characteristics of cholix across Caco-2 cells, suggesting that GM1 influences protein 
transport across polarised monolayers of epithelial cells. For these reasons, a series of 
experiments were performed on cholix in order to investigate the nature and possible 




BLI was used here to investigate the characteristics of the interaction between cholix and 
GM1 at acidic pH. Biotin-labelled ntCho and the streptavidin-functionalised biosensor tips 
previously described in Section 2.13 were again used in this case. Biotinylated ntPE was 
run in parallel for comparative purposes. Measurements were performed in collaboration 
with Dr Thomas Hunter who had access to a BLI instrument; results are presented below. 
Experiments were conducted at 37 °C in 0.1 M potassium-phosphate buffer at pH 5.5. GM1 
concentration used here was 41.3 nM. The plate layout is presented in Figure 6-22 and 
details of the various step times are summarised in Table 6-5. Sensorgrams obtained for 
both cholix and PE (Figure 6-23) showed that the association and dissociation curves were 
biphasic for both proteins. The data obtained were fitted to a 2:1 heterogeneous ligand-




Figure 6-22 – Plate layout diagram for the kinetics assay. 




Table 6-5 – Summary of kinetics assay procedure. 
Step # Step name Time (sec) 
Sample plate 
column 
1 Equilibration 60 1 
2 Loading 120 2 
3 Baseline 15 3 
4 Association 70 4 
5 Dissociation 120 5 
 
 
Figure 6-23 – Kinetic characterisation of the interaction between ntPE or ntCho and 
GM1 at pH 5.5. Sensorgrams obtained following interaction of GM1 and immobilised 
biotin-labelled ntPE or ntCho at pH 5.5. 
Table 6-6 – Summary of the parameters obtained by fitting experimental data to a 
heterogeneous ligand binding model. Parameters represent the average of two 
individual lanes. 





kd1 (s-1) kd2 (s-1) r2 
ntPE < 1 x10-12 1.96 x10-10 1.34 x106 1.24 x107 < 1 x10-7 2.35 x10-3 0.987 
ntCho 1.63 x10-9 7.17 x10-10 2.08 x106 8.90 x106 4.18 x10-3 4.18 x10-3 0.993 




The r² values obtained confirmed that the 2:1 heterogeneous ligand model applied was the 
most fitting representation of the interactions involved between GM1 and each protein (r² 
= 0.987 and 0.993 for ntPE and ntCho, respectively). Results acquired for ntPE are of the 
same order of magnitude than those presented in Section 4.3.1.2. The differing step times 
for the association and dissociation phases might account for the minor variations in the 
calculated parameters. 
Sensorgrams obtained for ntCho presented differences in the loading steps i.e. when the 
biotinylated protein was loaded on the surface of the streptavidin-functionalised tip. This 
might suggest that under the conditions of the assay the protein was in a conformation 
that slightly altered its interaction with the sensor tip, or that ntCho might not have been 
as efficiently labelled with the biotin compared to ntPE. 
As previously described for ntPE, two distinct KD values were calculated for ntCho at pH 
5.5. This discrepancy again likely reflects a possible dynamic behaviour of the protein in 
acidic conditions and its presence under different conformations on the tip surface. 
However, KD1 and KD2 values remained close and the two kd were of the same order of 
magnitude, suggesting that even if the protein was constantly shifting from one 
conformation to another, the respective affinities of all these conformations for GM1 was 
comparable. 
KD values calculated for ntCho at pH 5.5 were < 10-8 M, indicating that the interaction 
between the protein and the ganglioside was strong in acidic conditions. For a 
comprehensive understanding of the interactions taking place here, these studies would 




Spectrofluorometry was used here to investigate the location of the binding site between 
cholix and GM1. As the conformational change(s) undergone by ntCho resulted in the 
exposure of additional hydrophobic residues, GM1 interaction with a particular region 
uncovered as a result of decreased pH would trigger a change in ANS fluorescence. As 
mentioned earlier, GM1 was replaced by lysoGM1 in order to reduce ANS binding to the 
hydrophobic tail of the ganglioside. To test for specificity and ensure that the remaining 
hydrophobic tail of the ganglioside did not interfere with ANS fluorescence measurements, 
N-acetylneuraminic acid (NANA, sialic acid) was used as a control. Measurements were 
also performed after replacing lysoGM1 with sucrose to investigate whether potential 




interactions were sugar-specific. Fluorescence spectra obtained for each sample are 
presented in Figure 6-24 and collected values of λem, max and ΔF are gathered in Table 6-7. 
It was previously shown that individual addition of lysoGM1, NANA or sucrose to ANS did 
not modify the fluorescence characteristics of the dye, with ΔF = 0.978 ± 0.03 and λem, max = 
517 ± 2 nm (Figure 6-25 (A)). When ntCho was added in solution to lysoGM1, NANA or 
sucrose, only variations between AUC5.8(ANS + ntCho) and AUC5.8(ANS + ntCho + lysoGM1) 
were calculated as statistically significant (Figure 6-25 (B)). However, the ΔF values for 
these two samples were not significantly different (Figure 6-25 (C)). The λem,max values at 
both pHs also remained similar, whether or not lysoGM1 was present. These observations 
suggest that lysoGM1 did not induce any substantial changes in ANS fluorescence, 
implying that the molecules of lysoGM1 introduced in solution did not modify the dye 
binding enough for detection by a change in fluorescence intensity. However, as was 
already mentioned in the case of ntPE, these results do not prove that lysoGM1 did not 
bind to the protein, only that its presence did not affect the hydrophobic interactions 













Figure 6-24 – Fluorescence spectra of (A) ANS, (B) ANS + ntCho, (C) ANS + lysoGM1, 
(D) ANS + ntCho + lysoGM1, (E) ANS + NANA, (F) ANS + ntCho + NANA, (G) ANS + 
sucrose and (H) ANS + ntCho + sucrose in CP 5.8 (red) and 7.4 (black). For all 
measurements, [ANS] = 100 μM, [ntCho] = 1.52 μM and [lysoGM1] = [NANA] = 
[sucrose] = 2 μM. 
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Table 6-7 – Values of ΔF and λem,max collected by spectrofluorometry for different 
mixtures of ANS, ntCho and lysoGM1 or one of its substitutes. 




ANS 5.8 517 
ANS + lysoGM1 7.4 
0,952 
520 
ANS + lysoGM1 5.8 518 
ANS + NANA 7.4 
1,020 
515 
ANS + NANA 5.8 516 
ANS + sucrose 7.4 
0,964 
516 
ANS + sucrose 5.8 518 
ANS + ntCho 7.4 
2,143 
507 
ANS + ntCho 5.8 498 
ANS + ntCho + lysoGM1 7.4 
2,252 
508 
ANS + ntCho + lysoGM1 5.8 496 
ANS + ntCho + NANA 7.4 
1,985 
504 
ANS + ntCho + NANA 5.8 507 
ANS + ntCho + sucrose 7.4 
2,316 
500 
ANS + ntCho + sucrose 5.8 497 
 
   






Figure 6-25 – Influence of lysoGM1, NANA and sucrose on ANS binding to cholix.  
Statistical analysis of the areas under the curves of (A) ANS and (B) ANS + ntCho in 
presence of lysoGM1, NANA and sucrose. (C) ΔF of cholix in presence of lysoGM1, 
NANA or sucrose. In (A) and (B), data at pH 7.4 and 5.8 are represented in black and 
red, respectively. Bars show mean ± SD for n = 3 independent samples where * P < 
0.05, NS non-significant. 
6.3.3.3 GM1	is	involved	in	the	uptake	of	cholix	by	non-polarised	cells	
 
BLI studies confirmed that GM1 could bind to ntCho at pH 5.5 with high affinity, which 
suggests that interaction(s) between the protein and the ganglioside could be important in 

































































































































































































































































similarities with PE, cholix might also bind to GM1 in more physiological conditions. This 
could imply a role for this ganglioside as a cell-surface receptor. 
The role of GM1 in the uptake of cholix (Cho) by non-polarised (NP) cells was assessed by 
examining the effects of neuraminidase pre-treatment and/or the addition of CTB. This 
approach should also provide information about the role of the ganglioside’s SA group in 
the interaction with the protein. NP Caco-2 cells were seeded on glass coverslips and 
incubated with 2.7 µM full-length, non-toxic Cho GS TEV protein modified to have a C-
terminal Alexa Fluor® fluorescent tag (ntCho-A568). After 2 h, a limited amount of ntCho-
A568 could be observed in NP cells, which appeared to localise at individual spots at the 
periphery of nuclei (Figure 6-26). When cells were pre-treated with 1 U/ml 
neuraminidase for 15 min before being incubated for 2 h with ntCho-A568 in presence of 1 
U/ml neuraminidase, no major changes were detected. This is consistent with previous 
observations using ntPE, in which cellular uptake was not enhanced following a 15-minute 
neuraminidase pre-treatment (Chapter 4). Next, cells were pre-treated with 
neuraminidase for 2 h before applying the ntCho-A568/neuraminidase mixture for 
another 2 h. This seemed to trigger a significant increase in cell entry of the fluorescent 
tag, and the internalised material appeared to be more clearly localised, and in well-
defined, individual areas close to the nuclei. Cells were also subjected to the same 
treatment plus 3.5 µM CTB; the level of cell-associated fluorescence did not seem to be 
affected by the addition of CTB. Finally, ntCho-A568 added to cells exposed to CTB but not 
neuraminidase appeared to enter at higher levels compared to those in untreated cells but 
slightly lower than those observed following 2 h neuraminidase treatment with or without 
CTB application. Co-localisation studies were not conducted for these experiments and 
would be required to determine accurately which intracellular compartment(s) were 
reached by the internalised ntCho-A568. However, observation of the fluorescence pattern 
could, as for PE, indicate that fluorescently-labelled ntCho might have trafficked as far as 
the Golgi network or possibly the ER. This would need to be confirmed by co-localising 
ntCho with a Golgi marker such as GM130 or TGN46. 
These observations could indicate that ntCho can interact with GM1 at the cell surface in 
absence of neuraminidase treatment, as addition of CTB to untreated cells significantly 
enhanced protein entry. Moreover, possible cleavage of SA groups from cell surface 
components using neuraminidase seemed to have the same effect, suggesting that ntCho 
could interact with SA moieties; binding between ntCho and GM1 could therefore be 
mediated by this group on GM1. Overall, neuraminidase treatment should decrease the 
extent of GM1 present at the plasma membrane, even if the remaining ganglioside 




molecules would be more exposed. Therefore, these results suggest that decreasing the 
toxin’s potential to interact with GM1 (either with neuraminidase or by addition of CTB) 
resulted in a significant increase in ntCho uptake by NP cells. However, unlike ntPE, this 
interaction appears to lower the aptitude of ntCho to penetrate and traffic inside cells. It is 
therefore possible that interaction with GM1 could divert ntCho from a more efficient 
trafficking pathway. This interpretation would be consistent with data previously 
reported by Carter (2014) which suggested that addition of CTB enhanced ntCho 
transcytosis by potentially redirecting the toxin away from a secondary pathway involving 
GM1 in polarised cells [27]. 
Why cholix could interact with GM1 at the surface of untreated cells while PE did not seem 
able to do so remains unexplained. It could be related to a complex set of interactions 
involving cholix receptor, as GM1 is suggested here to only act as a secondary receptor for 
this protein. Finally, these observations underline that treating the cells with 
neuraminidase is not an absolute requirement for cholix to be internalised, as a low 
amount of protein was taken up even in the absence of the enzyme. As cholix is a potent 
toxin, penetration of even a low quantity of protein would be enough to intoxicate a cell 
[105]. However neuraminidase could play a role in enhancing the uptake of the virulence 
factor as previously discussed in Section 4.3.3.2 and by others [277-279]. 





Figure 6-26 – Treatment with neuraminidase and CTB affects the entry of non-toxic 
cholix into NP epithelial cells. Fluorescent images of NP Caco-2 cells incubated for 2 
h with 2.7 μM ntCho-A568 on its own or with 3.5 µM CTB, with or without cell 
treatment with 1 U/ml neuraminidase. Cell nuclei were stained with DAPI (blue). 
Images are representative of three independent experiments. 






Due to its great structural similarities with PE, including the division of the full-length 
protein into three independent functional domains, cholix could potentially also be used as 
a delivery system to carry therapeutic proteins across the intestinal epithelium as was 
observed for PE. Moreover, cholix is a virulence factor secreted by an intestinal pathogen, 
while PE is secreted by a respiratory pathogen. Thus, cholix might prove more efficient 
than PE with respect to oral delivery as the system would be placed in an environment 
resembling more accurately that of the native toxin. In fact, Carter (2014) showed that 
cholix seemed to traffic more efficiently across polarised intestinal epithelial cells than PE. 
Therefore, the internalisation of these proteins coupled to a fluorescent tag or fused with a 
GFP protein in NP epithelial cells was examined to determine the individual and combined 
effects on protein entry and intracellular transport of truncation and addition of a cargo 
protein. Transepithelial transport of full-length and truncated versions of cholix coupled 
to a fluorescent tag or cargo protein was also assessed in	vitro and in	vivo. 
6.3.4.1 In	vitro	uptake	of	two	truncated	versions	of	cholix	
 
In an attempt to get a better understanding of the behaviour of truncated versions of 
cholix, the ability of Cho386 GS TEV (medium-length mutant) and Cho313 GS TEV (short-
length mutant) to be internalised by NP epithelial cells was assessed in	vitro. NP Caco-2 
cells cultured on glass coverslips were incubated with 20 μg fluorescently-tagged proteins 
diluted in 100 µl complete growth medium (concentration of ntCho-A568 = 2.8 µM, 
Cho386-A568 = 4.6 µM, and Cho313-A568 = 5.6 µM, respectively) for 2 h at 37 °C before 
being fixed and stained with DAPI. Fluorescent images obtained by confocal microscopy 
showed that, as observed in Section 6.3.3.3, a low amount of full-length ntCho appeared to 
be internalised by NP cells after 2 h. The two shorter proteins, Cho386-A568 and Cho313-
A568, did not seem able to enter the cells (Figure 6-27). 
These results could suggest that while FL ntCho might be able to carry a fluorescent tag 
inside NP cells, shortened versions of the protein were unable to be internalised. A 
possible explanation is that removal of amino acids 387-634 or 314-634 (Cho386-A568 
and Cho313-A568, respectively) led to improper folding, resulting in the protein’s inability 
to penetrate the cells. Alternatively, it was suggested that the GM1 binding site on PE 
would be located before residue 303 (between α-helices A and B). Sequence alignment 
revealed that this amino acid corresponds to Iso316 in cholix (Appendix 6). The two toxins 




were shown to display similar pH-dependent behaviours and, assuming that the GM1 
epitopes could also have comparable locations on both proteins and be revealed upon 
exposure to low pH, the GM1 binding site could be located between residues 1-316 on 
cholix. Therefore, this sequence might be more accessible on the truncated mutants than 
the full-length protein, even at neutral pH. As GM1 was suggested to reduce the efficiency 
of ntCho entry into cells (Section 6.3.3.3), an increase in binding to the ganglioside could 
diminish the ability of the truncated mutants (Cho386-A568 and Cho313-A568) to 
penetrate the cells, which could account for the lack of intracellular fluorescence. 
 
Figure 6-27 – Truncated forms of Cho have reduced rates of cell association by NP 
epithelial cells compared to the FL ntCho. Fluorescent images of NP Caco-2 cells 
incubated for 2 h with 20 μg of protein tagged with Alexa Fluor® 568 and diluted in 
100 µl complete growth medium (red). Final protein concentrations were 2.8 µM 
ntCho-A568, 4.6 µM Cho386-A568 and 5.6 µM Cho313-A568. Cell nuclei were 
stained with DAPI (blue). Images are representative of three independent 
experiments. 






In order to determine the trafficking properties of full-length, non-toxic cholix as well as 
several truncated versions of this protein to transport a cargo (e.g. therapeutic protein) 
into NP cells, six Cho truncation mutants were expressed as fusion proteins carrying a C-
terminal GFP molecule. 20 μg of each protein diluted in 100 µl complete growth medium 
was applied to NP Caco-2 cells and incubated at 37 °C for 2 h. Final molar concentrations 
for all proteins applied are given in Table 6-8. Cells were then fixed with PFA, labelled with 
an anti-GM130 antibody, and prepared for confocal microscopy. GM130 expression was 
used here to visualise the Golgi network [314]. 
Confocal images suggested that very little ntCho-GFP was internalised by these NP Caco-2 
cells (Figure 6-28). Very little GFP fluorescence could be detected in cells incubated in the 
presence of any of the five shorter mutants. This is consistent with results described 
previously for ntCho-A568, Cho386-A568 and Cho313-A568. As neuraminidase treatment 
was previously shown to enhance the uptake of ntCho-A568, cells were pre-treated with 1 
U/ml neuraminidase for 2 h before proteins were individually applied in presence of the 
same concentration of enzyme for another 2 h (Figure 6-29). Neuraminidase treatment 
significantly increased the uptake of ntCho-GFP (Figure 6-29, top) and also appeared to 
slightly enhance the penetration of Cho428-GFP. 
Conversely, no major increase in intracellular fluorescence could be observed for any of 
the other mutants. In order to confirm that the absence of intracellular fluorescence was 
due to the lack of protein entry, the fluorescence intensity of 20 μg of each protein diluted 
in 100 µl HBSS was measured (Figure 6-30 and Table 6-8). ntCho-GFP and Cho428-GFP 
both presented detectable fluorescence levels. On the other hand, all Cho386-GFP, 
Cho368-GFP, Cho332-GFP and Cho313-GFP displayed intensities of less than 1,000 AFU. 
Therefore, even if any of these proteins had entered into the cells, it is highly unlikely that 
it would have been detected. The lack of fluorescence from five truncated versions of 
ntCho-GFP could be explained by improper protein folding, as the properties of GFP rely 
upon its tertiary structure [334]. This assumption would be in agreement with the 
expression outcomes for these proteins. Cholix is usually more soluble than PE when 
expressed in E.	coli, and addition of GFP should have further improved the solubility of the 
fusion proteins. As all PE-GFP mutants were expressed as soluble proteins, it was 
surprising that most of the Cho-GFP proteins had to be expressed as inclusion bodies. 
Thus, misfolding could have accounted for both reduced protein solubility and a lack of 
fluorescence. 




As a result, further tests were performed using only ntCho-GFP. In an attempt to 
determine if the relationship between the GFP-labelled ntCho and GM1 was comparable to 
that of ntCho-A568, cells were pre-treated with neuraminidase, and ntCho-GFP was 
subsequently added at the same time as CTB (Figure 6-31). This resulted in increased 
intracellular fluorescence levels in NP Caco-2 cells. When both ntCho-GFP and CTB were 
applied to NP cells, the fluorescence levels observed after 2 h were higher than in cells not 
treated with CTB, but appeared to be lower than in neuraminidase-treated cells either in 
the presence or absence of CTB. Expression of GM130 was used in all samples to visualise 
the Golgi network and investigate the destination of internalised ntCho-GFP. However, 
observation of confocal images revealed that co-localisation between GFP (green) and 
GM130 (red) was rather low, suggesting that very little protein localised in the Golgi 
network after 2 h. 
These observations indicate that cell incubation with neuraminidase as well as application 
of CTB resulted in enhanced uptake of ntCho-GFP. They also suggest that either cleavage of 
SA groups from surface proteins and lipids, or targeted GM1 blocking, led to increased 
protein internalisation, consistent with the hypothesis that these elements hinder the 
entry process of ntCho-GFP. This would be in agreement with results previously described 
for ntCho-A568, which seemed to show that GM1 could interact with cholix via its SA 
moiety and that binding to the ganglioside would interfere with efficient protein 
internalisation and trafficking.  These data would therefore indicate that addition of the C-
terminal cargo protein GFP does not block the mechanism of ntCho entry. Co-localisation 
studies between ntCho-GFP and GM130, a protein situated exclusively in the Golgi matrix, 
revealed that ntCho-GFP did not traffic to this compartment following internalisation. The 
fluorescence patterns observed here are very similar to those detected for the various PE-
GFP mutants, which were suggested to be retained within endocytic vesicles following cell 
penetration. It is therefore conceivable that ntCho-GFP experiences a similar fate upon cell 
uptake. 





Figure 6-28 – Cho-GFP mutant proteins are not internalised by NP epithelial cells. 
Fluorescent images of NP Caco-2 cells incubated for 2 h with 20 μg of protein diluted 
in 100 µl complete growth medium. Molar concentrations are detailed in Table 6-8. 
Cell nuclei were stained with DAPI (blue) and expression of GM130 (red) was used 
to visualise the Golgi network. Images are representative of three independent 
experiments. 





Figure 6-29 – Treating cells with neuraminidase does not increase the uptake of all 
Cho-GFP mutants by NP epithelial cells. Fluorescent images of NP Caco-2 cells pre-
incubated for 2 h with 1 U/ml neuraminidase followed by another 2 h-incubation 
with 20 μg of protein diluted in 100 µl complete growth medium in presence of 1 
U/ml neuraminidase. Molar concentrations are detailed in Table 6-8. Cell nuclei 
were stained with DAPI (blue) and expression of GM130 (red) was used to visualise 
the Golgi network. Images are representative of three independent experiments. 




Table 6-8 – Molar equivalent of 20 µg protein for the Cho-GFP mutant series and 
concentrations used in uptake assays in NP Caco-2 cells. 
Protein 
designation 
Molar equivalent of 20 µg 
protein (nmol) 
Protein concentration in 
100 µl medium (µM) 
ntCho-GFP 0.20 2.0 
Cho428-GFP 0.27 2.7 
Cho386-GFP 0.28 2.8 
Cho368-GFP 0.29 2.9 
Cho332-GFP 0.31 3.1 
Cho313-GFP 0.32 3.2 
 
 
Figure 6-30 – Fluorescence of Cho-GFP mutant proteins. Fluorescence intensity of 20 
μg of fusion protein in HBSS (λex = 480 nm, λem = 520 nm). Corresponding molar 
concentrations are presented in Table 6-8. Data are presented as mean ± SD for 
each sample, for n = 3 microplate wells. 
 





































Figure 6-31 – Treatment with neuraminidase and CTB affects the entry of ntCho-GFP 
in NP epithelial cells. Fluorescent images of NP Caco-2 cells incubated for 2 h with 
2.0 μM ntCho-GFP alone or with 3.5 µM CTB, with or without cell treatment with 1 
U/ml neuraminidase. Cell nuclei were stained with DAPI (blue) and expression of 
GM130 (red) was used to visualise the Golgi network. Images are representative of 
three independent experiments. 
6.3.4.3 In	vitro	transport	of	cholix	in	polarised	cells	and	comparison	with	PE	
 
To investigate the ability of ntCho to transport across epithelial cells, the FL protein was 
labelled with a fluorescent Alexa Fluor® tag (A568) and 0.09 µM, 0.47 µM and 0.93 µM of 
ntCho-A568 (= 2, 10 and 20 μg diluted in 300 µl HBSS, respectively) were applied to the 
apical surface of polarised cells as described in Sections 2.16 and 5.3.5. Samples were 




taken from the basolateral well at t = 15, 30, 60, 120 and 240 min and assayed for 
fluorescence content. 
Linearity of the fluorescence intensity with increasing amounts of protein was verified for 
the concentration range of 0.001-0.1 mg/ml (Section 5.3.5, Figure 5-15). Results showed 
that the total fluorescence intensity in samples collected from the basolateral side 
increased linearly over time for the three curves, indicating that surface receptors were 
not saturated and that the maximum transport rate had not been reached (Figure 6-32 
(A)). Measurements of 4 kDa dextran permeability after incubation indicated that between 
7.6 and 13.3% dextran crossed the monolayer compared to the blank well (Figure 6-32 
(B)). When associated to the TEER values taken at the start of the assay (TEER > 350 
Ω·cm2), these results demonstrate that the integrity of the monolayer was maintained 
throughout the experiment. 
These data establish that ntCho is able to carry a fluorescent tag across polarised cells 
without damaging the epithelium, as illustrated by conservation of the monolayer 
integrity throughout the assay. Moreover, ntCho has a molecular weight (72 kDa) 
comparable to that of PE (66 kDa) and therefore paracellular transport is also unlikely to 
account for the transport of either protein across Caco-2 cells. Although the receptor for 
cholix remains unknown, data obtained here suggest that it seems to be present on the cell 
surface of polarised Caco-2 cells. As a conclusion, this assay validates the potential of 
ntCho to transport and carry a fluorescent tag across polarised monolayers of Caco-2 cells 
in these experimental conditions. 
Transport of ntPE and ntCho across polarised monolayers were then compared by 
application of 20 μg of either ntPE-A568 or ntCho-A568 (= 0.30 and 0.28 nmol, 
respectively) to the apical compartment. Samples were taken from the basolateral well at 
the same time points as previously mentioned and assessed for fluorescence content. The 
material remaining in the apical compartment after 240 min was also collected. This time, 
transport was not linear and both curves reached a plateau (Figure 6-33 (A)). This 
indicates that the maximum transcytosis rate had been attained and that surface receptors 
were saturated. Although the molar concentrations of the two proteins differed slightly, 
these results also showed that ntPE appeared to transport more efficiently than ntCho 
across polarised Caco-2 cells. In fact, the total fluorescence detected in the basolateral 
compartment after 240 min was approximately twice as high for ntPE than for ntCho 
while total fluorescence (apical + basolateral after 240 min) was approximately equal for 
both proteins (Figure 6-33 (B)). These results were surprising as cholix is naturally an 
intestinal pathogen and was expected to transport more efficiently than PE, a respiratory 




toxin. Moreover, Carter (2014) previously showed that in identical conditions the total 
amount of ntCho in the basolateral compartment after 240 min was higher than for ntPE 
[27]. 
The nature of the system used here could account for discrepancies observed in the 
proteins’ transport profiles (linear vs. non-linear transport curves). In fact, it is a cell-
based model, and although results seem to be reproducible within the same experiment, 
variations in cell characteristics, for example passage number, appear to have an impact 
on data. Indeed, one experiment resulted in linear transport of 0.93 µM cholix and a total 
fluorescence of ~175,000 AFU after 240 min, while another experiment conducted with 
the same amount of protein led to saturation of the system and detection of total 
fluorescence ~30,000 AFU.  
  
Figure 6-32 – Transport of ntCho-A568 across polarised epithelial cells. (A) 
Normalised total fluorescence of 0.93 µM, 0.47 µM and 0.09 µM of ntCho-A68 
present in the basolateral compartment over 240 min following initial application 
to the apical surface of polarised Caco-2 monolayers. Data are presented as mean ± 
SD for each time point, totalling three individual samples. (B) Amount of FITC-
labelled 4 kDa dextran present in the basolateral compartment 30 min after 
application to a blank Transwell® filter compared to Transwell® filters supporting a 
monolayer of polarised Caco-2 cells which had been incubated with various 
amounts of ntCho-A568 for 240 min. Data are presented as mean ± SD for each 
sample, for n = 3 samples where *** P < 0.001. 





























































































































































































































Figure 6-33 – Transport of ntPE-A568 and ntCho-A568 across polarised cells. (A) 
Normalised total fluorescence of 20 μg ntPE-A568 (= 0.30 nmol) (red) and ntCho-
A568 (= 0.28 nmol) (black) present in the basolateral compartment over 240 min 
following initial application to the apical surface of Caco-2 monolayers. (B) Amounts 
of ntPE-A568 (red) and ntCho-A568 (black) collected from the apical and 
basolateral compartments after 240 min, following the application of 20 μg protein 
to the apical or basolateral surface of Caco-2 monolayers. Data are presented as 
mean ± SD for each time point (n = 3 wells). 
6.3.4.4 In	vivo	transport	of	ntCho-A546	and	Cho386-A546	
 
Results described in this chapter showed that full-length non-toxic cholix (ntCho) labelled 
with a fluorescent tag can transport a fluorescent tag across a monolayer of polarised 
Caco-2 cells in	 vitro. To determine if this could be achieved in	 vivo, the uptake and 
trafficking of full-length and truncated versions of cholix attached to a fluorescent tag 
(ntCho-A546 and Cho386-A546) were studied in rat small intestine. 
ntCho-A546 and Cho386-A546 were diluted in PBS and injected directly in the lumen of a 
rat small intestine in	vivo. Sample segments were collected 20 min after administration 
and tissues were processed as described in Section 2.17.2. Controls (naïve tissue) are 
presented in Appendix 7. 
Microscopic examination of isolated intestinal tissue revealed that most of the 
administered ntCho-A546 did not penetrate the cells soon after intraluminal injection, 
with the protein apparently being trapped at the mucosal surface (Figure 6-34, top). The 
fluorescence pattern observed for Cho386-A546 was significantly different when it was 
evaluated similarly to ntCho-A546. In this case, the white light channel was used to 
visualise the border of the villus and epithelial cells (Figure 6-34). At the tip of the villus, 














































































































































































fluorescence could be detected at the apical and basolateral poles of the enterocytes 
whereas further down the sides, a clear fluorescent line could be visualised mostly at the 
basolateral cell surface and in the submucosa. This demonstrates that Cho386-A546 was 
rapidly internalised by enterocytes, transported across these cells and reached the cells of 
the underlying mucosa. 
 
Figure 6-34 – In vivo transport of ntCho-A546 and Cho386-A546 across rat small 
intestinal cells. While ntCho-A546 appeared to be retained at the surface of the villi, 
Cho386-A546 was internalised and underwent transepithelial transport across 
enterocytes. Cell nuclei were stained with DAPI (blue). 1 = intestinal villi, 2 = cells of 
the space underlying the villi and 3 = absorptive enterocytes. 
These results confirm that Cho386 is able to carry a fluorescent tag across a monolayer of 
polarised epithelial cells in	vivo. On the contrary, full-length non-toxic cholix (ntCho) was 
not taken up as efficiently by enterocytes. In the small intestine, these cells are covered 
with a mucus coat, separated from the epithelial cells by a thin layer of glycocalyx [83, 86]. 
The observed fluorescence pattern would be consistent with the idea that the entry of 
ntCho-A546 was hindered by the presence of this glycocalyx and thereby kept away from 
the epithelial cell surface. Variations in cell penetration observed between full-length and 
truncated cholix versions could therefore be due to differences in mucus content between 
animals. Alternatively, these discrepancies could be explained by degradation of the 
carrier protein by digestive enzymes in the small intestine. In fact, these enzymes are not 




uniformly distributed and it is therefore possible that ntCho-A546 was injected at an area 
containing large concentrations of enzymes, and subsequently degraded. Only the 
remaining undigested fluorescent tag would then be observed at the mucosal surface. 
These findings confirmed that a truncated version of cholix lacking the cytotoxic domain 
and linked to a fluorescent label was able to undergo transepithelial transport. To 
investigate whether Cho386 could carry a cargo protein in a similar fashion, it was 




Cho386 was shown to be able to transport a fluorescent tag across polarised enterocytes 
to the submucosa in	vivo. To further characterise the potential of cholix to be used as a 
carrier for oral delivery of protein therapeutics, Cho386 was genetically fused at its C-
terminus to the N-terminal of hGH molecule (Figure 6-35). The expressed and purified 
chimera protein was administered to the apical surface of enterocytes by direct injection 
into the small intestine of a rat. The dosed intestinal segment was collected 15 min after 
administration and tissues were processed and immunostained as described in Section 
2.17.2. Cho386 and hGH were individually detected with antibodies targeting each protein, 
used in conjunction with corresponding fluorescent secondary antibodies. The white light 
channel was used to visualise individual villi as well as the borders of epithelial cells 
composing them. Controls (naïve tissue) are presented in Appendix 8. 
Red and green fluorescence could be detected inside enterocytes lining the villus, showing 
that Cho386 and hGH were both present inside these cells (Figure 6-36). Moreover, 
observation of yellow fluorescence areas revealed that the two antibodies co-localised 
within the cells. Due to the trafficking characteristics of internalised hGH (see Section 
1.2.7), the detection of intracellular hGH implied that this protein remained connected to 
Cho386 and that the fusion protein was intact. 
Although this yellow signal was mainly visualised apically, it could also be detected at the 
basal pole of some of the enterocytes and in some cells of the submucosal space. This 
suggests that the fusion protein underwent transepithelial transport from the apical to the 
basolateral surface before being released from epithelial cells and taken up by some of the 
cells present in the underlying mucosa. Only red fluorescence signals could be visualised 
in other cells, implying that only the carrier domain was detected in these cases. 




These findings confirm the ability of Cho386 to transport a C-terminal cargo across a 
monolayer of polarised cells in	vivo. The detection of co-localised Cho386 and hGH inside 
epithelial cells and in the submucosa suggests that a fraction of the fusion protein reached 
the submucosal space intact. These data establish the potential of Cho386 to act as a drug 
carrier for oral delivery of therapeutic proteins. 
 
Figure 6-35 – Ribbon representations of Cho386-hGH. α-helices (red) and loops 
(green) of hGH are displayed in red and green, respectively.  Structures were 
generated using PyMOL [128]. 
 






Figure 6-36 –Transport of Cho386-hGH across rat small intestinal cells. (A) A section 
of rat intestinal tissue (5 μm) was indirectly immunostained with antibodies to 
Cho386 GS TEV (red) and hGH (green).  Cell nuclei were stained with DAPI (blue). 
(B) Higher magnification of white rectangle from merge of image (A). 




6.4 General discussion 
 
This chapter describes studies to characterise some of the aspects of the intracellular fate 
of ntCho in order to assess its potential to be used for the delivery of therapeutic proteins. 
The behaviour of the cholix toxin (tested here as full-length non-toxic and truncated 
forms) at acidic pH and its interaction with GM1 were discussed; potential applications as 
a drug delivery system were also examined. All these features were compared to the 
properties of a full-length non-toxic form and truncated versions of PE described in 
previous chapters. 
Conformational change 
Trypsin digestion showed that lowering the pH from 7.4 down to 5.8 triggers a 
conformational change in ntCho that appears to be completely reversible, but which 
results in the exposure of additional trypsin cleavage sites and hydrophobic residues. DLS 
and HPLC analysis revealed that a conformational transition could happen between pH 5.8 
and 6.2, but that it does not seem to result in any dramatic changes in protein size or 
tertiary structure. 
To date, little is known about the structure and trafficking pathway of cholix. Results 
obtained in this chapter suggest that the conformational change undergone by this toxin 
may present similarities to the one experienced by PE in mildly acidic conditions. In 
Chapter 3, three sets of residues were proposed to be involved in salt bridges, two of 
which (His249-Asp366 and His275-Glu80) were put forward as potentially crucial for the 
conformational change experienced by PE (Section 3.4). Alignment of PE and cholix 
sequences revealed that PE-His249 and PE-His262 directly align with two histidine 
residues in cholix (Cho-His262 and Cho-His275, respectively). However, PE-His275 does 
not align with a His but a Ser residue, whose side chain is much shorter and cannot 
become protonated upon lowering the pH. Therefore, this amino acid is highly unlikely to 
be involved in any conformational switch. Overlay of the crystal structures obtained at 
slightly alkaline conditions (pH 8) for PE and near neutrality (pH 7.5) for cholix showed 
that although they are very similar, they also present noticeable variations. Amongst these 
differences, the loop carrying the furin-cleavage site seems to be more exposed in cholix 
than in PE (Figure 6-37 and Figure 6-38), and the loop aligning directly with the loop 
carrying PE-Glu80 faces outward, making the amino acids of this segment improbable 
candidates for intramolecular interactions. However, the loop formed by cholix residues 
Thr95-Glu96-Asn97-Thr98 overlays with the loop bearing PE-Glu80, and Cho-Glu96 
directly faces Cho-His262 (Figure 6-37). Moreover, the distance between these two 




residues was estimated ~4 Å using PyMOL [128], suggesting that they could form a salt 
bridge upon protonation of the histidine at low pH [335].  Calculation of amino acid 
flexibilities using FlexPred [196] (Table 6-9) and ProtScale [181] (Figure 6-38) revealed 
that aligned residues present flexibility scores comparable to their corresponding residues 
in PE and that this region of cholix is on average more flexible and less buried than the rest 
of the protein. Therefore the residues constituting this segment could be involved in 
similar interactions, i.e. hydrogen bonds at neutral pH and salt bridges in acidic conditions. 
The two amino acids suggested here that might be involved in the formation of salt bridges 
at low pH (Cho-His262 and Cho-Glu96) are not located close to the furin loop. However, 
comparison of crystal structure information regarding this cleavage site suggests it to be 
more exposed in cholix than its equivalent on PE (crystal structure). Therefore, cholix may 
be induced to undergo a structural rearrangement that exposes its furin-cleavage site 
following a subtler pH-dependent prompt than that required for PE. This would be 
consistent with results obtained by trypsin digestion of truncated cholix mutants as, 
following removal of domain III, the digestion pattern varied only slightly between pH 5.8 
and 7.4. This could indicate that the conformational change undergone by these truncated 
proteins is not as important as the one experienced by the full-length toxin, possibly due 
to a decrease in structural constraints caused by removal of domain III. 
Altogether, these observations could indicate that due to an increased initial exposure of 
the furin-cleavage site at neutral pH, only a very subtle and localised conformational 
change is required for furin to cleave cholix. Therefore the formation of a single salt bridge 
rather than a combination of interactions might be enough to trigger this change in cholix.  
This conformational change seems to occur at pH ~6.0, suggesting that the transition 
experienced by the protein could also occur soon after internalisation, in the early 
endocytic pathway and might be important in directing the protein toward an efficient 
trafficking route. 





Figure 6-37 – Ribbon representation and overlay of domain II and a loop of domain I 
of PE (red) and cholix (blue). The residues potentially involved in salt bridges are 
indicated in white (PE) and yellow (cholix).The figure was generated using PyMOL 
[128]. 
 
Figure 6-38 – Graphic representation of the relative degree of amino acid flexibility, 
accessibility and concealment from the surface. Dotted lines represent the 
respective average values for each curve. (Data were generated using ExPASy 
ProtScale [181]). 
 
































Table 6-9 – Relative individual flexibility of the residues involved in the formation 
of salt bridges with His. (Flexibility scores were calculated using FlexPred [196] and 













Glu80 0.8680 His275 0.7302 3.2 
Asp366 0.4120 His249 0.4210 2.8 
Cho Glu96 0.8105 His262 0.4074 4.0 
 
Interaction with GM1 
In this chapter it was shown that cholix binds to GM1 with high affinity in mildly acidic 
conditions. This could indicate that interaction with the ganglioside occurs within the 
same compartment as, or possibly even following the conformational change. Uptake 
assays also suggested that exposure of the ganglioside at the plasma membrane had a 
direct effect on protein uptake and therefore it could also interact with cholix at a pH 
closer to physiological values. These studies also indicated that binding to GM1, potentially 
via its SA group, could interfere with the efficient trafficking of cholix. This could occur at 
the cell surface, where GM1 binding could possibly prevent internalisation by preventing 
access of cholix to its receptor. Alternatively, cholix binding to GM1 could occur following 
endocytosis, possibly in the early endosome where the environment becomes acidic, and 
result in alterations in the protein’s intracellular trafficking pathway. Assuming that cholix 
can bind GM1 with high affinity both at neutral and low pH, these events could even 
combine to reroute the protein to a secondary trafficking pathway. Finally, it cannot be 
excluded that neuraminidase itself might modify the trafficking route exploited by the 
toxin by disturbing its ability to traffic with GM1. Further studies would be required in 
order to determine accurately which stage(s) of the trafficking process are affected by 
GM1 binding. For instance, GM1 could be knocked out and protein entry could be 
compared to control cells. 
No conclusion could be drawn from the current studies regarding the location of GM1 
binding site on cholix. However, if the functions of the toxin’s respective domains 
correspond to those of PE, then it could be assumed that cholix might interact with its 
main receptor on the cell-surface via its domain I and with GM1 possibly via domain II. In 
order to verify this hypothesis, the host receptor(s) used by cholix to penetrate epithelial 
cells would need to be identified.  




Cholix as a carrier for protein delivery 
The potential of cholix as a carrier system for protein delivery into non-polarised systems 
and across the polarised intestinal epithelium was investigated. Unlike PE, shortening 
cholix appeared to significantly affect its uptake by NP epithelial cells. In fact, while full-
length ntCho-A568 seemed to be internalised, neither Cho386-A568 nor Cho313-A568 
were observed inside the cells. Two explanations were suggested to account for these 
observations. First, truncation of the protein could have led to improper folding during 
expression that limited receptor interactions required for uptake. This option is supported 
by the fact that all truncated versions of cholix were directed to inclusion bodies as an 
insoluble form rather than to the periplasm as a soluble protein. The refolding process 
from inclusion bodies may have resulted in mis- or poorly-folded forms of the truncated 
Cho proteins that affected their receptor-binding domain, possibly explaining why these 
proteins were unable to be taken up by cells. Alternatively, an increased interaction with 
GM1 could be responsible for the observed lack of intracellular fluorescence. In fact, it was 
proposed that the GM1 binding domain could be located at the beginning of cholix domain 
II (residues 264-313). In this case, removal of domain III and of half of domain II could 
have resulted in an increased exposure of the binding site and therefore enhanced the 
interaction between the protein and the ganglioside. Since GM1 binding was shown to 
decrease the amount of fluorescence detected inside NP cells (Section 6.3.3.3), this would 
lead to a decreased quantity of Cho truncated proteins that could be internalised 
compared to FL ntCho. Addition of a cargo protein at the C-terminus of full-length ntCho 
did not seem to affect its ability to be internalised by NP cells. In fact, blocking of GM1 had 
similar effects on both ntCho-A568 and ntCho-GFP. These findings are consistent with 
previous results observed for the PE-GFP protein series and confirm that FL cholix can be 
used to deliver a cargo protein in NP cells. 
In order to establish the potential of ntCho as a carrier system for oral protein delivery, its 
ability to transport a fluorescent tag across a monolayer of polarised intestinal epithelial 
cells was investigated in	 vitro	 and	 in	 vivo. Although cholix was shown to transport 
efficiently across polarised monolayers of Caco-2 cells and data was consistent in each 
assay, the characteristics of transport varied greatly between in	vitro experiments. In fact, 
while in one case up to 0.93 μM protein could be applied to the apical compartment 
without saturating surface receptors, in another the same initial concentration of material 
resulted in receptor saturation as demonstrated by a plateau phase in the transport data. 
The total quantity of protein trafficking from the apical to the basolateral compartment 
also varied. This demonstrates that the system used here remains an in	vitro model and 




that the biology of polarised monolayers of Caco-2 cells related to ntCho is not completely 
understood yet. Surprisingly, results obtained here also showed that the transport of ntPE 
across polarised cells appeared to be more efficient than that of cholix. This was 
unexpected as PE is a virulence factor originating from an airway pathogen, unlike cholix, 
which is secreted by an intestinal bacterium, and was therefore anticipated to transport 
more efficiently across the cells used here. However, these results would need to be 
confirmed either in	vitro or in	vivo using established and reliable models. 
In	vivo studies revealed that ntCho-A546 appeared to be retained at a distance from the 
mucosal surface, whereas Cho386-A546 penetrated the enterocytes and transported to 
the basolateral pole of the cells, and further to the submucosa. It was suggested that these 
discrepancies could be caused by variations in the thickness of the mucus layer or in the 
concentration of digestive enzymes at the site of injection. Next, the fluorescent label was 
replaced by hGH, a therapeutic protein currently administered by injection. The fusion 
protein was detected both at the apical and basolateral poles of intestinal enterocytes, as 
well as in some of the cells of the submucosal space. These findings therefore establish 
that replacement of cholix domain III by a protein drug does not affect its ability to 
transcytose in	vivo and that the cargo protein can be delivered to the underlying mucosa. 
As a conclusion, cholix was demonstrated to be able to carry a cargo protein inside non-
polarised cells in	vitro, and its potential to deliver a protein drug across the intestinal 
epithelium was confirmed in	vivo. These results establish the potential of this toxin to be 
used as a carrier system for both intracellular and oral delivery of protein therapeutics. 
  









7 GENERAL CONCLUSIONS AND 
FUTURE WORK 
The principal aims of this research were two-fold. Firstly, the project involved the 
characterisation of the intracellular pathway exploited by PE in order to assess the 
potential of this toxin to act as a carrier for oral protein delivery. This implied the 
examination of possible conformational changes experienced by PE that might affect its 
ability to interact with potential cell receptors such as the scavenger receptor LRP1 and 
the ganglioside GM1; interactions that could affect its internalisation and intracellular 
trafficking. It also involved the evaluation of PE’s ability to transport a cargo protein inside 
NP cells in	vitro and across polarised enterocytes	in	vivo. Secondly, a comparison between 
the trafficking mechanisms of PE and another ADP-ribosylating protein, cholix toxin, was 
carried out. In fact, cholix structurally resembles PE and could therefore also be 
reprogrammed for therapeutic purposes, as was shown in this thesis.  
PE conformational change 
The aim of this chapter was to gain a better understanding of the intracellular trafficking 
pathway exploited by PE by studying the conformational change experienced by the toxin 
at low pH. Results described here suggest that this conformational switch involved fairly 
subtle structural changes (the overall shape and size of the toxin remaining unchanged) 
occurring in the acidic environment of the endosome. More specifically, two pairs of 
residues (His275-Glu80 and His249-Asp366) were proposed to be crucial in this process: 
exposure to low pH would result in the protonation of these His residues and would 
trigger the transition from one conformation to the other by formation of salt bridges. 




To test this hypothesis, point mutations could be carried out on the amino acids suggested 
to be involved in the switch. His249 and His275 could be either individually or 
simultaneously mutated to residues which would i) form an H bond at physiological pH, 
but would not become protonated at lower pH (no formation of salt bridges) (example 
residues would be serine, asparagine or glutamine) or ii) form an H bond and electrostatic 
interaction (salt bridge) at both physiological and acidic pH (e.g. arginine or lysine). 
Glutamine and lysine would appear to best conserve the side-chain length compared to 
His.  While the introduction of glutamine should not affect trypsin cleavage sites on the 
protein, introduction of an additional lysine might lead to an additional cleavage site and 
this would have to be considered in studies involving trypsin digestion at pH 5.8 and 7.4. 
Alternatively, new disulphide bridges could be strategically created in order to impose 
higher structural constraints on the protein and thereby prevent movements between 
domains. 
Data presented in this chapter are consistent with the idea that the conformational change 
undergone by PE plays a major role in the protein’s escape from lysosomal degradation 
following endocytosis. In fact, it would allow the toxin to dissociate from its cell-surface 
receptor LRP1, thereby permitting complete binding to a secondary receptor, which could 
lead it away from the degradation compartment.  
PE interaction with GM1 
This chapter aimed to investigate the possible interaction between PE and the host 
receptor for CT, monosialoganglioside GM1, in order to determine whether this 
ganglioside could act as a secondary receptor for PE. High-affinity binding was confirmed 
at acidic pH and a possible role for GM1 on the cell surface was suggested, as protein entry 
appeared to be significantly increased after the ganglioside was made more accessible. 
These studies concluded that exposure of GM1 was required for efficient protein 
internalisation by NP cells. 
Although interaction between the protein and GM1 was confirmed, the binding site of GM1 
on PE could not be identified. It was suggested that it might be located between residues 1 
and 303 of PE. In order to verify this proposal, BLI studies could be conducted on 
truncated versions of the toxin (PE GS TEV mutants). Comparison of the binding affinity 
between GM1 and the various mutants would help refine the location of the binding site. 
Next, the potential of specific point mutations to trigger a significant decrease in binding 
affinity could be examined. 
 




PE as a carrier for intracellular and oral delivery of therapeutic macromolecules 
In this chapter, several versions of PE were shown to transport a cargo protein inside non-
polarised cells in	vitro and across a monolayer of polarised intestinal enterocytes in	vivo. 
To confirm the potential of PE as a delivery vehicle for macromolecular drugs, the cargo 
protein would have to be detected in the bloodstream, quantified, and its biological 
activity would need to be confirmed following transport. Eventually, the poly glycine-
serine linker connecting the carrier and cargo protein domains would be replaced by a 
cleavable linker that would allow for separation of PE from its payload following 
transcytosis, and would lead to the subsequent release of the therapeutic molecule in the 
bloodstream. 
The results presented established that a protein of molecular weight comparable to that of 
PE domain III could be transported across polarised cells in	vivo. The repertoire of cargo 
molecules that could be delivered using this system remains to be elucidated, and the 
impact of factors such as size and glycosylation, for instance, would need to be 
investigated. 
Cholix 
Cholix demonstrates great structural similarity with PE and its potential as a vehicle for 
oral drug delivery was therefore studied and compared to that of PE. Results showed that 
the two proteins experience a similar conformational switch and that cholix also binds to 
GM1 with high affinity at low pH. However, the ganglioside seems to play a different role 
in the entry of cholix, as increasing its exposure appeared to reduce protein entry in non-
polarised cells. This indicates that despite their many similarities, the two proteins do not 
exploit identical intracellular trafficking routes. Cholix was also shown to carry a cargo 
protein inside NP cells in	vitro and across a monolayer of polarised enterocytes in	vivo. 
These results highlighted the importance of considering truncated versions of the toxin as 
delivery vehicles, as these should present a lower risk of inducing a host immune response 
upon repeated administration. The relative transport efficiencies of PE and cholix would 
next have to be compared in	vivo to determine which protein would constitute the better 
candidate for delivery of biologics across the intestinal epithelial barrier. 
Final remarks 
The therapeutic benefits of bacterial toxins were first discovered with the creation of 
immunotoxins, which are now widely used in the treatment of various types of cancers. 
The studies described in this thesis reveal that the potential of these proteins to be 
reprogrammed for therapeutic purposes is even greater. It was demonstrated that both 




cholix and PE could be used to deliver a therapeutic payload into and across cells. 
Numerous systems are being continually developed and enhanced in order to increase 
bioavailability following oral administration of a therapeutic protein by preventing 
degradation, increasing residence time in the intestine or facilitating contact with the 
mucosa. Bacterial toxins represent powerful tools that, in association with these other 
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Appendix 1 – Expression plasmids and physiochemical 
properties of the versions of PE and cholix 
 
During cloning of Cho386-hGH, pETCHO was used for amplification of Cho386 sequence 
from full-length, non-toxic cholix, whose sequence had previously been cloned into pET-26 
b (+) plasmid from Novagen (Millipore Limited, Watford, UK) (Figure 9-1). 
 
Figure 9-1 – Schematic representation of pETCHO expression construct. The 
sequence encoding for full-length, non-toxic, cholix was cloned into pET-26 b (+) 
between the NdeI and EcoRI restriction sites. 
Table 9-1 presented below summarises the plasmids used in the expression process of the 
various versions of PE and cholix, as well as the calculated molecular weight and 
isoelectric point for these proteins. pET-26 b (+) was obtained from Novagen, while pET28 
was obtained from the David Liu laboratory (Harvard University, Cambridge, MA, USA). 













Table 9-1 – Plasmids and physicochemical properties of PE and cholix versions. 




plasmid Protein Calculated pI 
Predicted molecular 
weight (kDa) 
pUC13 pVC45D ntPE 5.28 66.7 
pET-26 b (+) 
pntPE GS TEV ntPE GS TEV 5.28 66.7 
pPE408 GS TEV PE408 GS TEV 5.28 44.4 
pPE364 GS TEV PE364 GS TEV 5.86 40.1 
pPE351 GS TEV PE351 GS TEV 5.97 38.9 
pPE320 GS TEV PE320 GS TEV 6.33 35.6 
pPE303 GS TEV PE303 GS TEV 6.33 33.8 
 phisPE-GFP ntPE-GFP 5.34 93.2 
 phis408-GFP PE408-GFP 5.36 71.4 
pET28 phis364-GFP PE364-GFP 5.33 69.2 
 phis351-GFP PE351-GFP 5.41 67.6 
 phis320-GFP PE320-GFP 5.53 64.4 
 phis303-GFP PE303-GFP 5.53 62.5 
pET28 phis364-hGH PE364-hGH 5.84 66.4 
pETCHO pcholix cholix 5.31 71.8 
pET-26 b (+) 
pntCho GS TEV ntCho GS TEV 5.31 71.8 
pCho428 GS TEV Cho428 GS TEV 5.31 48.0 
pCho386 GS TEV Cho386 GS TEV 5.42 43.7 
pCho368 GS TEV Cho368 GS TEV 5.37 41.6 
pCho332 GS TEV Cho332 GS TEV 5.65 37.5 
pCho313 GS TEV Cho313 GS TEV 5.59 35.4 
 phisCho-GFP ntCho-GFP 5.21 97.9 
 phis428-GFP Cho428-GFP 5.18 74.9 
 phis386-GFP Cho386-GFP 5.12 71.6 
pET28 phis368-GFP Cho368-GFP 5.08 69.7 
 phis332-GFP Cho332-GFP 5.16 65.3 
 phis313-GFP Cho313-GFP 5.19 63.1 








Appendix 2 – Summary of the antibodies used in the thesis 
The tables below detail, for each primary and secondary antibody applied, the target, 
clonality, host species and supplier, as well as the blocking solution and dilution used. 
Table 9-2 – Primary antibodies and dilutions used for Western blot (WB), 
immunofluorescence (IF) and/or immunohistochemistry (IHC). 
















Mouse Milk 1/10,000 WB Expressed 




























Table 9-3 – Secondary antibodies and dilutions. 
Secondary antibody Dilution Supplier 
HRP-conjugated anti-rabbit IgG 1/4,000 
GE Healthcare 
#NA934 
HRP-conjugated anti-mouse IgG 1/4,000 
GE Healthcare 
#NXA931 
Fluorescein-conjugated anti-goat IgG 1/100 
Vector Laboratories 
#FI-5000 
Alexa Fluor® 546-conjugated anti-rabbit IgG 1/100 Invitrogen #A10004 






Appendix 3 – Controls for uptake assays on PE-GFP and Cho-
GFP mutants 
CT, whose host cell-membrane receptor is GM1, is readily taken up by NP cells. Therefore 
CTB-A488 was used as a positive control in the assays investigating the role of this 
ganglioside in the uptake of ntPE, ntCho and various PE-GFP and Cho-GFP mutants 
(Sections 4.3.3.2, 5.3.4, 6.3.3.3 and 6.3.4.2). Unlike CT, GFP is not spontaneously 
internalised by NP cells and was therefore used as a negative control in the studies 
presented in the thesis. NP Caco-2 cells were incubated with 20 μg CTB-A488 or GFP in 
100 µl complete growth medium (concentration CTB-A488 = 3.5 µM and GFP = 7.4 µM) at 
37 °C for 2 h in the experimental conditions previously described. Cells were then fixed 
with PFA, labelled with an anti-GM130 antibody, and prepared for confocal microscopy. 
GM130 expression was also used here to visualise the Golgi network [314]. 
Following neuraminidase treatment, the amount of CTB-A488 internalised by NP cells was 
significantly reduced compared to untreated cells. Similarly, addition of CTB resulted in 
lower protein uptake (Figure 9-2). These observations are consistent with GM1 being the 
receptor for CT. Figure 9-3 shows that GFP was not readily taken up by untreated cells, 
and that neither treatment with neuraminidase or addition of CTB affected its entry as no 






Figure 9-2 – Treatment with neuraminidase and CTB affects the entry of CTB-A488 
in NP epithelial cells. Fluorescent images of NP Caco-2 cells incubated for 2 h with 
3.5 µM CTB-A488 (green) alone or with 3.5 µM CTB, with or without cell treatment 
with 1 U/ml neuraminidase. Cell nuclei were stained with DAPI (blue) and 
expression of GM130 (red) was used to visualise the Golgi network. Images are 






Figure 9-3 – GFP is not internalised by NP epithelial cells. Fluorescent images of NP 
Caco-2 cells incubated for 2 h with 7.4 μM GFP (green) alone or with 3.5 μM CTB, 
with or without cell treatment with 1 U/ml neuraminidase. Cell nuclei were stained 
with DAPI (blue) and expression of GM130 (red) was used to visualise the Golgi 










Appendix 4 – Correlation plots and masks for co-localisation 
of PE-GFP mutants and GM130 after 2 h neuraminidase 
treatment 
 
NP cells were pre-treated with 1 U/ml neuraminidase for 2 h. Following this, 20 μg of 
protein diluted in 100 µl complete growth medium containing 1 U/ml neuraminidase was 
applied for another 2 h. Cells were then fixed with PFA, labelled with an anti-GM130 
antibody, and prepared for confocal microscopy. GM130 expression was also used here to 
visualise the Golgi network [314]. A correlation plot and co-localisation mask were 
generated using Image Correlation J [306] and Colocalization [307] plugins on Image J 
[308], respectively (Figure 9-4 and Figure 9-5). Results showed that co-localisation of the 
PE-GFP mutants (green) with the Golgi network (red) was low in these conditions (Section 
5.3.4 and Table 9-4). 
 
Table 9-4 – Correlation coefficients for co-localisation of PE-GFP mutants and 
GM130 after 2 h neuraminidase treatment. r2 values were obtained following 























Figure 9-4 – Co-localisation of (A) ntPE-GFP, (B) PE408-GFP and (C) PE364-GFP with 
GM130 is low following internalisation by neuraminidase-treated cells. Scatter plots 
and co-localisation masks obtained following application of 20 µg protein (green) 
diluted in 100 µl complete growth medium containing 1 U/ml neuraminidase to NP 
Caco-2 cells pre-treated with 1 U/ml neuraminidase for 2 h at 37 °C. Cell nuclei were 
stained with DAPI (blue) and expression of GM130 (red) was used to visualise the 









Figure 9-5 – Co-localisation of (D) PE351-GFP, (E) PE320-GFP and (F) PE303-GFP 
with GM130 is low following internalisation by neuraminidase-treated cells. Scatter 
plots and co-localisation masks obtained following application of 20 µg protein 
(green) diluted in 100 µl complete growth medium containing 1 U/ml 
neuraminidase to NP Caco-2 cells pre-treated with 1 U/ml neuraminidase for 2 h at 
37 °C. Cell nuclei were stained with DAPI (blue) and expression of GM130 (red) was 
used to visualise the Golgi network. Areas of co-localisation are white. Images are 






Appendix 5 – In	vivo transport of PE364-hGH: Control tissue 
 
To test the specificity of the method used to detect PE364-hGH in	 vivo, naïve tissue 
sections were sampled from the small intestine of a rat following administration of PBS by 
luminal injection. Tissues were processed as described in Chapter 2 and immunostained 
using primary antibodies against PE and hGH. These antibodies were themselves detected 
using anti-IgG secondary antibodies conjugated to A546 (PE, red) or fluorescein (hGH, 
green). No signal could be detected, confirming that the antibodies used specifically 
targeted PE and hGH, respectively (Figure 9-6). 
 
Figure 9-6 – Section of rat naïve intestinal tissue (5 μm) sampled 20 min following 
intraluminal injection of PBS. The section was indirectly immunostained with 





Appendix 6 – Alignment of PE and cholix protein sequences 
 
Protein sequences of full-length PE and cholix were aligned using the Align tool of NCBI’s 
BLAST (BLASTP, http://blast.ncbi.nlm.nih.gov/). The Query and Subject sequences were 
those of PE (PDB_ID: 1IKQ) and cholix (PDB_ID: 2Q5T), respectively. Results showed that 
the two protein sequences showed 33% identity, with 49% positives and 10% gaps 
(Figure 9-7). 
 
Query  1    AEEAFDLWNECAKACVLDLKDGV-RSSRMSVDPAIADTNGQGVLHYSMVLEGGNDALKLA  59 
             E+  ++++EC   C L  + G    S++S+   +     +GVL+YSM +    + +K   
Sbjct  1    VEDELNIFDECRSPCSLTPEPGKPIQSKLSIPSDVVL--DEGVLYYSMTINDEQNDIKDE  58 
 
Query  60   IDNALSITSDG----------------------LTIRLEGGVEPNKPVRYSYTRQARGSW  97 
             D   SI + G                      L I  E G +      YSY R+  G + 
Sbjct  59   -DKGESIITIGEFATVRATRHYVNQDAPFGVIHLDITTENGTK-----TYSYNRK-EGEF  111 
 
Query  98   SLNWLVPIGHEKPSNIKVFIHELNAGNQLSHMSPIYTIEMGDELLA--KLARDATFFVRA  155 
            ++NWLVPIG + P++IK+ + EL+    +  +  +Y+I++ ++ L   K   + +F V   
Sbjct  112  AINWLVPIGEDSPASIKISVDELDQQRNIIEVPKLYSIDLDNQTLEQWKTQGNVSFSVTR  171 
 
Query  156  HESNEMQPTLAISHAGVSVVMAQAQPRREKRWSEWASGKVLCLLDPLDGVYNYLAQQRCN  215 
             E N     +AIS   VS   AQ +  R KRW+ W +G  LC L P+D +YNY+ QQ C  
Sbjct  172  PEHN-----IAISWPSVSYKAAQKEGSRHKRWAHWHTGLALCWLVPMDAIYNYITQQNCT  226 
 
Query  216  LDDTWEGKIYRVLAGNP----AKHDLDIKPTVISHRLHFPEGGSLAALTAHQACHLPLET  271 
            L D W G  Y  +AG P     K  ++ KP  +  R+HF +G +++AL AH+ C +PLET 
Sbjct  227  LGDNWFGGSYETVAGTPKVITVKQGIEQKP--VEQRIHFSKGNAMSALAAHRVCGVPLET  284 
 
Query  272  FTRHRQPRGWEQLEQCGYPVQRLVALYLAARLSWNQVDQVIRNAL--ASPGSG---GDLG  326 
              R R+PR       C Y  Q +V+L++A R+ ++ +D V    L    P       DL  
Sbjct  285  LARSRKPRDLTDDLSCAYQAQNIVSLFVATRILFSHLDSVFTLNLDEQEPEVAERLSDLR  344 
 
Query  327  EAIREQPEQARLALTLAAAESERFVRQGTG----NDEAGAANADVVSLTCPVAAGECAGP  382 
                  P      LT+A      +V    G       AGA  AD++SL CP A   C    
Sbjct  345  RINENNPGMVTQVLTVARQIYNDYVTHHPGLTPEQTSAGAQAADILSLFCPDADKSCVA-  403 
 
Query  383  ADSGDALLERNYPTGAEFLGDGGDVSFSTRGTQNWTVERLLQAHRQLEERGYVFVGYHGT  442 
            +++  A +     +G  +L +   V  + +G  NWT + L   H+ L   GYVFVGYHGT 






Figure 9-7 – Protein sequence alignment between PE and cholix. The furin-cleavage 



















Query  443  FLEAAQSIV--FGGV-RARSQDLDAIWRGFYIAGDPALAYGYAQDQE-------PDARGR  492 
               AAQ+IV     V R  + + +  W G Y+A    +A+GYA+ +E       P    R 
Sbjct  463  NHVAAQTIVNRIAPVPRGNNTENEEKWGGLYVATHAEVAHGYARIKEGTGEYGLPTRAER  522 
 
Query  493  IRNGALLRVYVPRSSLPGFYRTSLTLAAPEAAGEVERLIGHPLPLRLDAITGPEEEGGRL  552 
               G +LRVY+PR+SL  FYRT+  L   E    + ++IGH LPLR +A TGPE  GG   
Sbjct  523  DARGVMLRVYIPRASLERFYRTNTPLENAEE--HITQVIGHSLPLRNEAFTGPESAGGED  580 
 
Query  553  ETILGWPLAERTVVIPSAIPTDPRNVGGDLDPSSIPDKEQAISALPDY  600 
            ET++GW +A   V IPS IP +       +D  ++  KEQ+IS  P Y 





Appendix 7 – In	vivo transport of ntCho-A546 and Cho386-
A546: control tissue 
 
Naïve tissue sections were sampled from the small intestine of a rat following 
administration of PBS by luminal injection. Tissues were processed as described in 
Chapter 2. No signal could be detected, confirming that the signal detected in presence of 
Cho386-A546 (red) was not an artefact due to intrinsic sample fluorescence (Figure 9-8). 
 
Figure 9-8 – Section of rat naïve intestinal tissue (5 μm) sampled 20 min following 

















Appendix 8 – In	vivo transport of Cho386-hGH: control tissue 
 
To test the specificity of the method used to detect Cho386-hGH in	 vivo, naïve tissue 
sections were sampled from the small intestine of a rat following administration of PBS by 
luminal injection. Tissues were processed as described in Chapter 2 and immunostained 
using primary antibodies against Cho386 GS TEV and hGH. These antibodies were 
themselves detected using anti-IgG secondary antibodies conjugated to A546 (Cho386, 
red) or fluorescein (hGH, green). No signal could be detected, confirming that the 
antibodies used specifically targeted Cho386 and hGH, respectively (Figure 9-9). 
 
 
Figure 9-9 – Section of rat naïve intestinal tissue (5 μm) sampled 20 min following 
intraluminal injection of PBS. The section was indirectly immunostained with 
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